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ABSTRACT

The elderly are at increased risk for developing psychiatric
diseases, which include Alzheimer’s disease, depression, anxiety and
suicide. The probability of multiple disease comorbidity is also
increased in the elderly. At the cellular level, the loss of protein
homeostasis is often at the root of disease emergence, and thus the
scientific community is searching for ways to help maintain this
balance. A vast group of proteins that are paramount to balancing and
counterbalancing protein levels is the molecular chaperone protein
group, which has evolved a tremendous variety of functions in the cell.
They aid in protein trafficking, folding, receptor signaling,
neurotransmission, vesicle forming and fusion, protein degradation,
and apoptosis, among other activities. Despite their best efforts,
disease still ensues, but because of their vast number and multiple
abilities, it may be possible to modulate these proteins as a way to
treat and prevent disease. Chaperones are of particular interest in
diseases of aging, because chaperone induction and effectiveness is
reduced with age. In addition, many diseases of the elderly are
xi

brought on by aberrant protein accumulation, like Alzheimer’s disease.
As a result, the hypothesis of this dissertation is whether the
modulation of molecular chaperones changes disease pathology. A
molecular chaperone family that is important to protein degradation is
the Hsp70 chaperone complex. Hsp70 proteins have specialized
function depending on cell type and cellular compartment, but Hsp70
proteins are very important for protein synthesis and degradation. As a
result, they are in a position to contribute to the regulation of proteins
that become aberrant.

In recent years scientific literature has indicated that compounds
that inhibit the enzymatic ATP hydrolysis of these proteins promote tau
degradation, which accumulates in Alzheimer’s disease. Alzheimer's
disease is the sixth leading cause of death in the U.S., it is a
progressive neurodegenerative disease, and is caused by the aberrant
accumulation of the amyloid beta and tau proteins. Here, we show that
treatment with the Hsp70 inhibitor methylene blue, reduces tau, saves
neurons, and restores cognition, in a mouse model of tau accumulation
(rTg4510). Cognitive rescue occurred despite a severe tangle load,
equal to control treated tau transgenic mice. This study shows that
reducing soluble tau can restore cognition, reducing tangles is not
necessarily to ameliorate cognition, and saving neurons is not
xii

sufficient to increase cognition if they are burdened with soluble tau.
This work shows that methylene blue does not affect the the number
of tau tangles in this model, as suggested by in vitro data. It also
suggests that further work into the development of Hsp70 ATPase
inhibitors may find success in alleviating the soluble tau burden found
in Alzheimer’s disease.

The co-chaperone FKBP5 is also of extreme importance,
not because it is essential, but because research has implicated this
protein with a host of psychiatric diseases. Single nucleotide
polymorphisms in this gene, which increase the levels of FKBP5,
interact with averse traumatic events to enhance the likelihood of
developing mood and anxiety disorders, including major depressive
disorder, post-traumatic stress disorder, bipolar disorder, and suicide.
Moreover, we have found that FKBP5 protein levels increase with age
in the human brain, increasing the risk for the elderly of developing
disease if exposed to traumatic stress. Here, we tested the hypothesis
that FKBP5 negatively regulates resilient behavior. We found that
FKBP5 levels increase with age in the wild type mouse brain, and that
wild type mice display reduced resiliency with age. FKBP5-/- mice, on
the other hand, show enhanced resiliency to stress at all ages tested,
and are protected from aging-induced despair. At the molecular level,
xiii

FKBP5 is a robust inhibitor of the glucocorticoid receptor, which is
responsible for the shut-off of the hypothalamic-pituitary-adrenal axis.
In addition, excess glucocorticoid levels in the blood is a robust marker
of psychiatric disease. Consequently, FKBP5 may be causing disease
through enhanced levels of glucocorticoids. FKBP5-/- mice display
reduced corticosterone after stress. Moreover, corticosterone
production increases with age, and FKBP5-/- mice are protected from
this increase. These studies are the first to show that reducing the
levels of FKBP5 is a promising therapeutic option for the treatment of
mood disorders in the elderly, resiliency naturally declines with age
due to FKBP5, corticosterone levels after stress rise due to FKBP5, and
that the ablation of this gene increases resiliency and prevents aginginduced despair.

As a whole, these data show that the modulation of chaperone
proteins has the potential for developing new therapies for the
treatment of psychiatric diseases of the elderly.
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CHAPTER ONE:

Introduction

The explosion in medical research, discovery, and access to
medicine that occurred in the 20th century, dramatically increased the
lifespan of people all over the world. There was considerable growth in
the number of individuals reaching the age of 65 in the United States,
from 4.1% in 1900 to 12.4% in 2000 (Daccache et al., 2011).
Notwithstanding this increase of life expectancy, aging increases
susceptibility to psychiatric diseases (Sibille, 2013). And in spite of the
growing accumulation of medical knowledge, relatively minuscule
advancement has occurred in the development of hypothesis-driven
therapeutic approaches. As a result of this, this dissertation is focused
on the testing of hypotheses aimed at discovering novel methods to
treat psychiatric disorders that affect the elderly.

1

Alzheimer’s Disease

Alzheimer’s as a psychiatric disease
Alzheimer’s disease (AD), is traditionally considered a
neurological disorder. However, it is also officially sanctioned as a
psychiatric disorder in the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR). From the perspective of the mind, AD is
characterized by the loss of learning and episodic memory (Citron,
2010), personality changes (Robins Wahlin and Byrne, 2011), and the
loss of general cognitive and intellectual ability. Often, the loss of
motivation, anhedonia, and the overlap of symptoms with depression
can lead to a misdiagnosis(Landes et al., 2001; Landes et al., 2005).
In the later stages AD can produce aphasia (Weintraub et al., 2012),
and complete loss of the performance of basic human activities, like
eating, dressing, bathing, and even going to the bathroom (Desai and
Grossberg, 2001). As of the date of this writing, AD can only be
medically diagnosed postmortem, by the paired presence of amyloid
beta plaques and neurofibrillary tangles in the brain (Ittner and Gotz,
2011). AD was first recognized by Alois Alzheimer in 1907, and has
been researched ever since, marking this year as the 105th year since
its discovery (Hippius and Neundorfer, 2003). Notwithstanding, there is
currently no cure, preventative method, or disease-modulating agent.
2

What should we target?
There is some debate in the AD field as to what biological target
will yield a cure. As a whole, the answer to the question “what should
we target” is “everything.” We need to target all the different problems
in AD, like amyloid beta, tau, inflammation, blood brain barrier
deterioration, etc. Each one is likely to contribute to the extension of
life of the patient. Here, however, we have taken the route of exploring
the therapeutic options to reduce the tau burden.

Historically there has been an overrepresentation in the scientific
community of scientists and clinical trials that searched for therapeutic
avenues that reduce amyloid beta (Lee et al., 2007). This was due to
the strong evidence that amyloid beta is the initiator of the AD
cascade, including mutations that cause early onset (St George-Hyslop
et al., 1987), and, recently, the discovery of SNPs in the APP gene that
protect against Alzheimer’s (Jonsson et al., 2012). However, key
discoveries have shown that tau is of equal importance in AD research.

Mutations have been found in the tau gene that are responsible
for causing frontotemporal dementia with Parkinsonism linked to
chromosome 17. These mutations produce neurodegeneration and
neurofibrillary tangles that are very similar to those in AD. Thus, the
3

logical conjecture arose that tau, like in FTDP-17, may be capable of
producing neurodegeneration in AD. Mice transgenic for the human
APP gene do not develop tau tangles, but displayed robust cognitive
deficits (Spires and Hyman, 2005). The role of tau in AD was
subsequently diminished, as it was presumed that tau was not playing
as much of a role. A study from Lennart Mucke’s lab, on the other
hand, showed that when the tau gene is knocked out in mice
transgenic for the human APP gene, cognition is improved dramatically
(Roberson et al., 2007). The improvement of these mice ensued,
despite robust amyloid beta pathology. Additionally, evidence from the
human brain also shows that amyloid beta pathology is not the sole
source of AD, since there are people with a heavy amyloid burden in
the brain who do not develop AD (Crystal et al., 1988).

What kind of tau should we target?
In healthy individuals, the microtubule associated protein tau,
referred to herein as tau, is responsible for stabilizing microtubules,
which allow for the transport of materials throughout the cell (Brunden
et al., 2009). Tau, though, is the main component of the neurofibrillary
tangles found in AD (Brunden et al., 2009). Tau tangles are also called
tombstone tangles, since they are so insoluble they are often found at
the place of death of neurons. Because of this, the hypothesis was
4

formed that the formation of tau tangles is toxic for neurons and
causes them to die. The current scientific thought about tau, though, is
shifting due to research in the last decade that suggests otherwise.

In the publication describing the making of the rTg4510 tau
transgenic mouse, the authors utilized the model to test if suppression
of tau transgene expression would suppress tau pathology, memory
loss, and neuron loss (Santacruz et al., 2005). Tau transgene
suppression, via doxycycline, alleviated memory and neuron loss, but
neurofibrillary tangles continued to form. Thus, separating tau tangle
pathology from memory and neuron loss. This was the first indication
that excess soluble tau may be the culprit of acute, deadly
neurotoxicity, and not the tau tangles themselves. It also showed that
a reduction in soluble tau can be therapeutic, despite the increased
presence of tau tangles. Previous to this study it was thought that
without a reduction in tangle pathology, cognitive improvement was
not possible.

The work of Bradley Hyman shows that the emergence of tangles
in the rTg4510 mice does not cause the cell to die acutely, as they can
monitor the same neuron for up to 5 days (de Calignon et al., 2010).
Further examination of tangle bearing neurons in the cortex of 7-8
5

month old rTg4510 mice showed intact nuclei. Additionally, histological
sections of mice with six weeks of suppressed tau transgene
expression shows a large number of tangles, suggesting that tau
tangles are long lived and relatively stable. These data suggest that
tau tangles are not responsible for acute neuronal death experienced
in AD, and that tau neurofibrillary tangles are an atypical or later-stage
cause of neuron loss. Neurofibrillary tangles correlate with neuronal
death, but fall short in number to account for the size of the neuron
loss experienced (Gomez-Isla et al., 1997). In support of this notion
that soluble tau is the most toxic tau to neurons it was found that mice
overexpressing human wild type tau develop memory deficits, despite
the absence of neurofibrillary tangle formation in this model.

These data, as a whole, indicate that the depletion of soluble tau
could be a successful therapeutic strategy in the treatment of AD. Tau
knockout animals are also functionally intact (Ke et al., 2012),
although they do develop motor deficits with age. This may be due to
changes in development, since the gene is absent at this critical
period. The development and testing of conditional tau knockout mice
has yet to be determined. However, considering the vast majority of
AD patients are older than 65 it is not unreasonable to think that a
tau-reducing therapy may be suitable for the treatment of AD.
6

How should we target soluble tau?
One possibility for tau reduction is the modulation of the
degradation of the tau protein (Jinwal et al., 2009; Abisambra et al.,
2010; Jinwal et al., 2010). Molecular chaperones offer this possibility
because they are responsible, among other things, for the proper
degradation of proteins through many of the cells degratory pathways,
including proteasomal and autophagic protein degradation.

Molecular Chaperones

What are molecular chaperones?
Molecular chaperones are a family of proteins that are dedicated
to maintaining the proper function of proteins in the intercellular milieu
(Muchowski and Wacker, 2005). They assist in de novo protein folding,
and in protein refolding after a cellular stressor has caused protein
misfolding to occur (e.g. heat shock) (Barral et al., 2004). Apart from
protein folding, molecular chaperones are also necessary in protein
transport, targeting, degradation, signal transduction, apoptosis, and
vesicle fusion, among other things (Muchowski and Wacker, 2005).

During a cellular stress event all the major families of heat shock
proteins get transcribed, including Hsp90, Hsp70, Hsp60, Hsp40, and
7

Hsp20 families (Lindquist, 1986). However, chaperone proteins cannot
always fix the misfolded protein. As a result, the cell has evolved
chaperone-mediated targeting of proteins to the degratory pathways.
This occurs through the coordinated crosstalk between Hsp70, Hsp90
and representative proteins of the different degradation pathways, like
E3 ubiquitin ligases, and lysosome-associated membrane proteins
(Ballinger et al., 1999; Massey et al., 2006).

Protein misfolding occurs despite chaperones
It is thought that the induction and function of molecular
chaperones decrease with age (Muchowski, 2002; Soti and Csermely,
2002). Moreover, loss of Hsp70 chaperone function, via the
overexpression of a dominant negative form, has been shown to
produce neurodegeneration in a fruit fly. In addition, there is a
reduction in autophagy and proteasomal degradation with age.
Accordingly, there may be a reduction in the ability of neurons to
handle cellular stressors that require the protein activity of molecular
chaperones. This would lead one to the hypothesis that increasing the
activity of chaperones would reduce the aggregation of proteins, and
the subsequent neurodegeneration this produces, at least for tau.

8

Molecular chaperone levels or activity?
Despite the fact that chaperones decrease with age, research
has shown that chaperone stimulation is not always effective in the
management of aberrant tau accumulation (Jinwal et al., 2009). In
2009, the use of a high throughput screening system identified
chemical compounds that modulate the ATPase activity of Hsp70.
Oppositely of what the literature was suggesting, Hsp70 ATPase
activating compounds promoted tau accumulation, and Hsp70 ATPase
inhibiting compounds promoted tau degradation in cell models of
tauopathy (Jinwal et al., 2009).

The co-chaperone CHIP, C-terminus of Hsc70 interacting protein,
is an E3 ligase that works with Hsp70 and Hsp90 to promote tau
degradation. CHIP reduces the ATPase activity of Hsp70, and helps
ubiquitinate misfolded proteins that are beyond the repair that
chaperones can provide (Xu et al., 2002). Congruent with the idea that
chaperones help misfolded proteins, CHIP levels are reduced in the
rTg4510 tau mouse model (Dickey et al., 2009). Moreover, knockout of
CHIP exacerbates tau accumulation (Dickey et al., 2006). However,
overexpression of CHIP enhances folding activity, not degratory
activity of Hsp70. On the other hand, Hsp72 overexpression was found

9

to reduce the levels of tau in a cell model (Jinwal et al., 2013), and a
mouse model (Petrucelli et al., 2004).

These studies demonstrate that all chaperones are not made
equal, and the exact circumstance that may lead to tau degradation
has to be worked out.

FKBP5 and Psychiatric Diseases

Mood and anxiety disorders in the elderly
The percentage of people with major depressive disorder and
other mood disorders does not increase with age. In fact,
approximately 1% of older adults meet the DSM-IV criteria for major
depression (Weissman et al., 1988). This is substantially lower than in
younger individuals. Generally, mood and anxiety disorders tend to
decrease with age, despite the brain having less regenerative power,
and a general decline in health (Byers et al., 2010). Nonetheless,
15-25% of the elderly population experience depressive symptoms
that interfere with their quality of life (Koenig and Blazer, 1992).
Depression is the most common disease in the elderly, according to
the American Psychiatric Association. This phenomenon can also be
attributed to different factors, like the cohort effect, survivor bias,
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sampling methods, and epidemiological and diagnostic issues in the
proper diagnosis of disease in the elderly (Byers et al., 2010). There is
also a tendency to underreport mood and anxiety disorders in the
elderly (Wiener et al., 1997). This is evident in the suicide statistics;
suicide rates increase steadily and culminates in old age . The general
decline of the body with age gives these individuals reduced ability to
recover if extreme trauma is experienced; 71-97% of older adult
suicide victims suffer from a psychiatric illness. In terms of population
growth, the giant baby boomer generation is quickly coming to a head,
as they are beginning to age past 65 years, a critical barrier for the
onset of age-related disorders. And although the percentage of ill
individuals may drop with age, the number of people with psychiatric
disorders aged 65 and older is only going to increase.

FKBP5
FKBP5 is a co-chaperone of the Hsp90 chaperone complex. The
Hsp90 machinery is part of all hormone receptors, including androgen,
estrogen, mineralocorticoid, and glucocorticoid receptor (GR). The
glucocorticoid receptor is of great importance because glucocorticoid
resistance is one of the most commonly observed irregularities in
mood disorders (Pariante and Miller, 2001). FKBP5 is a potent inhibitor
of GR, and is the cause of a naturally existing form of glucocorticoid
11

receptor insensitivity in several species of new world monkeys
(Reynolds et al., 1999; Denny et al., 2000; Scammell et al., 2001;
Wochnik et al., 2005; Westberry et al., 2006). In addition, there are
single nucleotide polymorphisms in the GR gene, NR3C1, that are
associated with major depression (van Rossum et al., 2006).

Discovery of SNPs in the FKBP5 gene
GR activity in the hypothalamus and pituitary is responsible for
the inhibition of the hypothalamic-pituitary-adrenal (HPA) axis that
produces glucocorticoids in response to a stressor (de Kloet et al.,
2005), creating a negative feedback loop. Since basal
hypercortisolemia is common in depression, Binder et al., 2004,
hypothesized that genes that regulate the HPA axis, especially those
modulating GR sensitivity, could contribute to the susceptibility of
developing depression. They performed a search for SNPs in the
NR3C1, BAG1, STUB1, TEBP, FKBP4, FKBP5, CRH, and AVP genes, and
found that although none of the SNPs were statistically significant,
they found that FKBP5 SNPs significantly associated with a faster
response to antidepressant treatment. In particular, they looked at the
SNP rs1360780. They genotyped depressed patients at this location in
the FKBP5 gene and found an overrepresentation of the TT genotype,
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which corresponds to people that inherited a thymidine at this location
from both parents, hence “TT.” Although a quicker response to an
antidepressant treatment is definitely a positive phenotype, these
patients also develop a staggering number of depressive episodes
throughout their life, as compared to other depressed individuals that
have the CT or CC genotypes. The TT individuals also produce excess
FKBP5.

After this initial discovery other studies began to emerge looking
at SNPs in the FKBP5 gene, and several more have been discovered
and found to be overrepresented in people who experience trauma and
develop major depressive disorder (Zimmermann et al., 2011), posttraumatic stress disorder (Binder et al., 2008), commit suicide (Roy et
al., 2010; Roy et al., 2012), display aggressive behavior (Bevilacqua et
al., 2012), and develop bipolar disorder (Willour et al., 2009).

Interestingly, the experience of trauma is highly important for
the development of psychiatric disease, as the majority of these
require it for the associations with the SNPs to be significant, as was
the case for depression. In fact, the mechanism for this has recently
been found (Klengel et al., 2012).
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Gene x environment in FKBP5
Gene times environment is the emergence of a phenotype based
on the combination of a predisposing genotype in an environment that
allows the phenotype to express (Meaney, 2010). SNPs that promote
smoking behavior, for example, require an environment where an
introduction to smoking is possible (Duncan and Keller, 2011). Due to
the ability of this interaction to apply a context to the otherwise
isolated genome, and its ability to explain natural phenomena, this
approach to research has become very popular in the last decade. This
applies to FKBP5 and GR, since they are stress reactive proteins. As a
result, the combination of stressful environments and genetics may
help explain why the same stressor produces disease in some but not
others.

Gene x environment works with FKBP5 and GR in the following
way. GR produces its effects by the combination of the transactivation
and transrepression of ~100 genes (de Kloet et al., 2005). One of the
genes that is transactivated is FKBP5 (Scharf et al., 2011). FKBP5
contains several hormone responsive element sequences, which allow
it to be activated by hormone receptor complexes, including the
progesterone and androgen receptor, in addition to GR (Barik, 2006).
As a result, GR activity has a built-in attenuation. In this way, FKBP5
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serves as a GR activity rheostat. People who hare homozygous for the
T allele of the FKBP5 SNP rs1360780, display greater FKBP5
expression (Binder et al., 2004). This single nucleotide change
increases the binding between the RNA polymerase II and the TATA
box, yielding higher FKBP5 transcription (Klengel et al., 2012). FKBP5
levels are further increased by stress. This increased level of FKBP5
protein allows for the increased production of glucocorticoids after
stress. However, glucocorticoids promote the demethylation of genes,
one of which is FKBP5. This, in turn, is a positive feedback loop that
begins with an SNP, which is small, and in combination with extended
traumatic stress starts a snowball effect that results in a epigenetic
change in the FKBP5 gene that may be permanent.

Why is FKBP5 relevant to aging
The risk that FKBP5 poses is even greater with age, because the
basal expression levels of FKBP5 increase in the human brain with age
(Blair et al., In Press). In fact, they increase age-dependently due to
the natural demethylation of the FKBP5 gene (Figure 1.2). As a result
of this, elderly people in general, even those without predisposing
SNPs, may be at greater risk for developing disease if they are
exposed to environments that are extremely traumatic. Elderly
individuals who are carriers of the risk alleles are at even greater risk
15

of developing disease from traumatic stress. As a result, it is
extremely important to better understand the role of FKBP5 in the
development of mood and anxiety disorders.

References

Abisambra JF, Blair LJ, Hill SE, Jones J, Kraft C, Rogers J, Koren J,
Jinwal UK, Lawson LY, Johnson AG, Wilcock D, O'Leary J, Jansen
K, Muschol M, Golde TE, Weeber EJ, Banko J, Dickey CA (2010)
Phosphorylation dynamics regulate Hsp27-mediated rescue of
neuronal plasticity deficits in tau transgenic mice. Journal of
Neuroscience.
Ballinger CA, Connell P, Wu Y, Hu Z, Thompson LJ, Yin LY, Patterson C
(1999) Identification of CHIP, a novel tetratricopeptide repeatcontaining protein that interacts with heat shock proteins and
negatively regulates chaperone functions. Molecular and cellular
biology 19:4535-4545.
Barik S (2006) Immunophilins: for the love of proteins. Cellular and
molecular life sciences : CMLS 63:2889-2900.
Barral JM, Broadley SA, Schaffar G, Hartl FU (2004) Roles of molecular
chaperones in protein misfolding diseases. Semin Cell Dev Biol
15:17-29.
16

Bevilacqua L, Carli V, Sarchiapone M, George DK, Goldman D, Roy A,
Enoch MA (2012) Interaction between FKBP5 and childhood
trauma and risk of aggressive behavior. Arch Gen Psychiatry
69:62-70.
Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, Tang
Y, Gillespie CF, Heim CM, Nemeroff CB, Schwartz AC, Cubells JF,
Ressler KJ (2008) Association of FKBP5 polymorphisms and
childhood abuse with risk of posttraumatic stress disorder
symptoms in adults. JAMA : the journal of the American Medical
Association 299:1291-1305.
Binder EB et al. (2004) Polymorphisms in FKBP5 are associated with
increased recurrence of depressive episodes and rapid response
to antidepressant treatment. Nat Genet 36:1319-1325.
Blair L, nordhues BA, Hill SE, Scaglione KM, O'Leary JC, 3rd, Fontaine
SN, Breydo L, Zhang B, Li P, Wang L, Cotman C, Paulson HL,
Muschol M, Uversky VN, Klengel T, Binder EB, Kayed R, Golde TE,
Berchtold N, Dickey CA (In Press) Accelerated neurodegeneration
through chaperone-mediated oligomerization of tau

Journal of

clinical investigation.
Brunden KR, Trojanowski JQ, Lee VM (2009) Advances in tau-focused
drug discovery for Alzheimer's disease and related tauopathies.
Nature reviews Drug discovery 8:783-793.
17

Byers AL, Yaffe K, Covinsky KE, Friedman MB, Bruce ML (2010) High
occurrence of mood and anxiety disorders among older adults:
The National Comorbidity Survey Replication. Arch Gen
Psychiatry 67:489-496.
Citron M (2010) Alzheimer's disease: strategies for disease
modification. Nature reviews Drug discovery 9:387-398.
Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J,
Kawas C, Aronson M, Wolfson L (1988) Clinico-pathologic studies
in dementia: nondemented subjects with pathologically
confirmed Alzheimer's disease. Neurology 38:1682-1687.
Daccache A, Lion C, Sibille N, Gerard M, Slomianny C, Lippens G,
Cotelle P (2011) Oleuropein and derivatives from olives as Tau
aggregation inhibitors. Neurochemistry international
58:700-707.
de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones
TL, Hyman BT (2010) Caspase activation precedes and leads to
tangles. Nature.
de Kloet ER, Joels M, Holsboer F (2005) Stress and the brain: from
adaptation to disease. Nat Rev Neurosci 6:463-475.
Denny WB, Valentine DL, Reynolds PD, Smith DF, Scammell JG (2000)
Squirrel monkey immunophilin FKBP51 is a potent inhibitor of
glucocorticoid receptor binding. Endocrinology 141:4107-4113.
18

Desai AK, Grossberg GT (2001) Recognition and Management of
Behavioral Disturbances in Dementia. Prim Care Companion J
Clin Psychiatry 3:93-109.
Dickey C, Kraft C, Jinwal U, Koren J, Johnson A, Anderson L, Lebson L,
Lee D, Dickson D, de Silva R, Binder LI, Morgan D, Lewis J
(2009) Aging analysis reveals slowed tau turnover and enhanced
stress response in a mouse model of tauopathy. Am J Pathol
174:228-238.
Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, Zehr C,
West G, Cao S, Clark AM, Caldwell GA, Caldwell KA, Eckman C,
Patterson C, Hutton M, Petrucelli L (2006) Deletion of the
ubiquitin ligase CHIP leads to the accumulation, but not the
aggregation, of both endogenous phospho- and caspase-3cleaved tau species. The Journal of neuroscience : the official
journal of the Society for Neuroscience 26:6985-6996.
Duncan LE, Keller MC (2011) A critical review of the first 10 years of
candidate gene-by-environment interaction research in
psychiatry. The American journal of psychiatry 168:1041-1049.
Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC,
Parisi JE, Hyman BT (1997) Neuronal loss correlates with but
exceeds neurofibrillary tangles in Alzheimer's disease. Ann
Neurol 41:17-24.
19

Hippius H, Neundorfer G (2003) The discovery of Alzheimer's disease.
Dialogues in clinical neuroscience 5:101-108.
Ittner LM, Gotz J (2011) Amyloid-beta and tau--a toxic pas de deux in
Alzheimer's disease. Nat Rev Neurosci 12:65-72.
Jinwal UK, Koren J, 3rd, Borysov SI, Schmid AB, Abisambra JF, Blair LJ,
Johnson AG, Jones JR, Shults CL, O'Leary JC, 3rd, Jin Y, Buchner
J, Cox MB, Dickey CA (2010) The Hsp90 cochaperone, FKBP51,
increases Tau stability and polymerizes microtubules. The Journal
of neuroscience : the official journal of the Society for
Neuroscience 30:591-599.
Jinwal UK, Miyata Y, Koren J, 3rd, Jones JR, Trotter JH, Chang L,
O'Leary J, Morgan D, Lee DC, Shults CL, Rousaki A, Weeber EJ,
Zuiderweg ER, Gestwicki JE, Dickey CA (2009) Chemical
manipulation of hsp70 ATPase activity regulates tau stability. The
Journal of neuroscience : the official journal of the Society for
Neuroscience 29:12079-12088.
Jinwal UK, Akoury E, Abisambra JF, O'Leary JC, 3rd, Thompson AD,
Blair LJ, Jin Y, Bacon J, Nordhues BA, Cockman M, Zhang J, Li P,
Zhang B, Borysov S, Uversky VN, Biernat J, Mandelkow E,
Gestwicki JE, Zweckstetter M, Dickey CA (2013) Imbalance of
Hsp70 family variants fosters tau accumulation. Faseb J
27:1450-1459.
20

Jonsson T et al. (2012) A mutation in APP protects against Alzheimer's
disease and age-related cognitive decline. Nature 488:96-99.
Ke YD, Suchowerska AK, van der Hoven J, De Silva DM, Wu CW, van
Eersel J, Ittner A, Ittner LM (2012) Lessons from tau-deficient
mice. Int J Alzheimers Dis 2012:873270.
Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante
CM, Pace TW, Mercer KB, Mayberg HS, Bradley B, Nemeroff CB,
Holsboer F, Heim CM, Ressler KJ, Rein T, Binder EB (2012) Allelespecific FKBP5 DNA demethylation mediates gene-childhood
trauma interactions. Nature neuroscience.
Koenig HG, Blazer DG (1992) Epidemiology of geriatric affective
disorders. Clin Geriatr Med 8:235-251.
Landes AM, Sperry SD, Strauss ME (2005) Prevalence of apathy,
dysphoria, and depression in relation to dementia severity in
Alzheimer's disease. J Neuropsychiatry Clin Neurosci
17:342-349.
Landes AM, Sperry SD, Strauss ME, Geldmacher DS (2001) Apathy in
Alzheimer's disease. J Am Geriatr Soc 49:1700-1707.
Lee HG, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA (2007)
Amyloid-beta in Alzheimer disease: the null versus the alternate
hypotheses. J Pharmacol Exp Ther 321:823-829.

21

Lindquist S (1986) The heat-shock response. Annu Rev Biochem
55:1151-1191.
Massey AC, Zhang C, Cuervo AM (2006) Chaperone-mediated
autophagy in aging and disease. Curr Top Dev Biol 73:205-235.
Meaney MJ (2010) Epigenetics and the biological definition of gene x
environment interactions. Child Dev 81:41-79.
Muchowski PJ (2002) Protein misfolding, amyloid formation, and
neurodegeneration: a critical role for molecular chaperones?
Neuron 35:9-12.
Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by
molecular chaperones. Nat Rev Neurosci 6:11-22.
Pariante CM, Miller AH (2001) Glucocorticoid receptors in major
depression: relevance to pathophysiology and treatment.
Biological psychiatry 49:391-404.
Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De
Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH,
Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B,
Hardy J, Hutton M (2004) CHIP and Hsp70 regulate tau
ubiquitination, degradation and aggregation. Human molecular
genetics 13:703-714.

22

Reynolds PD, Ruan Y, Smith DF, Scammell JG (1999) Glucocorticoid
resistance in the squirrel monkey is associated with
overexpression of the immunophilin FKBP51. J Clin Endocrinol
Metab 84:663-669.
Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T,
Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau
ameliorates amyloid beta-induced deficits in an Alzheimer's
disease mouse model. Science 316:750-754.
Robins Wahlin TB, Byrne GJ (2011) Personality changes in Alzheimer's
disease: a systematic review. Int J Geriatr Psychiatry
26:1019-1029.
Roy A, Gorodetsky E, Yuan Q, Goldman D, Enoch MA (2010)
Interaction of FKBP5, a stress-related gene, with childhood
trauma increases the risk for attempting suicide.
Neuropsychopharmacology : official publication of the American
College of Neuropsychopharmacology 35:1674-1683.
Roy A, Hodgkinson CA, Deluca V, Goldman D, Enoch MA (2012) Two
HPA axis genes, CRHBP and FKBP5, interact with childhood
trauma to increase the risk for suicidal behavior. Journal of
psychiatric research 46:72-79.

23

Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M,
Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue
M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton
M, Ashe KH (2005) Tau suppression in a neurodegenerative
mouse model improves memory function. Science 309:476-481.
Scammell JG, Denny WB, Valentine DL, Smith DF (2001)
Overexpression of the FK506-binding immunophilin FKBP51 is
the common cause of glucocorticoid resistance in three New
World primates. Gen Comp Endocrinol 124:152-165.
Scharf SH, Liebl C, Binder EB, Schmidt MV, Muller MB (2011)
Expression and regulation of the Fkbp5 gene in the adult mouse
brain. PloS one 6:e16883.
Sibille E (2013) Molecular aging of the brain, neuroplasticity, and
vulnerability to depression and other brain-related disorders.
Dialogues Clin Neurosci 15:53-65.
Soti C, Csermely P (2002) Chaperones and aging: role in
neurodegeneration and in other civilizational diseases.
Neurochemistry international 41:383-389.
Spires TL, Hyman BT (2005) Transgenic models of Alzheimer's disease:
learning from animals. NeuroRx 2:423-437.

24

St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins
PC, Myers RH, Feldman RG, Pollen D, Drachman D, et al. (1987)
The genetic defect causing familial Alzheimer's disease maps on
chromosome 21. Science 235:885-890.
van Rossum EF, Binder EB, Majer M, Koper JW, Ising M, Modell S,
Salyakina D, Lamberts SW, Holsboer F (2006) Polymorphisms of
the glucocorticoid receptor gene and major depression. Biological
psychiatry 59:681-688.
Weintraub S, Wicklund AH, Salmon DP (2012) The neuropsychological
profile of Alzheimer disease. Cold Spring Harb Perspect Med
2:a006171.
Weissman MM, Leaf PJ, Tischler GL, Blazer DG, Karno M, Bruce ML,
Florio LP (1988) Affective disorders in five United States
communities. Psychol Med 18:141-153.
Westberry JM, Sadosky PW, Hubler TR, Gross KL, Scammell JG (2006)
Glucocorticoid resistance in squirrel monkeys results from a
combination of a transcriptionally incompetent glucocorticoid
receptor and overexpression of the glucocorticoid receptor cochaperone FKBP51. J Steroid Biochem Mol Biol 100:34-41.
Wiener P, Alexopoulos GS, Kakuma T, Meyers BS, Rosenthal E, Chester
J (1997) The limits of history-taking in geriatric depression. Am J
Geriatr Psychiatry 5:116-125.
25

Willour VL, Chen H, Toolan J, Belmonte P, Cutler DJ, Goes FS, Zandi PP,
Lee RS, MacKinnon DF, Mondimore FM, Schweizer B, DePaulo JR,
Jr., Gershon ES, McMahon FJ, Potash JB (2009) Family-based
association of FKBP5 in bipolar disorder. Molecular psychiatry
14:261-268.
Wochnik GM, Ruegg J, Abel GA, Schmidt U, Holsboer F, Rein T (2005)
FK506-binding proteins 51 and 52 differentially regulate dynein
interaction and nuclear translocation of the glucocorticoid
receptor in mammalian cells. J Biol Chem 280:4609-4616.
Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L (2002)
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a
degradative pathway for c-ErbB2/Neu. Proceedings of the
National Academy of Sciences of the United States of America
99:12847-12852.
Zimmermann P, Bruckl T, Nocon A, Pfister H, Binder EB, Uhr M, Lieb R,
Moffitt TE, Caspi A, Holsboer F, Ising M (2011) Interaction of
FKBP5 Gene Variants and Adverse Life Events in Predicting
Depression Onset: Results From a 10-Year Prospective
Community Study. The American journal of psychiatry.

26

CHAPTER TWO 1:

Phenothiazine-Mediated Rescue of Cognition in Tau Transgenic
Mice Requires Neuroprotection and Reduced Soluble Tau
Burden

Abstract

Background
It has traditionally been thought that the pathological
accumulation of tau in Alzheimer's disease and other tauopathies
facilitates neurodegeneration, which in turn leads to cognitive
impairment. However, recent evidence suggests that tau tangles are
not the entity responsible for memory loss, rather it is an intermediate
tau species that disrupts neuronal function. Thus, efforts to discover
1

This work was previously published in the journal Molecular
Neurodegeneration (O'Leary III, John C., et al. "Phenothiazinemediated rescue of cognition in tau transgenic mice requires
neuroprotection and reduced soluble tau burden." Molecular
neurodegeneration 5.1 (2010): 1-11), and is used here with
permission of the publisher. The permissions are available in Appendix
F.
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therapeutics for tauopathies emphasize soluble tau reductions as well
as neuroprotection.

Results
Here, we found that neuroprotection alone caused by methylene
blue (MB), the parent compound of the anti-tau phenothiaziazine drug,
Rember™, was insufficient to rescue cognition in a mouse model of the
human tauopathy, progressive supranuclear palsy (PSP) and frontotemporal dementia with parkinsonism linked to chromosome 17
(FTDP17): Only when levels of soluble tau protein were concomitantly
reduced by a very high concentration of MB, was cognitive
improvement observed. Thus, neurodegeneration can be decoupled
from tau accumulation, but phenotypic improvement is only possible
when soluble tau levels are also reduced.

Conclusions
Neuroprotection alone is not sufficient to rescue tau-induced
memory loss in a transgenic mouse model. Development of
neuroprotective agents is an area of intense investigation in the
tauopathy drug discovery field. This may ultimately be an unsuccessful
approach if soluble toxic tau intermediates are not also reduced. Thus,
MB and related compounds, despite their pleiotropic nature, may be
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the proverbial "magic bullet" because they not only are
neuroprotective, but are also able to facilitate soluble tau clearance.
Moreover, this shows that neuroprotection is possible without reducing
tau levels. This indicates that there is a definitive molecular link
between tau and cell death cascades that can be disrupted.

Introduction

The current clinically available options for treating Alzheimer’s
disease (AD) are limited to acetylcholinesterase inhibitors and NMDA
receptor antagonists (Doody, 1999; Reisberg et al., 2003). For
tauopathies like PSP and FTDP17, treatment is restricted to supportive
therapies. Thus the demand to identify compounds that can remove
the microtubule associated protein tau is extremely high.

Modifying tau pathophysiology has been the primary goal of
first-generation tau therapeutics. For example, kinase inhibitors
(Mazanetz and Fischer, 2007), microtubule stabilizers (Zhang et al.,
2005), tau aggregation inhibitors , immunotherapy (Sigurdsson,
2009), and chaperone-based drugs targeting disease-specific tau
species (Dickey et al., 2007), have all been proposed based largely on
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in vitro data. However, their efficacy for ameliorating cognitive deficits
in mouse models of tauopathy have not been tested, primarily due to
the fact that few models of tau accumulation are available that develop
memory loss. One of the more controversial tau modifying compounds,
to recently emerge as a potentially clinically relevant drug, is the
phenothiazine methylthionium chloride better known as methylene
blue (MB). MB is best known for its function in the laboratory as a
redox indicator and as an antiseptic (Oz et al., 2009); however, it,
along with other phenothiazine derivatives, have been used
extensively in the clinic since the 1950’s to treat a number of different
conditions, including schizophrenia, mania, anxiety, emesis, cancer,
high blood pressure, allergies and even parasitic infections (Mosnaim
et al., 2006). These compounds are generally well tolerated and have
minimal side effects, including discoloration of urine and ocular
vitreous.

More recently MB has been shown to inhibit the aggregation
propensity of proteins that can adopt a ß-sheet conformation in vitro
(Medina et al.; Taniguchi et al., 2005; Necula et al., 2007), and it was
this property that critically linked MB to AD as a possible plaque or
tangle buster. However, the propensity of the phenothiazines to
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liberally bind to proteins and donate electrons has resulted in a
number of other mechanisms being ascribed to them. For example, MB
can regulate mitochondrial function (Hassan and Fridovich, 1979;
Visarius et al., 1997) and inhibit Hsp70 ATPase activity (Deiana et al.,
2009; Jinwal et al., 2009). Interestingly, these pleiotropic mechanisms
and clinical applications combined with its relatively innocuous side
effects and high bioavailability are what make the phenothiazines such
an interesting therapeutic option for tauopathies. Most of the outcomes
ascribed to MB could converge to ameliorate symptoms associated
with tau accumulation. Here, we sought to determine whether MB
could potentially be beneficial as a therapeutic option for tauopathies,
based on its pleiotropic anti-tau efficacy, we investigated how its
chronic administration might impact the rTg4510 tau transgenic mice.
We show that MB is capable of protecting neurons, however, only high
dose MB treatment was able to reduce tau and also improve cognition.
However, pathology was unaffected. This shows that MB does not
reduce tau pathology, but reduces soluble tau levels. Also, it shows
that neuroprotection alone is not sufficient to improve behavior, but
only when MB levels are sufficiently high to reduce soluble tau levels
can memory be improved.

31

Materials & Methods

Mice
The rTg4510 mice and parental mutant tau and tTA lines were
generated and maintained for this study as previously described
(Santacruz et al., 2005).

Central administration
A concentration of 1 mM MB in saline was infused by pump into
the CA3 of the right hippocampus of rTg4510 mice. Alzet pumps
(Model 1004, 100µL, 0.11 µl/hr; Alzet Osmotic Pumps) were filled with
100 µl of 1 mM MB or with saline 0.9% . The pumps were incubated in
0.9% saline at 37°C for 48 hr. Mice were operated in a stereotaxic
apparatus (51725D, Stoelting, Wood Dale, IL). A mid-sagittal incision
was made to expose the cranium and a small aperture was drilled with
a dental tool over the right hippocampus to the following coordinates
from bregma: anterior-posterior, -2.7 mm; lateral, -2.5 mm. The
osmotic pump was inserted into a subcutaneous pocket on the back of
the mouse, leading the catheter to the site of cannula (Brain infusion
kit 3, Alzet) placement. The cannula, with a thin layer of cyanoacrylate
(Loctite 454, Alzet), was attached to the stereotaxic cannula holder
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(Cannula holder 51636, Stoelting) and then lowered 3 mm ventral
through the midline aperture. The incision was cleaned with saline and
closed with surgical sutures. After surgery, the mice were housed
individually. Infusion lasted for 28 days. Six mice were administered
with MB and 7 with Saline. The mice were 7 months old at the time of
surgery and they were 7 months and three weeks old at the time of
water maze testing.

Peripheral administration
Ten age and gender-matched rTg4510 mice and ten wild type
littermates were administered MB (Sigma) and saccharine (Acros
Organics, Geel, Belgium) in their drinking water, while another ten
rTg4510 mice and ten wild type littermates received drinking water
with saccharine only. A treatment of 650 mg/day in a 70 kg human
equates to 9.3 mg/kg/day. Based on a 4.5 ml of water/day rate of
consumption of a 30 g mouse, ad libitum, we estimated mice to
receive 9.3 mg/kg/day (0.062 mg/ml). MB or vehicle administration
was initiated in 12 week-old rTg4510 and wild type mice using drinking
water supplemented with 2mM saccharine. Treatment was maintained
for four months and the supplemented water was replaced three times
per week. Mice were 6 months old at the time of initial behavioral
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assessment and they were 6.5 months old at the time of the water
maze analysis. During the course of the study one mouse died of
unknown circumstances and drug, tau levels and stereological
analyses were not able to measured.

Determination of methylene blue concentrations in the
cerebellum
Frozen brain tissue was thawed on ice and homogenized for 2
minutes at a concentration of 100 mg/ml in homogenizing solution
(ACN:PBS = 9:1). A 30 µL aliquot of the brain homogenate was added
to a 1.5 mL polypropylene microcentrifuge tube and spiked with 30 µL
of the internal standard solution (Methylene Violet 3RAX, 250 ng/ml).
Analytical grade acetonitrile was then added (90 µL) and the sample
was vortexed again for 30 s. Following high speed centrifugation at
13,200 rpm for 10 minutes at 4°C, the supernatant was transferred to
a glass vial and subjected to LC-MS analysis. The LC-MS system used
for these studies was a Shimadzu (Columbia, MD) series 2010EV
instrument equipped with an APCI probe to minimize ion suppression.
Quantification was performed using LCMSolution Version 2.05 and a
set of external standards.
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Open field
The open field is used as a standard test of general activity.
Animals are monitored for 15 minutes in a 40 cm square open field
with a video tracking software (ANY-Maze, Stoelting, Illinois), under
moderate lighting. General activity levels were evaluated by
measurements of horizontal and vertical activity.

Rotorod test
This test was performed on an accelerating rotorod apparatus
(Ugo Basile, Italy) with a 3cm diameter rod starting at an initial
rotation of 4 RPM accelerating to 40 RPM over 5 minutes. Mice were
tested for the time spent on the rod during each of four trials with a
thirty-minute inter-trial interval. Each trial was completed when the
mouse fell off the rod (distance of 12 cm) onto a spring-cushioned
lever.

Elevated plus maze.
Anxiety can be assessed through the elevated plus maze
(EPM).The EPM consists of two well-lit open arms (35 cm) facing each
other and two enclosed arms (30.5 cm) also facing each other. Each
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arm is attached to a common center platform (4.5 cm square) and
elevated 40 cm off the floor. The mouse is placed in the center
platform and allowed to explore for 5 min. Video tracking software
measures movement in each section (ANY-Maze, Stoelting, Illinois).
MWM. A circular pool (1.38-m diameter) filled with opaque water at
room temperature with an escape platform (15 cm x 15 cm) hidden
beneath the water level (3 cm) was used. Each mouse was given four
trials per day with an intertribal interval of 1 hour for 6 consecutive
days. The time to find the platform (escape latency), the total distance
traveled and the swim speed of the animals was recorded. Each animal
was given a maximum of 60 seconds to find the platform. During
training, if the mice failed to find the platform after 60 seconds, they
were placed on the platform for 30 seconds. They were then toweldried and placed in a cage with a heating pad underneath until dry and
returned to their home cage. On day 7 the mice were subject to one
probe trial in which the platform was removed and each animal had 60
seconds to search the training pool for the platform.
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Brain tissue fractionation and western blot analysis
Brain tissue was homogenized as previously described (Dickey et
al., 2006). Measurements of tau levels were performed by western blot
analysis.

Immunohistochemistry
Fixed mouse brains were cryoprotected in successive 24 hours
incubations of 10%, 20%, and 30% solutions of sucrose and then
sectioned as previously described [Gordon, 2002]. Stained sections
were imaged using an Olympus BX51 microscope at original 40x,
100x, or 200x final magnification. For quantification, images (original
100x magnification) of cornu ammonis (CA)1, CA3, entorhinal cortex,
cortex and dentate gyrus were taken using spatial orientation cues.
Quantification of positive staining product was determined using
Image-Pro Plus (Media Cybernetics, Silver Springs, MD). Nissl staining
was done in 0.05% cresyl violet for 5 minutes followed by
differentiation in acidic water until desired color. Tissue was
dehydrated through a graded series of ethanol (75%, 95% and
100%). Slides were cleared in Histoclear (xylene substitute) and cover
slipped with DPX. Silver stain was performed as previously described
(Lewis et al., 2000).
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Stereological analysis
Neurons that were stained with cresyl violet were counted in the
the cornu ammonis 1 (CA1), the cornu ammonis 2 and 3 (CA2+3), the
dentate gyrus (DG), the cerebral cortex (CX) and the striatum (STR)
using the optical fractionator method of stereological counting (West et
al., 1991) with commercially available stereological software
(StereoInvestigator, MBF Bioscience, Williston, VT). A systematic
random sampling of sections throughout the left hemibrain were
stained as described above and coded to ensure blinding. The regions
of interests (ROI) were defined using specific landmarks within the
brain to maintain consistency. A grid was placed randomly over the
region of interest slated for counting. At regularly predetermined
positions of the grid, cells were counted within three-dimensional
optical dissectors. Within each dissector, a 1µm guard distance from
the top and bottom of the section surface was excluded. Section
thickness was measured regularly on all collected sections to estimate
the mean section thickness for each animal after tissue processing and
averaged 35.24 µm ± 0.46 µm for all sections analyzed. The total
number of neurons was calculated using the equation:
N = Q- x 1/ssf x 1/asf x 1/hsf
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where N is total neuron number, Q- is the number of neurons counted,
ssf is section sampling fraction, asf is the area sampling fraction and
hsf is the height sampling fraction. Tissue from one mouse in the MBtreated rTg4510 cohort was unusable for this study. Therefore, n=8 for
this group.

Antibodies
Tau antibodies S202/T205 and MC1 were provided by Dr. Peter
Davies, Albert Einstein College of Medicine; total tau antibody was
purchased from Stantacruz Biotech, Stantacruz, CA. Horseradish
peroxidase conjugated secondary antibodies were obtained from
Southern Biotech, Birmingham, AL. Glyceraldehyde-3-phosphate
dehydrogenase antibody was obtained from Meridian Life Science,
Saco, ME.

Statistical analysis
Statistical analysis comparing 2 groups was done using an
unpaired, two tailed t-test. Analysis comparing more than 2 groups
was done using a one-way analysis of variance (ANOVA) with the
Tukey-Kramer post-hoc test. Analysis of three or more groups during
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different time points (water maze learning and rotorod) was done
using repeated measures 2-way ANOVA with the Bonferroni post-hoc
test. Statistical analysis was done in the GraphPad Prism software.

Results & Discussion

Previously, biochemical analyses of hippocampal tissue from tau
transgenic mice [rTg4510; (Santacruz et al., 2005)] injected with MB
showed reduced tau levels after 24 hours (Jinwal et al., 2009).
Hippocampi of wild type mice were then injected with either 1mM or
0.1mM MB [based on a recent study in Zebrafish (van Bebber et al.,
2010)] to determine its effective therapeutic window for reducing tau
levels. Only 1mM MB reduced tau levels (Figure 2.1 A). Based on these
results, 1mM MB (1mM; n=6) or saline (n=7) was administered to the
right hippocampi (Smith and Milner, 1981) of 7-month old rTg4510
mice for 1 month using mini-osmotic pump implantation (Figure 2.1
B). The accumulation of soluble mutant human tau in the forebrain of
this model causes spatial memory deficits as early as 3 months of age,
which precede neuronal loss (Santacruz et al., 2005). Morris water
maze (MWM) during the final week of treatment revealed that MBtreated mice showed significant improvements in learning the location
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of the escape platform compared to those receiving saline (Figure 2.1
C). Probe trial analysis using target quadrant discrimination, number of
platform crossings and search strategy imaging showed significantly
improved cognitive recall in MB-treated mice compared to those
treated with saline (Figure 2.1 D-F). Biochemical analysis of
hippocampal lysates showed that both phosphorylated (S202/T205)
and total tau levels were significantly reduced (Figure 2.2 A&B). Thus,
despite the focal distribution of osmotic pump administration and the
age of the mice, MB was still able to improve cognitive function; an
effect that was concomitant with reductions in hippocampal tau levels.
Contrastingly, pathology was unaffected (Figure 2.2 C&D).
Furthermore, nissl staining was done in order to determine if any
damage was done to the hippocampus due to pump implantation. No
such damage was found (Figure 2.2 E&F).

Based on this evidence, a new trial was initiated in rTg4510 mice
to test the effects of long-term MB administration not only on behavior
and tau biochemistry, but also on neuronal survival and tau pathology.
Practical limitations with osmotic pump applications required that this
study be done using non-invasive peripheral administration. Dose
selection for this study was based on two factors: 1) FDA conversion
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tables show that a 10 mg/kg dose in a mouse is equivalent to ~1 mg/
kg in humans, which is within the range of current MB clinical
applications (FDA, 2005; Walter-Sack et al., 2009), and 2)
pharmacokinetic analyses showed that MB could concentrate in the
brain 500-fold, making the effective concentration (>100µM) possible
(Figure 2.3 A&B).

Thus, two groups (n=10) of 3 month-old rTg4510 mice and two
groups of 10 wild type littermates received either ~10 mg/kg (165µM;
5x maximum recommended dose) of MB via drinking water
supplemented with 2mM saccharine or saccharine water alone (Figure
2.4 A). Following 12 weeks of treatment, behavioral assessment
showed no overt alterations in motor coordination or task acquisition
(See Appendix A: Figure A1). MWM was then used to assess cognitive
function. Probe trial analysis and search strategy imaging showed that
MB, but not saccharine, prevented the significant progressive
impairment in target quadrant discrimination that is a hallmark of the
rTg4510 phenotype (Figure 2.4 B&C). Furthermore, wild type
littermates showed normal spatial memory recall irrespective of MB
treatment (for visible trial and swim speed see Figure A3). Biochemical
analyses of half-brain homogenates (excluding cerebellum) showed a
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reduction in soluble tau levels in some mice, but not others (Fig.
5A,B). Histochemical analyses revealed no change in tau pathology in
any mice (Figure 2.5 C&D).

Given the variability in behavioral performance as well as
reductions in tau levels, we hypothesized that the MB concentration in
the brain may have also varied due to the ad libitum administration
strategy. To test this idea, brain concentrations of MB were assessed
using LC-MS analysis of the cerebellar tissue from these mice. Indeed,
MB concentration was positively correlated with MWM performance
(p<0.05) and was inversely correlated with soluble tau levels (p<0.05)
(Figure 2.6 A&B). The differences in brain MB concentration between
mice could not be attributed to body weight or gender (See Appendix
A: Figure A2). Moreover, mice with >470µM MB brain concentration
accounted for a preponderance of the effects on memory function and
tau reductions, consistent with our previous results showing that very
high concentrations of MB were required for anti-tau efficacy (Figure
2.1 A). Surprisingly, stereological assessment of five different brain
regions from these mice showed that MB treatment significantly
delayed neurodegeneration by ~30% in all forebrain regions of all
rTg4510 mice (Figure 2.6 C), but neuronal number failed to correlate
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with memory performance or soluble tau levels (Figure 2.6 D, and data
not shown).

Post-hoc analysis of the behavioral performances of rTg4510
mice with brain MB concentrations above or below ~470µM (High [MB]
or Low [MB], respectively), elucidated that the High [MB] cohort
performed equivalent to wild type mice, while the Low [MB] cohort was
significantly impaired (Figure 2.7 A). We again used the cameratracking software to map the areas of the pool most traversed by each
cohort (Figure 2.7 B). High [MB] rTg4510 mice were predominantly
found in the target quadrant, while the Low [MB] cohort displayed an
unguided search strategy. Furthermore, we wanted to see if MB
treatment in the High [MB] mice had an effect on motor learning. The
mice were subjected to the rotorod task for two days and the latency
to fall onto a spring-cushioned lever was measured. We found that
motor learning from day 1 to day 2 of MB treated rTg4510 was
significantly improved, dissimilar to the saccharine treated rTg4510
analogs (Figure 2.7 C).
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Conclusion

In conclusion, these findings are consistent with recent evidence
showing that reducing tangle burden does not beget functional
recover(de Calignon et al.; Santacruz et al., 2005; Spires-Jones et al.,
2008); however, the unexpected result that neuroprotection is
insufficient to preserve cognitive function suggests that preventing
neuronal loss may not be enough to alter cognitive deficits in
tauopathies either. In fact, it was only when soluble tau levels are
reduced in the brain that functional recovery was observed. Moreover,
these data show that there is a link between tau and cell death
signaling cascades that can be altered with therapeutics since
neurodegeneration can be decoupled from tau accumulation with MB.
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Figure 2.1. Direct hippocampal infusion of methylene blue by
mini-osmotic pump reverses spatial navigation related learning
and memory deficits by reducing tau levels in rTg4510 mice. (A)
Four groups of wild type mice (n=3) were injected with 100 µM MB, 1
mM MB, or saline into the hippocampus for 24 hours. Western blot
from hippocampal lysates show reductions in tau at 1 mM MB in
phospho- and total tau. (B) Experimental design of central
administration of MB (MB central n=6, saline central n=7). (C) Infusion
of MB increased ability of rTg4510 mice to learn the location of the
hidden platform in the MWM, **p<0.01). (D) Probe trial of Morris
water maze shows that MB treated rTg4510 mice were able to
recognize the target from the opposite quadrant, unlike saline treated
rTg4510 mice, (F(3,20)=8.202, p=0.0009), ***p<0.001. (E) Number
of crossing across the area where the hidden platform was located
during training. (F (7, 44) = 2.757, p=0.0183), p<0.05. (F) Search
strategy imaging using a camera tracking system shows that MB
treated rTg4510 mice have a more focused strategy than saline treated
rTg4510 mice.
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Figure 2.2. MB treatment reduces tau levels, but does not affect
pathology in mice with pre-existing tangle formation and
neurodegeneration. (A) Western blot analysis of tau protein levels
from hippocampal lysates. (B) Quantitation of the optical density as a
percentage of saline treated rTg4510 mice shows a significant
difference in pS202/T205 and total tau levels, *p<0.05. (C)
Representative images of the Gallyas silver stain. (D) Percentage of
area of silver positive staining shows no statistical difference between
the means (n=2 per group). (E) Representative images of the staining
of neuronal nissl substance in the ipsilateral side of drug infusion (right
hippocampus). (F) Quantitation of the percent area positive for nissl
staining of ipsilateral versus the contralateral brain side of each group
of mice shows that there is no detectable neuron loss due to pump
implantation.
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moderate effect in behavior. (A) Experimental design, n=10. (B)
Percent of time spent in each quadrant during the probe trial of MWM
(F (15,144) = 8.781, p<0.0001). MB rTg4510 recognize target versus
opposite quadrant (F (3,36) = 3.38, p = 0.0286) (* p<0.05,). (C)
Search strategy imaging using a camera tracking system.
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Figure 2.6. Chronic dosing of methylene blue enhances
neuronal survival. (A) Parenchymal drug concentrations correlated
significantly with memory retention in the probe trial of MWM
p=0.016, Pearson r=0.766, r2=0.587. (B) Tau levels inversely
correlate significantly with parenchymal drug concentration, p<0.05,
Pearson r=-0.6724, r2=0.452. (C) Number of neurons counted in five
regions as a percentage of sacc treated rTg4510 (MB treated rTg4510
n=8, sacc treated rTg4510 n=10) (DG stands for dentate gyrus, CX
stands for cortex and STR stands for striatum). (D) Number of neurons
does not correlate significantly with time spent in the target quadrant.

63

B

A
Trained
80

Opposite

***

40
20
0

High

Low

High

rTg4510

Low [MB]

wt

High [MB]
rTg4510

C
**

300

***

***

200

1

ay

ay
D

ay
D 1
ay
2
D
ay
D 1
ay
2
D
ay
D 1
ay
2

0

2

100

D

Low

D

[MB]

Time (s)

% Time

***

**

60

Figure 2.7

64

High [MB] rTg4510
Sacc rTg4510
MB wt
Sacc wt

Figure 2.7. High concentrations of MB repair spatial and motor
memory deficits. (A) Post-hoc analyses reveal that High [MB]
rTg4510 mice (n=5) perform similar to wild-type MB treated mice,
while Low [MB] rTg4510 mice (n=4) did not display memory retention.
Wild type mice performed similarly regardless of MB (F (7,30) =
10.64, p<0.0001) (**p<0.01, ***p<0.001). (B) Camera tracking
software imaging of MB treated rTg4510 mice divided by low and high
parenchymal MB concentrations. (C) Motor learning was assessed by
comparing the average latency to fall from the rotorod apparatus of
day 1 with the average of day 2. High [MB] rTg4510 mice (n=5) learn
better than saccharine treated rTg4510 (n=10). Wild Type groups,
n=10 (**p<0.01, ***p<0.001).
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CHAPTER THREE2:

A New Anti-Depressive Strategy for the Elderly: Ablation of
FKBP5/FKBP51

Abstract

The gene FKBP5 codes for FKBP51, a co-chaperone protein of the
Hsp90 complex that increases with age. Through its association with
Hsp90, FKBP51 regulates the glucocorticoid receptor (GR). Single
nucleotide polymorphisms (SNPs) in the FKBP5 gene associate with
increased recurrence of depressive episodes, increased susceptibility to
post-traumatic stress disorder, bipolar disorder, attempt of suicide, and
major depressive disorder in HIV patients. Variation in one of these
SNPs correlates with increased levels of FKBP51. FKBP51 is also
2

This work was previously published in the journal PLoS One
(O'Leary III, John C., et al. "A new anti-depressive strategy for the
elderly: ablation of FKBP5/FKBP51." PloS one 6.9 (2011): e24840),
and is used here with permission of the publisher. The permissions are
available in Appendix F.
66

increased in HIV patients. Moreover, increases in FKBP51 in the
amygdala produce an anxiety phenotype in mice. Therefore, we tested
the behavioral consequences of FKBP5 deletion in aged mice. Similar
to that of naïve animals treated with classical antidepressants FKBP5−/
− mice showed antidepressant behavior without affecting cognition
and other basic motor functions. Reduced corticosterone levels
following stress accompanied these observed effects on depression.
Age-dependent anxiety was also modulated by FKBP5 deletion.
Therefore, drug discovery efforts focused on depleting FKBP51 levels
may yield novel antidepressant therapies.

Introduction

Genes regulating the hypothalamus-pituitary-adrenal (HPA) axis
are associated with susceptibility to depression as well as
antidepressant efficacy (Binder et al., 2004; Liu et al., 2006; van
Rossum et al., 2006). The HPA axis has a well-characterized role as a
regulator of the neuroendocrine stress response (Lupien et al., 2009).
Its activation leads to the production of glucocorticoids in the adrenal
axis, of which the major constituent in humans is cortisol and in
rodents is corticosterone. Over the past decade, genome wide
association studies for single nucleotide polymorphisms (SNPs)
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revealed significant associations between susceptibility to depressive
episodes and variants in both the NR3C1, that encodes the
glucocorticoid receptor (GR), and FKBP5, that encodes a GR binding
protein thought to attenuate GR activity (Lahti et al.; Binder et al.,
2004). While most studies have focused on the variants in GR because
of its role as a transcriptional regulator (Derijk et al., 2008), the
involvement of FKBP5 and its gene product, FKBP51, have received
little attention.

This is largely due to uncertainty about how to

approach this relatively unknown protein. In fact, it remains to be
proven whether FKBP51 is a valid therapeutic target for treating
depression, despite its clear genetic link.

Since the initial discovery of the association between FKBP5
SNPs and depression, other psychiatric disorders have been found to
be associated with FKBP5 SNPs including PTSD (Xie et al., 2010),
bipolar disorder (Willour et al., 2009), anxiety (Binder, 2009),
peritraumatic dissociation (Koenen et al., 2005), and major depression
in HIV patients (Tatro et al., 2010). The TT variant of the rs1360780
SNP was associated with both an increased incidence of depressive
episodes throughout a carrier’s lifetime, and increased sensitivity to
common neurotransmitter-based anti-depressants (Binder et al.,
2004). Interestingly, individuals with the rs1360780 TT SNP had
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significantly higher FKBP51 protein levels in their lymphocytes. FKBP51
levels are also elevated in patients with HIV infection, perhaps playing
a role in the depression that commonly occurs with chronic highly
active antiretroviral therapies (HAART)(Tatro et al., 2009). Recently,
stress was shown to induce neuropsin activity in the amygdala,
inducing anxiety in mice through an FKBP51-dependent mechanism
(Attwood et al., 2011). How FKBP51 directly modulates GR has been
investigated in vitro. In these systems, increases in FKBP51 levels
decreased GR activation by lowering GR affinity for glucocorticoid
(Binder, 2009). In new world monkeys FKBP51 has been shown to be
the cause of glucocorticoid resistance, but this has yet to be shown
using a genetic in vivo model (Denny et al., 2005; Westberry et al.,
2006).

While the causes of major depressive disorders are unknown,
there is an emerging genetic diathesis for its occurrence within genes
regulating the HPA axis; however few animal models have been
developed or utilized for aetiologic validation studies. Genetic variation
in FKBP51 appears to be one factor that facilitates liability to anxiety
and mood disorders.

Thus, the goal of this study was to determine

whether decreasing FKBP51 expression could make mice less
susceptible to inducible “depression-like” states through a
69

corticosterone-dependent mechanism in vivo in well established
models with high predictive value (Frazer and Morilak, 2005). Indeed,
aged FKBP5-deficient mice were resistant to stress-induced
depressive-like behavior. Moreover, despite robust hippocampal and
forebrain expression patterns, deletion of FKBP5 did not result in
cognitive impairment or other behavioral abnormalities. Circulating
levels of corticosterone in the same FKBP5-/- mice were also reduced
after stress, confirming the proposed mechanism previously described
(Binder, 2009). These data suggest that not only is FKBP51 a valid
therapeutic target, but targeting this protein may also have minimal
consequences for other behavioral characteristics.

Materials & Methods

Generation of FKBP5-/- mice
By PCR screening the 129SvJ mouse BAC library (Genome
Systems, St. Louis, MO), bacterial artificial chromosome (BAC) clones
that contained genomic regions for FKBP5 were isolated. Restriction
fragments were subcloned into pBluescript (pBS; Stratagene, La Jolla,
CA) or pZero (Invitrogen, Carlsbad, CA) cloning vectors. The PCR
products were amplified from the BAC clones and were then used to
construct a targeting vector in the pPGKneo vector (a generous gift of
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James Lee, Mayo Clinic Scottsdale). The targeting vector contained a
beta-galactosidase/neomycin cassette flanked by regions homologous
to the FKBP5 gene and was recombined to remove all of exon 2, which
is the first coding exon. ES cells were isolated from the 129SvJ mouse
and cultured in Knockout DMEM media (Invitrogen) supplemented with
10% FBS, penicillin/streptomycin, essential amino acids, and ESGRO
(103 U/ml; Chemicon, Temecula, CA) with irradiated embryonic
fibroblast feeder cells. The ES cells were then electroporated at 0.2 kV,
950µF (Gene Pulser II; Bio-Rad, Hercules, CA) with linearized targeting
vectors and selected with G418. DANN from G418-resistant clones was
isolated for Southern blot analysis. A DNA probe was used to
distinguish PstI restriction fragments from wild-type (~7.5 kb) and
mutant (~10 kb) alleles. Appropriate homologous recombination in ES
cell clones was confirmed by PCR using primers complementary to
sequences within the neomycin cassette and to 3’ FKBP5 sequences
downstream from the recombination site. ES cell clones containing a
mutant FKBP5 allele were injected into C57BL/6 blastocysts and
implanted into pseudopregnant 129SvJ females. Chimeric offspring
were identified by coat patterns and mated to C57BL/6 mice to obtain
germline transmission of the mutant allele. For colony maintenance
mice were crossed from C57BL6 onto Swiss-Webster for purposes of
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fecundity and genetic diversity to be more representative of a human
population.

Brain tissue fractionation and western blot analysis
Brain tissue fractionation and western blot analysis were done as
previously described (Dickey et al., 2006).
PCR. mRNA was isolated and purified from the brain of four wild type
and four FKBP5-/- mice using RNAeasy kit (QIAGEN, Valencia, CA).
cDNA was synthesized from isolated mRNA by reverse transcription
using Super Script III First-Strand cDNA Sythesis Kit (Invitrogen,
Carlsbad, CA) from 50ng of isolated mRNA. PCR was performed with
synthesized cDNA and FKBP5 specific primers to confirm presence or
absence of FKBP5 gene.

Antibodies
Horseradish peroxidase conjugated secondary antibodies
(Southern Biotech, Birmingham, AL), Glyceraldehyde-3-phosphate
dehydrogenase antibody (Meridian Life Science, Saco, ME), AntiFKBP51 was provided by Drs. David F. Smith and Marc Cox (Mayo
Clinic, Scottsdale, AZ).
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Immunohistochemistry
Fixed mouse brains were processed for sectioning as previously
described (Gordon et al., 2002). β-galactosidase staining was
performed using the in situ β-gal staining kit (Stratagene, La Jolla,
CA).

Behavior
N=9 unless otherwise noted. Video tracking software was used in
several tests (ANY-Maze, Stoelting, Illinois).
Open Field. Animals were monitored for 15 min in an open field with
video tracing software.

Rotorod test
Testing started at an initial rotation of 4 rpm accelerating to 40
rpm over 5 min.

Mice were tested for 4 trials per day, for 2

consecutive days with a 30-min intertrial interval. Latency to fall from
the rod onto a spring-cushioned lever was measured.
Morris water maze (MWM). Mice were trained to locate an escape
platform hidden beneath the water (3 centimeter).

Each mouse was

given 4 trials per day with an intertrial interval of 1 hour for
6 consecutive days.

Each animal was given 60 seconds to find the

platform. Afterwards the mice were placed on the platform for 30 s. On
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day 7, mice were subjected to a trial in which the platform was
removed, and had 60 s to search for it.

Associative fear conditioning
Two mild foot shocks (0.5 milliamps) were paired with an
auditory conditioned stimulus (CS, white noise, 70 decibels) within a
novel environment. The CS was given for 30 s before each foot shock
(2 s). Twenty-four hours later, the mice were placed in the chamber
and monitored for freezing for 3 min (no shocks or CS). Immediately
after the test, mice were placed into a novel context for 3 min without
CS and then exposed to the CS for 3 min (cued).
Prepulse Inhibition (PPI). Mice were placed in a restrainer (Panlab,
Barcelona Spain) and placed inside a sound attenuation chamber. The
test consisted of 7 trial types in pseudorandom order: 1) 40 ms, 120
decibels sound burst (startle); 2-6) 5 different acoustic prepulses 100
ms in length, a 20 ms duration at 74, 78, 82, 86, and 90 dB; 7) no
stimulus for baseline measurement . The intertrial interval was 15 s.
The startle response peak was measured within a second after the
stimulus.
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Elevated plus maze (EPM)
EPM consisted of 2 open arms facing each other and two
enclosed arms also facing each other.

Each arm is attached to the

center platform and elevated 40 centimeters off the floor. The mouse
was placed on the platform and allowed to explore for 5 min.

Video

tracking software measured movement.

Porsolt forced swim test (FST)
Each mouse was placed in a 45 centimeters high and 20
centimeters diameter clear Plexiglas cylinder filled with room
temperature water to a depth of 12 centimeters for 6 min. Amount of
time spent immobile was recorded.

Tail suspension test (TST)
Mice were suspended from their tail for 6 min. Amount of time
spent immobile was recorded.

Novel object
Mice were placed in an area with two objects similar in scale to
the mouse. Each animal was given 3 acclimation trials of 5 min with a
5-min intertrial interval. Then one acclimated object was replaced with
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a novel object. Animals were given a 5-min exploratory trial monitored
by video recording.

Y-maze
Animals were started at the center of the Y and allowed to
explore for 8 min. Each session was video-monitored. The number of
arm entries was recorded. The percent of spontaneous alternation was
calculated as the number of triads containing entries into all three
arms divided by the maximum possible of alternations (total number
of entries minus 2).

Corticosterone assay, blood collection and stress paradigm
The levels of corticosterone were measured using an ELISA kit
(Enzo Life Sciences, Plymouth Meeting, PA). Blood from mice was
collected in the morning one hour after the light cycle began and 30
min after a 10-min tube restraint using the submandibular vein
puncture method.

Statistics
The student’s t-test was used to compare 2 groups. The paired ttest was used to compare paired observations within 2 groups. The 2way RMANOVA was used to compare the interaction between two
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dependent variables and an independent variable. All error bars
represent standard error of the mean.

All animal procedures were approved by the Institutional Animal
Care and Use Committee (IACUC).

Results

FKBP5-/- mice were used to determine the effect of gene
deletion on behavior. The mice contain a β-galactosidase reporter
cassette, which expresses wherever the FKBP5 gene is normally
expressed. To confirm gene knockout and establish cerebral
distribution of FKBP51, tissue from 5.5 and 20-month-old FKBP5-/mice was stained using an X-gal kit that produces a blue product when
β-galactosidase is present. An age-dependent increase in β-gal
expression was observed particularly in the upper cortical layers of the
forebrain (Figure 3.1 A). This was consistent with the age-dependent
increase in FKBP51 expression that had been previously reported in
normal mice (Jinwal et al., 2010). To confirm the absence of FKBP51
protein, whole brain homogenates were analyzed by immunoblot and
probed using an FKBP51 antibody. No detectable FKBP51 was observed
(Figure 3.1 B). To verify that FKBP51 mRNA was absent, oligo d(T) RT77

PCR was performed using reverse transcriptase to produce cDNA. No
FKBP5 PCR product was detected in the FKBP5-/- mice, confirming that
no FKBP51 mRNA was present (Figure 3.1 C).
FKBP5-/- mice aged 17-20 months were submitted to two
behavioral models of depressive-like activity; the classical forced swim
test (FST) and the tail suspension test (TST) (Porsolt et al., 1977;
Steru et al., 1985).

Results from these tests are based on the total

time spent immobile over a 6-minute period, interpreted as despair.
These tests are typical for assessing antidepressant efficacy (Steru et
al., 1985). Aged FKBP5-/- mice displayed a shorter immobility time
than their wild type counterparts (Figure 3.1 D&E). The weight,
activity, and physical fitness of the mice were evaluated to account for
possible confounding factors, but these variables did not contribute to
the effect (Figure 3.1 F-H).

Stress causes increased levels of cortisol in humans and
depressed patients have higher-than-normal levels of cortisol in the
blood (Burke et al., 2005). The dexamethasone-corticotropin releasing
hormone (DEX-CRH) test, a commonly used tool to detect HPA system
changes, has been used to link depressive behavior with glucocorticoid
receptor (GR) insensitivity (Holsboer et al., 1987). To determine if
FKBP5 deletion was altering glucocorticoid levels, circulating
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corticosterone levels were assessed in the same aged cohort of
FKBP5-/- mice that were used for behavioral analyses. Early morning
blood draws were collected from both FKBP5-/- and wild type
littermates before and 30 minutes after being placed in a restrainer for
10 minutes. Levels of basal corticosterone were predictably low,
consistent with previous reports showing low levels of corticosterone
production in the earliest part of the murine diurnal cycle (Kakihana
and Moore, 1976)(Figure 3.1 I). After stress corticosterone levels rose
in both wild type and FKBP5-/- mice, but this induction was attenuated
in the FKBP5-/- mice. These findings suggest that the lack of FKBP51
permits unrestrained GR transcription activity, which decreases HPAaxis activity and corticosterone levels, improving resilience to
depressive-like behavior.

However, untoward consequences of FKBP51 ablation were a
distinct possibility given the ubiquitous expression of FKBP51
throughout the brain. Given the high levels of expression of FKBP5 in
the hippocampus (Figure 3.1 A) memory formation was assessed.
Therefore, short-term memory in the FKBP5-/- mice was tested with
the use of the novel object recognition and Y-maze paradigms. Both
tests are performed in a short period of time to capture the working
memory ability of the mice. Neither test showed statistically significant
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differences between FKBP5-/- and wild type littermates (Figure 3.2
A&B). Long-term spatial memory function was then tested using the
Morris water maze (MWM). Memory retention was tested 24 hours
after the training was completed.

The training phase of the MWM

displayed that wild type and FKBP5-/- mice were equally capable of
learning the location of a hidden platform (Figure 2C). Moreover wild
type and FKBP5-/- mice displayed an equivalent capacity to locate the
hidden platform 24 hours after training (Figure 2D-2E).

The amygdala controls emotional learning in the brain and
FKBP5 expression can be upregulated by GR activation (Scharf et al.,
2011). As a consequence, function of the amygdala could be affected
by FKBP5 deletion. To test the impact of FKBP5-/- on emotionally
derived memory function, a fear-conditioning paradigm was employed.
In this test, a tone played for 30 seconds is followed by a small foot
shock. Thus the animal learns to associate the tone with the shock.
The amygdala-associated fear response caused by the tone is able to
bypass the hippocampus once the association is made, allowing for
assessment of emotionally driven memory formation. Surprisingly, no
differences between wild type and FKBP5-/- mice were observed in
either contextual (environmentally-based) or cued (tone-based) fear
conditioning paradigms (Figure 2F-2H). These findings suggest that
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neither spatially nor emotionally driven long-term memory is affected
by FKBP5 deletion. In addition to these learning and memory tasks, no
observable differences between wild type and FKBP5-/- mice were
noted in tasks designed to assess activity, motor performance, motor
coordination, motor learning, hearing, or prepulse inhibition, which
measures startle response inhibition (Figure 3.3).

Brain-specific knockout of GR in mice reduces anxiety (Tronche
et al., 1999). Also, FKBP51 expression was recently correlated to
anxious behavior (Attwood et al., 2011). Based on this and the novel
link now established between FKBP51, GR activity and glucocorticoid
production, the effects of FKBP5 deletion on anxiety were tested. The
longitudinal impact of FKBP5 deletion on anxiety was assessed in mice
aged 11-14 months and then again in the same mice aged 18-22
months using the elevated plus maze (EPM).

A repeated measures

two-way analysis of variance was conducted to examine the effect of
time and genotype on anxiety. The behavioral correlates of anxiety in
the EPM were significantly affected by age, and this change depended
on the genotype at FKBP5 as reflected by a significant age*genotype
interaction, F(1,14)=6.71, p=0.02 (Figure 3.4 A&B). Indeed, in wild
type mice behavioral correlates of anxiety decreased with age,
whereas they appeared to increase in FKBP5-/- mice. To further
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examine whether anxiety was indeed being modified in these mice, the
18-22 month-old mice were subjected to the light-dark chamber
paradigm, which is another standard measure of anxiety. The mice
were allowed to explore between a well-lit and unprotected area and a
dark covered area that the mice had access to through a small
opening. Normal mice typically move to the dark chamber. The lightdark maze did not reveal any statistical differences between the
groups (Figure 3.4 C-E). These data suggest that suppression of
FKBP51 may have a differential effect on anxiety depending on the
developmental stage; however, the effect is not pervasive enough to
manifest itself through several indices of anxiety.

Discussion

Major depression is a devastating disease with a course that is
frequently chronic or recurrent and affects millions of people.
Research in the last decade has shown that variation in the FKBP5
gene is associated with depression and several other mood and anxiety
disorders. And although in vitro data suggests the possibility of a
causal relationship between FKBP5 expression levels and depression,
this has never been tested in vivo. Here we show for the first time that
ablation of FKBP5 in mice led to reduced immobility in two behavioral
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models that are routinely used to assess anti-depressant efficacy. This
behavioral effect coincided with attenuation of corticosterone
production after a stressful episode. Moreover, no defects in
locomotion, somato-sensation or learning and memory were observed.
Thus, therapies developed to reduce FKBP51 levels may be highly
efficacious as next generation anti-depressants. Furthermore, because
FKBP51 ablation results in reduced anxiety-like behavior in mice
(Attwood et al., 2011), we provide experimental support for the notion
that genetically-driven variations in expression of FKBP51 may underlie
susceptibility to anxiety and mood disorders, as suggested by
association studies in humans (Binder et al., 2004; Binder, 2009).
FKBP51 is a peptidyl-prolyl cis-trans isomerase (PPIase) enzyme that
also associates with the chaperone Hsp90 and is distributed
ubiquitously throughout the brain. This isomerase activity is thought to
be important for structural rearrangements and phosphorylation
dynamics of client proteins bound by Hsp90. Several diseases in
addition to psychiatric conditions have implicated FKBP51 as having a
role in their pathogenesis. These include prostate cancer (Ni et al.),
and neurodegenerative diseases, specifically tauopathies (Jinwal et al.,
2010). In fact, these effects on tau may somehow be tied to the
manifestation of these psychiatric conditions. Indeed, depleting
FKBP51 levels was shown to also reduce tau levels, while inhibiting its
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PPIase activity actually lead to increased stability of phosphorylated
tau. Thus it is certainly possible that FKBP51 is involved in Alzheimer’s
disease progression, since one of its earliest clinical features is
depression. More recently, the extracellular protease neuropsin was
shown to mediate anxiety-like behavior via an FKBP51 dependent
mechanism (Attwood et al., 2011). Thus, an important role for FKBP51
in maintaining proper brain function is emerging. Its relationship with
major depressive disorder in HIV, bipolar disorder and possibly anxiety
and Alzheimer’s disease further underlie its significance.
Current treatment for depression includes the use of medications that
extend the amount of time neurotransmitters are present in the
synaptic cleft including serotonin, norepinephrine, and dopamine. It is
estimated that 60-70% of patients reach remission with the use of
anti-depressant drugs (Rush et al., 2006). These low rates of efficacy
have prompted research into other potential therapeutic targets in the
HPA axis, particularly GR. However, there are many different isoforms
of GR, making selective targeting with compounds challenging.
Therefore, the results presented here show that FKBP51 may be the
most appropriate target for treating depression via the modulation of
the HPA axis in terms of its risk/benefit equation and potential
therapeutic window. Also, and most noteworthy, because FKBP51 may
act on the genetic liability to abnormal mood and anxiety states, it
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may provide a much needed treatment tool for secondary prophylaxis
of depression recurrence and relapse.

Acknowledgments
We would like to acknowledge Dr. David F. Smith for antibodies
and for the FKBP5-/- mice, and the following grants NIH R01NS073899
and R00AG031291, Alzheimer’s association IIRG-09-130689 and
NIRG-10-174517, Rosalinde and Arthur Gilbert New Investigator
Awards in Alzheimer's Disease/AFAR and Irene and Abe Pollin Fund for
Corticobasal Degeneration Research/CurePSP.

References

Attwood BK, Bourgognon JM, Patel S, Mucha M, Schiavon E, Skrzypiec
AE, Young KW, Shiosaka S, Korostynski M, Piechota M,
Przewlocki R, Pawlak R (2011) Neuropsin cleaves EphB2 in the
amygdala to control anxiety. Nature.
Binder EB (2009) The role of FKBP5, a co-chaperone of the
glucocorticoid receptor in the pathogenesis and therapy of
affective and anxiety disorders. Psychoneuroendocrinology 34
Suppl 1:S186-195.

85

Binder EB et al. (2004) Polymorphisms in FKBP5 are associated with
increased recurrence of depressive episodes and rapid response
to antidepressant treatment. Nat Genet 36:1319-1325.
Burke HM, Davis MC, Otte C, Mohr DC (2005) Depression and cortisol
r e s p o n s e s t o p s yc h o l o g i c a l s t r e s s : a m e t a -a n a l y s i s .
Psychoneuroendocrinology 30:846-856.
Denny WB, Prapapanich V, Smith DF, Scammell JG (2005) Structurefunction analysis of squirrel monkey FK506-binding protein 51, a
potent inhibitor of glucocorticoid receptor activity. Endocrinology
146:3194-3201.
Derijk RH, van Leeuwen N, Klok MD, Zitman FG (2008) Corticosteroid
receptor-gene variants: modulators of the stress-response and
implications for mental health. Eur J Pharmacol 585:492-501.
Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, Zehr C,
West G, Cao S, Clark AM, Caldwell GA, Caldwell KA, Eckman C,
Patterson C, Hutton M, Petrucelli L (2006) Deletion of the
ubiquitin ligase CHIP leads to the accumulation, but not the
aggregation, of both endogenous phospho- and caspase-3cleaved tau species. J Neurosci 26:6985-6996.
Frazer A, Morilak DA (2005) What should animal models of depression
model? Neuroscience and biobehavioral reviews 29:515-523.

86

Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW,
Connor K, Melachrino J, O'Callaghan JP, Morgan D (2002) Time
course of the development of Alzheimer-like pathology in the
doubly transgenic PS1+APP mouse. Exp Neurol 173:183-195.
Holsboer F, von Bardeleben U, Wiedemann K, Muller OA, Stalla GK
(1987) Serial assessment of corticotropin-releasing hormone
response after dexamethasone in depression. Implications for
pathophysiology of DST nonsuppression. Biological psychiatry
22:228-234.
Jinwal UK, Koren J, 3rd, Borysov SI, Schmid AB, Abisambra JF, Blair LJ,
Johnson AG, Jones JR, Shults CL, O'Leary JC, 3rd, Jin Y, Buchner
J, Cox MB, Dickey CA (2010) The Hsp90 cochaperone, FKBP51,
increases Tau stability and polymerizes microtubules. J Neurosci
30:591-599.
Kakihana R, Moore JA (1976) Circadian rhythm of corticosterone in
mi ce: the effect of chroni c consumpti on of al cohol .
Psychopharmacologia 46:301-305.
Koenen KC, Saxe G, Purcell S, Smoller JW, Bartholomew D, Miller A,
Hall E, Kaplow J, Bosquet M, Moulton S, Baldwin C (2005)
Polymorphisms in FKBP5 are associated with peritraumatic
dissociation in medically injured children. Molecular psychiatry
10:1058-1059.
87

Lahti J, Raikkonen K, Bruce S, Heinonen K, Pesonen AK, Rautanen A,
Wahlbeck K, Kere J, Kajantie E, Eriksson JG Glucocorticoid
receptor gene haplotype predicts increased risk of hospital
admission for depressive disorders in the Helsinki birth cohort
study. J Psychiatr Res.
Liu Z, Zhu F, Wang G, Xiao Z, Wang H, Tang J, Wang X, Qiu D, Liu W,
Cao Z, Li W (2006) Association of corticotropin-releasing
hormone receptor1 gene SNP and haplotype with major
depression. Neuroscience letters 404:358-362.
Lupien SJ, McEwen BS, Gunnar MR, Heim C (2009) Effects of stress
throughout the lifespan on the brain, behaviour and cognition.
Nature reviews Neuroscience 10:434-445.
Ni L, Yang CS, Gioeli D, Frierson H, Toft DO, Paschal BM FKBP51
promotes assembly of the Hsp90 chaperone complex and
regulates androgen receptor signaling in prostate cancer cells.
Molecular and cellular biology 30:1243-1253.
Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal
model sensitive to antidepressant treatments. Nature
266:730-732.

88

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW,
Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD,
McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J,
Fava M (2006) Acute and longer-term outcomes in depressed
outpatients requiring one or several treatment steps: a STAR*D
report. The American journal of psychiatry 163:1905-1917.
Scharf SH, Liebl C, Binder EB, Schmidt MV, Muller MB (2011)
Expression and regulation of the Fkbp5 gene in the adult mouse
brain. PloS one 6:e16883.
Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension
test: a new method for screening antidepressants in mice.
Psychopharmacology 85:367-370.
Tatro ET, Nguyen TB, Bousman CA, Masliah E, Grant I, Atkinson JH,
Everall IP (2010) Correlation of major depressive disorder
symptoms with FKBP5 but not FKBP4 expression in human
immunodeficiency virus-infected individuals. Journal of
neurovirology 16:399-404.
Tatro ET, Everall IP, Masliah E, Hult BJ, Lucero G, Chana G,
Soontornniyomkij V, Achim CL (2009) Differential expression of
immunophilins FKBP51 and FKBP52 in the frontal cortex of HIVinfected patients with major depressive disorder. J Neuroimmune
Pharmacol 4:218-226.
89

Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, Bock R,
Klein R, Schutz G (1999) Disruption of the glucocorticoid
receptor gene in the nervous system results in reduced anxiety.
Nature genetics 23:99-103.
van Rossum EF, Binder EB, Majer M, Koper JW, Ising M, Modell S,
Salyakina D, Lamberts SW, Holsboer F (2006) Polymorphisms of
the glucocorticoid receptor gene and major depression. Biological
psychiatry 59:681-688.
Westberry JM, Sadosky PW, Hubler TR, Gross KL, Scammell JG (2006)
Glucocorticoid resistance in squirrel monkeys results from a
combination of a transcriptionally incompetent glucocorticoid
receptor and overexpression of the glucocorticoid receptor cochaperone FKBP51. J Steroid Biochem Mol Biol 100:34-41.
Willour VL, Chen H, Toolan J, Belmonte P, Cutler DJ, Goes FS, Zandi PP,
Lee RS, MacKinnon DF, Mondimore FM, Schweizer B, DePaulo JR,
Jr., Gershon ES, McMahon FJ, Potash JB (2009) Family-based
association of FKBP5 in bipolar disorder. Molecular psychiatry
14:261-268.
Xie P, Kranzler HR, Poling J, Stein MB, Anton RF, Farrer LA, Gelernter J
(2010) Interaction of FKBP5 with childhood adversity on risk for
post-traumatic stress disorder. Neuropsychopharmacology
35:1684-1692.
90

5.5 Mo. FKBP5-/-

A

B

FKBP5+/+

20 Mo. FKBP5-/-

C

FKBP5-/-

Actin

Tail Suspension

*

Forced Swim

E

150
100
50
0

wt

150
100
50
0

FKBP5-/-

G

60

**

200

Time Immoble (s)

Time immoble (s)

200

F

FKBP5-/-

FKBP51

FKBP51
Actin

D

FKBP5+/+

wt

FKBP5-/-

wt

FKBP5-/-

250

Latency (s)

Mass (g)

200

40

20

150
100
50

H

wt

I

Distance (cm)

5000
4000
3000
2000
1000
0

0

FKBP5-/-

wt

FKBP5-/-

Serum corticosterone (ng/mL)

0

Figure 3.1
91

***
FKBP5-/-

300

200

wt
FKBP5-/-

100

0

Basal

Stress

Figure 1. FKBP5-/- mice display resistance to depression
inducing stimulus. (A) Representative images of β-gal staining in
horizontal brain slices of 5.5 and 20 month old FKBP5-/- mice. (B)
Western blot analysis of wild type and FKBP5-/- whole brain
homogenates. (C) FKBP5 primer-specific PCR of cDNA synthesized
from brain-isolated mRNA by reverse transcription. (D) Total time
immobile in the tail suspension test. (E) Total time immobile in the
forced swim test. (F) No significant difference was observed between
mass measurements of groups. (G) Latency to fall from a gradually
accelerating rotorod apparatus displays no difference between groups.
(H) Activity levels in the open field display no differences between
groups. (I) Levels of corticosterone in serum right before a 10-minute
tube restraint and 30 minute after (wt n=5, FKBP5-/- n=6). * p<0.05,
** p<0.01.
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no tone
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360
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Figure 2. Deletion of the FKBP5 gene does not alter learning
and memory despite robust expression of FKBP5 in the
hippocampus. (A) Discrimination index between familiar and novel
object in the novel object recognition test. (B) Percent of spontaneous
alternation shows no difference between the groups. (C) Learning of
the location of the hidden platform in the MWM (interaction
F(5,80)=0.14, p=0.98; genotype F(1,16)=0.0, p=0.98; time
F(5,80)=12.71, p<0.0001) . (D) Percent time spent in quadrant during
the probe trial of MWM. (E) Software generated heat plot representing
amount of time spent in an area. (F) Percent freezing during training
portion of fear conditioning (interaction F(6,90)=1.32, p=0.26;
genotype F(1,15)=0.01, p=0.92; time F(6,90)=14.35, p<0.0001). (G)
Percent freezing during contextual exposure to fear-conditioning
chamber. (H) Percent freezing during the cued fear-conditioning test.
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Figure 3.3. Behavioral characterization of FKBP5-/- mice. (A)
Distance traveled in the open field test. (B) Assessment of motor
learning from comparison between the average of all four trials of
rotorod from day one with those of day two. (C) Latency to fall from
the rotorod apparatus. (D) Percent inhibition of startle response by
increasing prepulse intensity. (E) Comparison of no pulse (no tone)
with a 120 dB pulse (tone) to test hearing.
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Figure 3.4. Age-associated changes in anxious behavior in
FKBP5-/- mice. (A) Time spent in the arms of the EPM as a
percentage of the control group (wt and FKBP5-/- 11-14 mo. n=9, wt
and FKBP5-/- 18-21 mo. n=8). (B) Number of entries into the arms of
the EPM as a percentage of control. (C) Time spent in the areas of the
dark-light chamber (wt n=8, FKBP5-/- n=8). (D) Number of entries
into the areas of the dark-light chamber (wt n=8, FKBP5-/- n=8). (E)
Software generated heat plot representing amount of time spent in
area. *p<0.05, **p<0.01, ***p<0.001.
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CHAPTER FOUR:

FKBP5-/- Enhances Cognitive Flexibility, and Protects From Age
and Genotype Dependent Loss of Resilience.

Abstract

The ability to respond effectively to, and recuperate from
stressful events is a key aspect of survival, and emotional health.
However, it is not clear if there is a reduction in stress resiliency with
age, and particularly, how age-related changes in gene expression in
the Hypothalamic-Pituitary-Adrenal axis modulate the response to
stress. Moreover, there is a relationship between memory and
resiliency, but it is not known how. In particular, it is not known if
there are proteins that regulate resiliency and memory. Here we show
that wild type mice display decreased stress resiliency with age in the
tail suspension test, a behavioral pattern of resignation and loss of
effort that can be modulated with antidepressants. They also display
greater serum corticosterone levels after stress with age. The FKBP5
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gene, which codes for a hypothalamic-pituitary-adrenal-axis regulating
protein, may be partly responsible for this age-dependent decrease in
resiliency, as FKBP5-/- mice display protection from stress and age
induced despair. Deletion of this protein provides wild type mice with
greater cognitive flexibility in the reversal of the 6 radial arm water
maze. In addition, the absence of this protein is not deleterious to the
lifespan or healthspan of the mice, suggesting that this gene is a
possible therapeutic target for stress and aging induced psychiatric
disease.

Introduction

Resilience is the ability to recover and to spring back into shape
after difficulties, to have elasticity (Russo et al., 2012). Although there
are myriad environmental factors that have been shown to help
patients recover from traumatic events, like strong social networks
(Ozbay et al., 2007; Ozbay et al., 2008), positive outlook (Black and
Lobo, 2008; Schmiege et al., 2011), and access to mental health
professionals (Dowrick et al., 2009), several biological factors have
also been found to be involved in resiliency, like patterns of brain
activity (Shin et al., 2005), signaling molecules (Morgan et al., 2000),
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genes (Binder et al., 2008), and epigenetic mechanisms (Klengel et al.,
2012).

Several genes have been singled out for their effect on stress
resiliency in animals and humans, and one of them is the FK506Binding Protein 5 (FKBP5) (O'Leary et al., 2011; Touma et al., 2011;
Hartmann et al., 2012). People who experience childhood trauma, like
physical and sexual abuse, who carry certain FKBP5 single nucleotide
polymorphisms (SNPs), are predisposed to develop PTSD (Binder et
al., 2008), major depressive disorder (MDD) (Zimmermann et al.,
2011), and suicide (Brent et al., 2010; Roy et al., 2010; Supriyanto et
al., 2011; Roy et al., 2012). One particular SNP, rs1360780, has been
shown to increase the levels of FKBP5 in the cell and cause longlasting epigenetic effects that further increase FKBP5 levels, providing
a plausible mechanism for gene x environment interactions (Binder et
al., 2004; Klengel et al., 2012). In mice, knockdown of FKBP5 in the
amygdala produces an anxiolytic effect after stress (Attwood et al.,
2011), and global knockout of this gene increases resiliency to the
forced swim, tail suspension (O'Leary et al., 2011; Touma et al.,
2011), and chronic social defeat stress (Hartmann et al., 2012). FKBP5
is expressed widely throughout the brain, but its role has been mostly
studied within the Hypothalamic-Pituitary-Adrenal (HPA) axis (Barik,
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2006). It is a regulator of the glucocorticoid receptor (GR), as it
reduces the affinity of glucocorticoids for the GR, negatively impacting
its activity (Reynolds et al., 1999; Denny et al., 2000; Scammell et al.,
2001; Denny et al., 2005; Wochnik et al., 2005). GR activity is
extremely important protein, as global knockout of the gene is lethal
perinatally (Cole et al., 1995). In particular, GR is responsible for the
shut-off of the HPA-axis (Tasker and Herman, 2011). Consequently, by
inhibiting the GR, FKBP5 allows for the HPA-axis to be turned on for a
longer period of time, producing greater amounts of glucocorticoids.
Hyperglucocorticoidism is common in depression (Herbert, 2013), and
it is also linked to the perception of anguish during stress. A study that
subjected active duty personnel to 24 hours of U.S. Navy survival
school stress, revealed that distress perception was significantly
correlated to cortisol expression (Morgan et al., 2002).

However, what happens to our emotional elasticity as we age?
Although very little is known about the longitudinal effects of
resiliency, research in the aging brain suggests that it is more
susceptible to neurodegenerative and psychiatric diseases, with
Alzheimer’s and depression in particular (Sibille, 2013). This leads to
the speculation that the brain has reduced resiliency with age.
Moreover, several of the disease processes involved in aging,
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neurodegeneration, and mental illness, share pathological
commonalities like inflammation, dysfunction in the HPA axis, and
metabolic syndrome. This makes it conceivable that age-dependent
gene expression may play an important role.

Memory, like resilience, is also modulated by age, emotion, and
stress, and may play a role in resilience. An overactive amygdala has
been shown as a feature of PTSD (Shin et al., 2011). Presumably,
excessive amygdaloid activity enhances emotional memory formation,
increasing the effect of a traumatic event. Another protein involved in
resiliency, anxiety, and psychiatric disorders, NPY, has also been
implicated in the acquisition, consolidation and extinction of memory
(Lach and de Lima, 2013). Conceivably, memory strength is important
for emotional processing of events. FKBP5 is expressed in virtually all
of the brain regions involved with memory. In particular, the
hippocampus, the amygdala, and prefrontal cortex (O'Leary et al.,
2011; Scharf et al., 2011). However, a previous study showed no
impact in the ability to form new memories in the FKBP5-/- mice
(O'Leary et al., 2011).

FKBP5 has recently been found to be expressed age-dependently
in humans and mice. This, in combination with its stress inducement
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and the clinical studies implicating it with disease, places FKBP5 in a
unique position to be capable of being an age-dependent enabler for
reduced stress resiliency. In addition, its role in resiliency and its
topography in the brain indicate a possibility of altered memory
processing, since FKBP5 is present in all the regions of the brain that
handle memory. Here, we aged C57BL/6 mice and longitudinally tested
their ability to respond to the forced swim and tail suspension tests.
We found that wild type mice display reduced resiliency in the tail
suspension test with age, and the FKBP5-/- mice display increased
resiliency due to genotype and aging. Moreover, the FKBP5-/- display
reduced serum corticosterone after stress at all ages, and the wild
type mice produce increased serum corticosterone after stress with
age. Additionally, the FKBP5-/- mice display greater cognitive
flexibility, as they learn the reversal of the hidden platform faster than
the wild type mice. Moreover, the FKBP5-/- mice have equal rates of
survival as wild type mice up to 800 days. These data suggest that
FKBP5-/- is beneficial for resiliency and cognitive flexibility, and that
reduction of FKBP5 is a promising therapeutic strategy.

104

Materials & Methods

FKBP5-/- mice
The mice have been generated as previously described (O'Leary
et al., 2011) (Touma et al., 2011). Briefly, by PCR screening, the
129SvJ mouse BAC library (Genome Systems, St. Louis, MO), and the
bacterial artificial chromosome (BAC) clones that contained genomic
regions for FKBP5 were isolated. Restriction fragments were subcloned
into pBluescript (pBS; Stratagene, La Jolla, CA) or pZero (Invitrogen,
Carlsbad, CA) cloning vectors, and the PCR products were amplified
from the BAC clones, which were then used to construct a targeting
vector in the pPGKneo vector (a generous gift of James Lee, Mayo
Clinic Scottsdale). The targeting vector contained a betagalactosidase/neomycin cassette flanked by regions homologous to the
FKBP5 gene. Due to the size of the protein it is more practical to
partially delete the gene. Consequently, when the targeting vector
integrates into the chromosome through homologous recombination it
removes all of exon 2, which is the first coding exon. Since the only
deleted portion of the gene is exon 2, the expression of the betagalactosidase protein is dependent on the FKBP5 promoter and
transcription machinery, and expresses in frame with the initiation
codon. ES cells were isolated from the 129SvJ mouse and cultured in
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Knockout DMEM media (Invitrogen) supplemented with 10% FBS,
penicillin/streptomycin, essential amino acids, and ESGRO (103 U/ml;
Chemicon, Temecula, CA) with irradiated embryonic fibroblast feeder
cells. The ES cells were then electroporated at 0.2 kV, 950 µF (Gene
Pulser II; Bio-Rad, Hercules, CA) with linearized targeting vectors and
selected with G418. DNA from G418-resistant clones was isolated for
Southern blot analysis, and a DNA probe was used to distinguish PstI
restriction fragments from wildtype allele (~7.5 kb) and targeting
vector (~10 kb). Appropriate homologous recombination in ES cell
clones was confirmed by PCR using primers complementary to
sequences within the neomycin cassette and to 3′ FKBP5 sequences
downstream from the recombination site. ES cell clones containing the
targeting vector were injected into C57BL/6 blastocysts and implanted
into pseudopregnant 129SvJ females. Chimeric offspring were
identified by coat patterns and mated to C57BL/6 mice to obtain
germline transmission of the targeting vector. For colony maintenance
mice were crossed from C57BL6 onto Swiss-Webster for purposes of
fecundity and genetic diversity to be more representative of a human
population.
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Porsolt forced swim test (FST)
This test was performed as previously published (O'Leary et al.,
2011). Each mouse was placed in a tall (45 centimeters high and 20
centimeters diameter) clear Plexiglas cylinder filled with room
temperature water to a depth of 12 centimeters for a total of 6
minutes. The total time immobile was measured. Any immobility
episode below two seconds was not used towards the total.

Tail suspension test (TST)
Each mouse was suspended from the tail for 6 minutes. The total
time spent immobile was measured. Any immobility episode below two
seconds was not used towards the total.

Radial arm water maze
A six arm apparatus was placed inside a black painted pool, filled
with 10 cm of water. The pool was close to the room’s walls for queue
visibility. The hidden platform was located in a different arm for each
mouse (goal arm), and the arm in which they were placed at the
beginning of each trial (start arm) was changed every trial. Each
mouse had 60 seconds to find the hidden platform in any given trial.
The number of incorrect arm entries and the escape latencies were
recorded. An entry is considered as such when all four limbs have
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entered the arm. An error was also scored when the mouse did not
choose an entry for 15 sec. If the mouse did not find the platform after
1 minute, the mouse was gently guided to and placed on it.
Afterwards, the mouse was kept on the platform for 15 seconds. The
mice were towel dried and placed under a heat lamp to dry completely.
On day one, trial one through twelve alternated between visible and
hidden platforms, and trial thirteen through fifteen were performed
using the hidden platform only. A total of fifteen trials a day were
performed. On day two, only the hidden platform was used. On day
four, a goal arm reversal was performed, where the hidden platform
was placed in the directly opposite arm. The same procedure was
repeated for the revearsal, for a total of six days of training: three
days for initial platform training and three days for retraining. This
protocol is based on a previously published one (Alamed et al., 2006).

Corticosterone assay, blood collection and stress paradigm
The levels of corticosterone were measured using an ELISA kit
(Enzo Life Sciences, Plymouth Meeting, PA). Blood from the mice was
collected in the morning one hour after the light cycle began and 30
min after a 10-min tube restraint using the submandibular vein
puncture method.
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Glucose challenge
Mice were fasted overnight. The next morning they were injected
with a 2g/kg dose of sucrose (Sigma) into the peritoneum. Blood drops
were collected and analyzed in a standard glucometer at baseline, 30,
75, and 120 minutes after injection.

Western blotting and tissue processing
Western blotting was performed as previously described (Dickey
et al., 2006). Briefly, mouse brain samples were homogenized in lysis
buffer containing 50 mM Tris-HCl pH 8.0, 274 mM NaCl, 5 mM KCl,
phosphatase inhibitor cocktail I (Sigma), phosphatase inhibitor cocktail
II (Sigma), mammalian protease inhibitor cocktail (Sigma), and 1 mM
PMSF (Sigma). Protein concentration was determined using a
bicinchoninic acid protein assay (Peirce). Samples were heated for five
minutes in Laemmli’s buffer and 5% B-mercaptoethanol (Sigma).
Equal amounts of protein were loaded onto 10% Tris-glycine SDSPAGE gels. Afterwards, the gels were transferred onto polyvinalidene
fluoride membranes (Millipore) using the Biorad transfer system, and
blocked for 1 hour in 5% non-fat dry milk diluted in Tris buffered
Sailne and 0.2% Triton-X 100 (Fischer).
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Complete blood count
Complete blood count measurements were performed with a
blood analyzer (Heska).

Size measurements
Size measurements were performed using a standard digital
caliper.

Cytokine measurements
Cytokine levels were measured using the Bioplex system from
Biorad with the Biorad 8-panel cytokine kit.

Long-term potentiation
LTP was performed as previously described (Abisambra et al.,
2010). For the stress experiment, mice were restrained in their cages
for 1 hour.

Statistics and chance levels
Assuming that the mice can adjust their performance to make
no more than 6 errors, only entering an arm once, we can determine
the chance level using a a negative hypergeometric distribution with
the following equation, (α(n + 1)/(α + 1)) - α. “α” is the total number
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of arms with an escape (platform), and “n” is the total number of
arms. This results in 2.5. This was previously published (Diamond et
al., 1996; Diamond et al., 1999).

Results

FKBP5-/- mice have been shown to display stress resiliency
(O'Leary et al., 2011; Hartmann et al., 2012). At three months of age
the amount of stress required to precipitate this phenotype was much
greater than at 21 months of age, since they required prior restraint
stress to display a phenotype in the forced swim test, and 21 month
old mice do not. However, age also increases the levels of FKBP5 (Blair
et al., In Press)(Jinwal et al., 2010; O'Leary et al., 2011).
Consequently, we wanted to investigate if there is a relationship
between age and behavior due to FKBP5. We subjected two cohorts of
FKBP5-/- mice and their wild type littermates ages 6, and 21 months
to the tail suspension and forced swim tests. In the tail suspension
test, analysis by a two-way ANOVA revealed that there was a strong
genotype (F(1,30)=13.30, ***p=0.001), and aging effect
(F(1,30)=10.33, *p=0.00031) for increased resilience in the FKBP5-/mice (Figure 4.1 A). In the forced swim test, there was a strong
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genotype effect (F(1,33)=14.12, p=0.0007), but no aging effect
(F(1,33)=0.70, p=0.4102) (Figure 4.1 B).

Due to the strong inhibition FKBP5 confers on GR we also
measured serum corticosterone levels after stress longitudinally
(Figure 4.2). There is a strong genotype effect for the FKBP5-/- mice
to produce less corticosterone after stress (F(1,50)=13.26,
***p=0.0006). There is also a significant effect for the increase in
corticosterone with age (F(1,50)=4.46, *p=0.0397) which the
FKBP5-/- mice are protected from.

Glucocorticoids are very important for general metabolic
processes and immune system function. They are known to promote
fat deposition and glucose metabolism (Lee et al., 2013).
Glucocorticoids are given routinely to reduce inflammation (Barnes,
1998).

Since these mice produce less glucocorticoids during stress,

we tested their weight, and size. There were no significant changes
between these (Table 4.1). To test for glucose metabolism we
challenged these mice with a 2g/kg of sucrose injected into the
peritoneum after an overnight fast. We tested blood levels at 0 (before
injection), 30, 75 and 120 minutes after injection. There was no
significant change in glucose metabolism in these mice (Figure 4.3).
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FKBP5 is actually primarily known as an immune protein, since it is
part of a family of proteins that provide immunosuppressive properties
to FK506 and cyclosporine. Because of this and the corticosterone
phenotype, we also tested for changes in the number of white blood
cells, and there were no differences between the groups (Table 4.1).

Glucocorticoids also have important immunosuppressive
properties. Since FKBP5-/- mice produce less corticosterone after
stress, we tested the effect of this hypoglucocorticoid phenotype on
the levels of serum cytokines at different ages (Figure 4.4). We found
that at 7 months FKBP5-/- mice display a reduction in IL-1β, and IL-5.
However, this difference is not present at 10 and 22 months old.
We, and others, have previously shown that FKBP5 is highly
expressed in the hippocampus (O'Leary et al., 2011; Scharf et al.,
2011). Consequently, we previously performed the Morris water maze
on the FKBP5-/- mice to test if the ablation of the gene had any effect
on learning and memory. Despite its robust expression in this highly
important memory center, there were no changes. Even so, It may be
that the absence of FKBP5 has an effect in other regions of the brain
involved with memory. The radial arm water maze offers an advantage
for this question, since the mice are forced to make a decision as to
which arm they should enter. Decision-making requires a group of
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brain regions working together (Clark et al., 2004). Using a reversal
experiment, where the platform is changed to an alternative arm, the
mice have to relearn the position of the platform. Consequently, we
can test for cognitive flexibility and the ability to relearn. We did not
observe any changes between the initial acquisition of the of RAWM
training (Figure 4.5 A). When we reversed the location of the platform,
however, the FKBP5-/- mice were better able to relearn (Figure 4.5 B).
They quickly reached the learning criteria. This criteria consists of
committing fewer errors than chance, which is 2.5 errors per trial in
this paradigm, as established previously (Diamond et al., 1996). The
FKBP5-/- mice achieved this on trial 18 (day four), but the wild type
mice did not cross this threshold until trial 21 (day five). The total
number of errors per day shows no change in the first three days
(Figure 4.5 C), but the reversal displays a significant genotype effect
(F(1,16)=4.9, p=0.0417), as the knockout mice learn the new location
faster, and make fewer errors (Figure 4.5 D). Despite the greater
ability to display cognitive flexibility, there is no change in hippocampal
long-term potentiation (Figure 4.6 A), suggesting this could be an
enhancement from another brain region, perhaps the prefrontal
cortex. There is also no significant difference between the slopes of the
amplitude of the fiber volley and the slopes of the field excitatory post-
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synaptic potential, which indicates a normal relationship between the
presynaptic and postsynaptic response (Figure 4.6 B).

One potential role for FKBP5 is to protect from GR activity, since
the hippocampus is very sensitive to glucocorticoids (Popoli et al.,
2012). To test for this we challenged 12 month old wild type and
FKBP5-/- mice to acute restraint stress for one hour prior to the
performance of long term potentiation. We found that FKBP5-/- mice
display reduced potentiation and do not maintain long term
potentiation as compared to the wild type mice (Figure 4.7 A). There is
a significant genotype effect F(1,624)=75.47, ***p<0.0001), and time
effect (F(29,624)=3.95, ***p<0.0001). The last five minutes are also
significantly different F(1,105)=39.24, ***p=0.0001). This difference
is not altered due to an altered postsynaptic response due to a
presynaptic stimulus(Figure 4.7 B).

Due to the strong genotype effect in resilient behavior and
corticosterone signaling, FKBP5 is a promising therapeutic target for
the treatment of psychiatric disease and emotional endurance. As a
result, it is important to study the effect of longterm FKBP5 ablation on
the lifespan. We aged wild type and FKBP5-/- mice up to ~800 days
and both populations displayed 50% survival of the cohort (Figure
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4.8). There was no statistical significance between the groups (Logrank, Mantel-Cox, test, χ2=0.001354, p=0.9707).

Discussion

Here we show that FKBP5 has an effect in resiliency with aging
and genotype and that its ablation is beneficial in responding to
emotionally stressful situations. We also show that the lack of FKBP5
allows for greater cognitive flexibility in non-emotional memory, as the
FKBP5-/- mice quickly adapt to the reversal of the hidden platform in
the 6 radial arm water maze. Moreover, the lack of FKBP5 does not
affect the lifespan or healthspan of these mice.

One interesting observation from these data is that there is an
age dependent increase in immobility in the tail suspension test that is
not present in the forced swim test. From observation of the videos of
the mice in these tests, it is plausible that the tail suspension test is a
more uncomfortable test than the forced swim test, as they seem to
struggle more. In the forced swim test the water is at room
temperature, ~23-25 , and although the mice do not like swimming,
they are very good swimmers. Thus, the level of discomfort may be
less than the tail suspension test. This could explain the discrepancy
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between the two tests. However, there is still a strong genotype effect
regardless of aging.

Because glucocorticoids promote anti-inflammation, and the
FKBP5-/- mice display hypoglucocorticoidism after stress, we expected
the levels of basal cytokines to increase in these mice with age.
However, this did not occur. In fact, the exact opposite was observed
for the 7-month old cohort. One possible explanation is that the
chronic absence of FKBP5 causes the activation of a compensatory
mechanism for inflammation.

Previously, the FKBP5-/- mice did not exhibit any hippocampal
memory deficits (O'Leary et al., 2011), and here we show no change in
hippocampal LTP, proving that there is no abnormalities to the
hippocampus in the FKBP5-/- mice. As a result, we tested these mice
in the radial arm water maze, as the mice are required to make a
decision. Decision-making is dependent on several brain regions
working together (Clark et al., 2004; Euston et al., 2012). This may be
better able to show if there is a change in memory processing as a
whole. The results here show that FKBP5 reduces cognitive flexibility.
Interestingly, it has been shown that in depression, patients also
display reduced cognitive flexibility (Deveney and Deldin, 2006;
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Murphy et al., 2012). The prefrontal cortex has been identified as an
important brain region for cognitive flexibility (Clark et al., 2004;
Armbruster et al., 2012). This area has also been identified as under
active in patients with PTSD (Shin et al., 2006), and it is also involved
in resilience, since its activity is enhanced in people who experience
trauma, but do not develop PTSD (Fani et al., 2012). These resilient
subjects also display stronger physical connections in the circuitry
connecting the hippocampus with the anterior cingulate cortex, an
area of the prefrontal cortex. PTSD-subjects also display greater
amygdaloid activity (Shin et al., 2006). In context with these data,
FKBP5 deletion may manifest its effects by reducing amygdaloid
activity and increasing prefrontal cortex activity during or even after a
stressful event. Mice treated with an shRNA virus against FKBP5 in the
amygdala display reduced anxiety in the elevated plus maze, after six
hours of restraint stress (Attwood et al., 2011). In the same study, Nmethyl-D-aspartate receptor activity in the Amygdala resulted in a
massive increase in FKBP5, which led to anxious behavior.

Astonishingly, in all the literature regarding FKBP5, we have
found only a few benefits to having this protein. Patients with the
FKBP5 SNP rs1360780 display a more rapid response to antidepressant
treatments compared to other depressed patients without this FKBP5
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allele (Binder et al., 2004). This includes treatment with selective
serotonin reuptake inhibitors, tricyclic antidepressants, and
mirtazapine. However, these same patients have a greater number of
depressive episodes throughout their life. The aging data in this study
further presses the point that the lack of this gene is not damaging,
and may even be beneficial.

However, it has been shown that acute stress enhances memory
(Shors, 2001; Spyrka et al., 2011). Here, we show that FKBP5-/- mice
are not able to display enhanced LTP due to acute stress. As a result, it
is possible that FKBP5 protects the hippocampus from damage due to
excessive glucocorticoid receptor activity. It may be that chronic stress
given to the FKBP5-/- mice may damage the hippocampus to a greater
extent than wild type mice. This would be a good future study.

Conclusion

In conclusion, this study shows that FKBP5 knockout animals are
protected from an age and genotype dependent reduction in resilience,
and increased corticosterone production. Moreover, FKBP5 knockout
provides greater cognitive flexibility, and does not reduce lifespan. As a
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result, FKBP5 may be an excellent target for the treatment of
psychiatric diseases of the elderly.
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Table 4.1. FKBP5-/- mice display no changes in body weight,
size, or white blood cell counts.
Wild type
Units
Mass

g

Value

FKBP5-/S.D.

Value

S.D.

N

P value

11.6 12

38.82 8.382 13 0.3043

Width mm

26.78 7.674 12

24.35 4.294 13 0.3338

Depth mm

23.94 6.734 12

21.57

WBC

4.155 2.282 11

10^3/uL

43.04

N

3.88 13 0.2868

3.3 2.854 12 0.4394

WBC, white blood cells; S.D., standard deviation; N, sample size. Pvalue was derived by t-test comparing wild type with FKBP5-/animals.
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Figure 4.1. FKBP5-/- mice display a protection from FKBP5induced decrease in resiliency. (A) Amount of time spent immobile
in the tail suspension test in three separate cohorts of mice at two
different ages. Analysis by 2-way ANOVA revealed a genotype effect
(F(1,30)=13.30, ***p=0.001), aging effect (F(1,30)=10.33,
*p=0.00031). (B) Amount of time spent immobile in the forced swim
test in three separate cohorts of mice at three different ages. Analysis
by 2-way ANOVA revealed a genotype effect (F(1,33)=14.12,
p=0.0007), but no aging effect (F(1,33)=0.70, p=0.4102).
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Figure 4.2. FKBP5-/- mice exhibit reduced serum
corticosterone after stress, which is exacerbated with age.
Several cohorts of mice were tested in this experiment, n=25 wt,
n=29 FKBP5-/-. Post hoc, the mice were plotted by groups according
to the age of 10 months. Serum corticosterone after stress shows a
strong genotype effect (F(1,50)=13.26, ***p=0.0006). Serum
corticosterone after stress also increases with age, (F(1,50)=4.46,
*p=0.0397).
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120

Figure 4.3. FKBP5-/- mice display normal glucose processing.
Glucose challenge of wild type and FKBP5-/- mice. Mice were fasted
overnight and challenged the next morning with a 2 g/kg dose of
sucrose and their glucose levels were monitored for two hours (F
(1,15)=0.17, p=0.6855).
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0

Figure 4.4. IL-1β and IL-5 are reduced in the FKBP5-/- mice at
7 months of age. (A) FKBP5-/- mice of 7 months of age display
reduced levels of basal serum IL-1β, and IL-5 as compared to wild type
mice. (B) FKBP5-/- mice do not show statistical difference in the levels
of basal serum cytokines at 10 months of age. (C) FKBP5-/- mice do
not show a statistical difference in the levels of basal serum cytokines
at 22 months of age. *p<0.05, **p<0.01.
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6

Figure 4.5. FKBP5 ablation increases cognitive flexibility. (A)
Acquisition phase of the six radial arm water maze. Each number is a
group of three trials. (B) Reversal of the location of the hidden
platform. (C) Total number of errors per day in the initial acquisition
phase of learning the location of the escape platform. (D) Total number
of errors per day in the reversal of the escape platform (F(1,16)=4.9,
*p=0.0417). Dashed line represents the probability of the number of
errors per day by chance. Chance is accepted as 2.5 errors per trial,
and there are 15 trials per day.
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Figure 4.6. Knockout of FKBP5 gene does not affect long term
potentiation. (A) 30 minutes of long term potentiation does not show
a deficit between wild type and FKBP5-/- mice. (B) Equal presynaptic
stimulus does not produce differential postsynaptic response.
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Figure 4.7. Long-term potentiation is enhanced in wild type
mice after acute restraint stress, but not in FKBP5-/- mice. (A)
Hippocampal long-term potentiation of mice after 1 hour of acute
restraint stress displays FKBP5-/- mice do not potentiate or maintain
LTP to the extent of wild type mice. (B) Equal presynaptic stimulus
does not produce differential postsynaptic response.
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Figure 4.8. Ablation of the FKBP5 gene does not alter lifespan.
Survival curve of wild type and FKBP5-/- mice. Approximately 50% of
both cohorts are still alive at 800 days (
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2

= 0.0014, p=0.9707).

CHAPTER FIVE:

Discussion & Conclusions

Hsp70 and Methylene Blue

In the introduction we outlined that the targeting of soluble tau
is a promising therapeutic avenue for the treatment of AD. In “Chapter
Two” we tested this hypothesis with methylene blue, due to its ability
to inhibit Hsp70 ATPase activity and reduce tau levels in various
neuronal and non-neuronal cell models. Methylene blue was able to
reduce tau when found in large concentrations in the brain. It was also
able to rescue neuronal death. Interestingly, cognition was only
restored in animals where tau levels were lowered. Mice with low
levels of methylene blue displayed robust neuroprotection, but no
reduction in tau. As a result, there was no improvement in cognition,
suggesting that protection from tau-induced neuronal malfunction
came from lessening the tau burden. Keeping more neurons alive was
only beneficial when tau was reduced. This indicates that keeping
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neurons alive is not sufficient for the treatment of AD. Removing tau,
however, allows neurons to communicate properly to establish
function, in this case memory. This idea is further discussed in
Appendix C.

Methylene blue is a tau fibril inhibitor?
Despite its success in clinical trials and in animal models, there is
some controversy as to the mechanism(s) of methylene blue. In vitro,
methylene blue displays an inhibition of tau fibrillization, potentially
through the oxidation of cysteine residues (Wischik et al., 1996;
Miyata et al., 2012; Akoury et al., 2013). However, there is yet to be a
study where methylene blue treatment retards, prevents or reduces
tau tangles in vivo, including the study in this dissertation, “Chapter
Two.” Here, there were no differences in tangle load in mice treated
with methylene blue in their water at 165 µM, or direct injection to the
brain at 1 mM concentration. But as has been previously established, a
change in tangle load may not be necessary to improve cognition.
Others have also found methylene blue treatment to be beneficial in
other AD, tau, and other neurodegenerative mouse models (Deiana et
al., 2009; Medina et al., 2010; Congdon et al., 2012; Hosokawa et al.,
2012).
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Future work
Although we do not know the precise mechanism of how
methylene blue affects tau, it is important to note that it has shown
positive effects in phase 2 clinical trials (Gura, 2008; Wischik and
Staff, 2009). TauRxⓡ, the company that put methylene blue through
the trials, has patented an analog of the compound called leucomethylthioninium, LMTX™, and has begun enrolling patients into phase
three clinical trials (Yan, 2012). This is the most exciting part, to think
that soon a new therapeutic option may be available. However, further
work into the Hsp70 chaperone network has revealed that different
Hsp70 proteins have differential effects on tau levels (Jinwal et al.,
2013). In fact, there are 11 human Hsp70 genes, according to one
article (Tavaria et al., 1996). However, an extensive discussion on
these genes argues that 5 of these are not real, and thus there are
really 7 Hsp70 genes that make a protein (Moran). The HSPA1L gene
is specific to the testis, the HSPA5 is specific to the ER, and the
HSPA9B is specific to the mitochondria. The rest are cytosolic, the
HSPA1A and he HSPA1B, are inducible, and HSPA2 and HSPA8, are
constitutively expressed.The work of Dr. Chad Dickey and Dr. Umesh
Jinwal suggest that there is a chaperone “code,” which helps create
proteostasis in the cell (Jinwal et al., 2010; Jinwal et al., 2011; Jinwal
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et al., 2013). Future work must elucidate which genes are good for tau
degradation and which ones promote tau accumulation. Then, we have
to develop strategies to fine tune the activities of these genes to
promote tau clearance.

Implications
This study on methylene blue goes beyond the ability of
methylene blue to affect cognition in Alzheimer’s disease. It is part of a
fuselage of work from Dr. Dickey’s laboratory showing the potential
that chaperone proteins have as targets from which therapies can be
developed for the treatment of neurodegenerative diseases. This study
is also important for the tau field, as these data support the previous
work showing that reducing the levels of soluble tau is beneficial
(Santacruz et al., 2005) (de Calignon et al., 2010) . The reduction of
the tau burden in these mice was not detrimental to their locomotion
or motor skills, as suggested it would be by the study showing tau
knockout mice having motor issues with age. On the contrary, mice
regained cognitive function from tau removal. Tau tangles were not
removed and the number of tangles remained steady, and the result
was not affected by this.
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FKBP5 and Stress Disorders

FKBP5 levels are elevated in people with SNPs in the FKBP5
gene. These people are overrepresented in the population of those
who have experienced severe trauma and develop mood disorders. In
“Chapter Three” and “Chapter Four,” we tested the hypothesis that the
absence of FKBP5 would protect from developing disease. The
FKBP5-/- mice were protected from an increase in age-related
corticosterone levels, and displayed increased resilience and cognitive
flexibility, both due to stress and age. Natural resilience decreased
with age in wild type mice, but the FKBP5-/- mice were protected from
this. Moreover, global knockout of this gene was not deleterious in any
measurements done in these studies.

Future work
Several experiments need to be done to further validate the
results in this dissertation. First, we performed these experiments on a
permanent knockout mouse line. Accordingly, we need to test if the
transient knockout of this gene is as effective in treating disease.
Moreover, this mouse line is a global knockout, thus the transient
knockout mouse should be a brain only knockout as well. After this
validation, therapeutic strategies need to be developed to reduce the
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levels of FKBP5 in the brain, and then translated into human clinical
trials.

Implications
There has been a lack of development of new therapies in the
realm of mood and anxiety disorders from the use of hypothesis driven
science (2007). As a result, these studies are very exciting, as we
have a good general understanding of the mechanism of how the
environment is changing our genetic regulation, thus making us more
susceptible to disease. Traditionally, the ideas are first developed in
animal models and then tested in humans. Here, it has been the
opposite. Since FKBP5 is ubiquitous in the human body, mRNA levels
can be tested in blood cells, and these highly correlate with brain
mRNA levels (Sullivan et al., 2006). As a result, we know that chronic
elevation of FKBP5 levels is bad for people. Armed with this knowledge
we can develop therapies aimed at decreasing the levels of FKBP5.
Very little work has been done with resilience and the genetic
causes of resilience, but even less on the resilience of the elderly. This
work shows that the absence of FKBP5 provides mice with an
enhancement in resilience that extends on to old age. There is also a
very strong correlation between elevated cortisol levels and psychiatric
disease (Pariante and Miller, 2001). As a result, the reduced cortisol
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phenotype observed in these mice has the potential to alleviate the
risk of developing different types of mood and anxiety disorders.

Conclusion

Chaperone proteins are very important in the cell. They are
responsible for folding, transporting, receptor function, assisting
endocytic vesicles, decreasing levels of reactive oxygen species,
vesicle fusion, protein degradation, preventing protein aggregation,
and ER associated degradation, among others (Muchowski and Wacker,
2005). Despite this, their function is not always sufficient to prevent
disease. Because of their multiple talents, though, we can modulate
them to restore health, and prevent disease.
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APPENDIX A:

Chapter Two Supplementary Material

Appendix A consists of the supplementary material from
“Chapter 2: Phenothiazine-mediated rescue of cognition in tau
transgenic mice requires neuroprotection and reduced soluble tau
burden.”
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Figure A1. Chronic MB treatment does not cause abnormal
changes in mice behavior. (A) Mice were assessed in the open field
task for abnormal locomotion and exploratory behavior for 30 minutes.
No statistical differences were observed. (B) Mice were evaluated for
anxiety in the elevated plus maze task. The amount of time spent in
the open and closed arms, and the center area was evaluated and at
least one mean was indicated to be significant (F (3,36) = 3.414,
p<0.05). Post-hoc evaluation shows that MB treated wild type mice
displayed significantly more time in the closed arms and significantly
less time in the open arms than both cohorts of transgenic mice. (C)
Mice were subjected to the rotorod apparatus for 4 trials a day for 2
days. No overt differences were observed. (D) Mice positive for human
P301L tau transgene expression and their wild type littermates were
grouped based on genotype and MB treatment. On the 14th week of
chronic MB treatment they were subjected to the water maze
paradigm. Learning was evaluated by the latency of the mice to find
the hidden platform. The mice were trained until the wild type mice
plateaued. Wild Type animals learned significantly better than
transgenic animals (n=10 per group, F (3, 236) = 19.71, p<0.0001).
(E) Graphic representation of the mean latency of all mice in all trials
of plot d.
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Figure A2. Differences in parenchymal drug concentrations
could not be attributed to gender or weight. (A) All drug treated
mice (both transgenic and wild type) separated by gender show no
statistical difference between the means, p=0.7197 (males n=10,
females n=9). (B) Linear regression and correlation between weight
and drug concentration show that slope is not significantly non-zero
and correlation is not statistically significant, p=0.7778 (n=19).
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Figure A3. Mice treated with methylene blue display normal
vision and swim speed. (A) Visible trial in the Morris water maze
displays no significant difference between groups. (B) Swim speed in
the Morris water maze shows no significant difference between the
groups.
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APPENDIX B3:

Hsc70 Rapidly Engages Tau after Microtubule Destabilization

Abstract

The microtubule-associated protein Tau plays a crucial role in
regulating the dynamic stability of microtubules during neuronal
development and synaptic transmission. In a group of
neurodegenerative diseases, such as Alzheimer disease and other
tauopathies, conformational changes in Tau are associated with the
initial stages of disease pathology. Folding of Tau into the MC1
conformation, where the amino acids at residues 7–9 interact with
residues 312–342, is one of the earliest pathological alterations of Tau
in Alzheimer disease. The mechanism of this conformational change in
3

This work was previously published in the Journal of Biological
Chemistry (Jinwal, U. K., O'Leary, J. C., Borysov, S. I., Jones, J. R., Li,
Q., Koren, J., ... & Dickey, C. A. (2010). Hsc70 rapidly engages tau
after microtubule destabilization. Journal of Biological Chemistry,
285(22), 16798-16805.), and is used here with permission of the
publisher. The permissions are available in Appendix F. © the American
Society for Biochemistry and Molecular Biology.
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Tau and the subsequent effect on function and association to
microtubules is largely unknown. Recent work by our group and others
suggests that members of the Hsp70 family play a significant role in
Tau regulation. Our new findings suggest that heat shock cognate
(Hsc) 70 facilitates Tau-mediated microtubule polymerization. The
association of Hsc70 with Tau was rapidly enhanced following
treatment with microtubule-destabilizing agents. The fate of Tau
released from the microtubule was found to be dependent on ATPase
activity of Hsc70. Microtubule destabilization also rapidly increased the
MC1 folded conformation of Tau. An in vitro assay suggests that Hsc70
facilitates formation of MC1 Tau. However, in a hyperphosphorylating
environment, the formation of MC1 was abrogated, but Hsc70 binding
to Tau was enhanced. Thus, under normal circumstances, MC1
formation may be a protective conformation facilitated by Hsc70.
However, in a diseased environment, Hsc70 may preserve Tau in a
more unstructured state, perhaps facilitating its pathogenicity.

167

Introduction

Deposition of Tau after its sequestration from microtubules is a
neuropathological hallmark of a group of diseases termed tauopathies.
This family of diseases includes Alzheimer disease (AD),3 hereditary
frontotemporal dementia with parkinsonism linked to chromosome 17,
progressive supranuclear palsy, and corticobasal degeneration (1,–4).
The Tau protein is normally expressed in the cytoplasm of neurons and
performs the critical function of stabilizing and maintaining the
microtubule networks that are essential for axonal transport. During
the development of Tau pathology, Tau dissociates from microtubules,
and unknown factors converge to cause abnormal polymerization of
Tau into highly insoluble paired helical filaments (PHF) and forms
neurofibillary tangles. The number of neurofibillary tangles directly
correlates with the degree of dementia seen in the progressing stages
of AD (5, 6); however, it is now speculated that it is intermediate
species of Tau rather than the pathologically visible tangles that are
the most toxic (7, 8). It has been hypothesized that in disease,
hyperphosphorylation and conformational changes lead to the loss of
function and pathogenic assembly of Tau (9,–11). This idea of Tau
adopting a conformation, or “fold,” is somewhat paradoxical because
Tau is almost entirely an unstructured protein. However, evidence for a
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folded Tau species emerged from studies that used paired helical
filaments from AD brain as haptens for monoclonal antibody
production (10,–12). Several antibodies were generated that had
discontinuous epitopes within the Tau molecule. One of these
antibodies, MC1, recognizes Tau when its N terminus is positioned near
residues of the ninth exon. Pathological studies with this antibody
revealed that formation of this species was an early event in Tau
pathology in AD (10,–12). Thus, detection of Tau in the MC1
conformation could result from either folding of a single Tau molecule,
or it could be due to anti-parallel stacking/filament formation of Tau.
The emergence of molecular chaperones as key regulators of Tau
processing suggests that conformational changes to the structure of
Tau may indeed be key events in the pathogenesis of AD and other
tauopathies (13,–17). Aggregation of Tau in vitro is negligible and
typically requires accelerants such as heparin (18, 19), an indication
that conformation plays an important role in its assembly. In a cellular
environment, post-translational processing of Tau is likely essential for
facilitating its aggregation, and certainly this could be regulated by the
chaperone network. One of the first described chaperone regulators of
Tau is the Hsp70 chaperone family. This family is comprised of 13
members; however, the cytoplasm is predominated by two members,
the constitutive heat shock cognate (Hsc) 70 protein and the inducible
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Hsp70. Hsc70 and Hsp70 share 92% primary sequence homology.
Both have highly conserved N-terminal ATPase domains as well as
substrate-binding domains located just upstream of a more variable/
regulatory domain (20). The cyto-protective role of Hsc70 may be
particularly relevant in neurons where an attenuated Hsp70 response
has been correlated with aging. Hsc70 and Hsp70 can each bind Tau in
the nervous system, but endogenous Hsc70 is typically in much higher
abundance than Hsp70 in the cytosol (21, 22). Based on previous
work, we hypothesized that the highly abundant Hsc70 protein would
be the most likely member of the Hsp70 family to regulate Tau
processing. We also speculated that the time when Hsc70 would be
most engaged with Tau would be following its release from
microtubules (17). Lastly, we investigated what affect Hsc70 might
have on Tau in distinct cellular environments. For the first time, we
have connected microtubule dysfunction with chaperone-mediated
regulation of Tau, as well as conformational changes to and
hyperphosphorylation of Tau in a comprehensive way. These findings
could be useful for implementing therapeutic strategies based on
Hsc70, given its apparent early involvement in Tau pathogenicity.
These studies may also point to a mechanism of how Tau dysfunction
begins in AD and other tauopathies.
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Materials & Methods

Antibodies and chemicals
MC1 and PHF1 (anti-S396/S404 p-Tau) were provided by P.
Davies (Albert Einstein College of Medicine, Yeshiva University, New
York, NY). Anti-Hsc70 was obtained from Stressgen Biotechnologies
(Ann Arbor, MI). Anti-actin was obtained from Sigma-Aldrich. Anti-Tau
(total Tau) was obtained from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA). Secondary antibodies were obtained from Southern Biotech
(Birmingham, AL). All of the antibodies were used at a 1:1,000 dilution
with the exception of PHF1, which was used at a dilution of 1:200.
Secondary antibodies conjugated to fluorophore were purchased from
AlexaFluor (Molecular Probes). Albendazole, colchicine, paclitaxel,
okadaic acid, and phenothiazine (methylene blue) were purchased
from Sigma. Nocodazole was purchased from Tocris Bioscience.

Recombinant protein purification
Wild type 4R Tau and Hsc70 gene sequences cloned into pET28
vector with His tag and were transformed into the Escherichia coli
strain BL21 (DE3) codon Plus. Bacterial culture condition and protein
purification protocol were followed as described earlier (23). The purity
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of all proteins was verified on a Coomassie Brilliant Blue-stained SDSpolyacrylamide gel.

Xenopus oocytes
S phase Xenopus egg extracts were prepared according to a
standard protocol (24) and supplemented with 5% Me2SO to stimulate
microtubule polymerization as described (23). Purified recombinant
wild type Tau and Hsc70 proteins were added at a final concentration
of 80 ng/µl. The extracts were treated with nocodazole and incubated
for 30 min at room temperature, and newly formed microtubule
structures were visualized by fluorescence of incorporated rhodaminetubuline. Image quantification was performed as previously described
(25). Briefly, tubulin-positive signal was detected using the same
threshold for each image in ImageJ (26, 27), and the fraction of the
total area of the field covered by the tubulin signal was collected for
statistical analysis.

Cell culture and western blot analysis
HeLa cells stably transfected with V5-tagged 4R0N Tau were
generated using G418 selection. HeLa cells were grown in Opti-Mem
plus 10% fetal bovine serum (complete media; Invitrogen) and
passaged every 3–5 days based on 90% confluence. IMR32 cells were
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maintained in Opti-Mem plus 10% fetal bovine serum and 2% of 200
mm l-glutamine (Cellgro, Mediatech, Inc., Herndon, VA). The cells
were harvested in M-PER buffer (Pierce) containing 1× protease
inhibitor mixture (Calbiochem), 1 mm phenylmethylsulfonyl fluoride,
and 1× phosphatase inhibitor I and II cocktails (Sigma). The
measurements of Tau levels in cell culture were performed by Western
blot analysis. Plasmid transfections were done utilizing Lipofectamine
2000 reagent from Invitrogen. HeLa cells stably transfected with V5tagged 4R human Tau were transfected with 3 µg of DNA. The cells
were incubated for 4 h with the Lipofectamine/plasmid mixture in OptiMEM medium, and this was replaced with fresh complete medium for
an additional 44–48 h. For the immunoprecipitation (IP) studies, cell
culture lysates were incubated with 2 µg of antibody for 2–3 h at 4 °C
with rocking. Then 50 µl of protein G were added and rocked at 4 °C
for overnight. The protein G beads were pelleted and washed five
times with phosphate-buffered saline.

Drug preparations
All of the drugs for the cell culture experiments were solubilized
in Me2SO to get a 20 mm stock. For the in vivo study in mice,
albendazole used in the hippocampal injections in Figure B3 panel C
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were prepared by dissolving 3 g of albendazole in 40% hydroxypropylβ-cyclodextrin in water.

Immunocytochemistry
IMR32 cells were plated onto a chamber slide (Fisher) and
maintained in the medium described above. The cells were treated
with nocodazole for 30 min and were fixed in high pressure liquid
chromatography grade methanol for 15 min. Blocking and
permeabilization were done by incubating samples with Tris-buffered
saline containing 5% normal goat serum, 0.1% Tween 20, and 0.03
NaN3 for 60 min at 25 °C. Primary antibodies rabbit anti-Tau and rat
anti-Hsc70 (1:100) were added and incubated overnight at 4 °C. The
slide was washed five times for 5 min in 1× Tris-buffered saline.
Secondary antibodies AlexaFluor 488 (anti-rabbit; 1:1000) and 594
(anti-rat; 1:1000) were added to the slides and incubated for 60 min
at 25 °C. The slides were washed and coverslipped. A Leica confocal
microscope was used to take images. Significance was assessed by
Pearson's correlation coefficient.

Albendazole injections in mouse brains
All of the procedures using mice were done in accord with the
guidelines set forth by the University of South Florida's Institutional
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Animal Care and Use Committee. The wild type FVB/N background
mice brain hippocampus were injected with 2 µl of vehicle and 3 mg/
ml albendazole. The surgical procedure was performed as previously
described by Carty et al. (28) with some modifications. The mice were
anesthetized using isofluorane, and the cranium was exposed with a
small incision along the skin covering the medial sagittal plane. Holes
were drilled through the cranium over the desired injection sites as
measured with a stereotaxic apparatus. Burr holes were drilled using a
dental drill bit (SSW HP-3; SSWhiteBurs) or a 21-gauge needle (BD). A
2-µl total volume of vehicle or albendazole were dispensed into the
each injection site. The animals were recovered within 10 min of postsurgery and were singly housed. 24 h after the injections, the brains
were harvested as described earlier (29) and processed for
immunoprecipitation as described above.

Enzyme-linked immunosorbent assay
Tau and HSP complex containing Hsc70, DNAJB2, and ATP were
preincubated for 30 min. Paraformaldehyde was added into the
samples and coated on to 96-well plate for 1 h at 37 °C followed by
washing five times with wash buffer containing 0.45% NaCl and 0.05%
Tween 20. Blocking of plate was done for 1 h at 37 °C by using
starting blocking solution (Pierce and Thermo Fisher Scientific),
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followed by a wash. MC1 antibody was added at 1:50 dilutions and
incubated at 37 °C for 1 h, and the plate was washed again.
Horseradish peroxidase-linked secondary antibody was added and
incubated at 37 °C for 1 h. The plate was washed. 3,3′,5,5′Tetramethylbenzidine dihydrochloride (Sigma) solution was added, and
the reaction was stopped by adding 2 m H2SO4. The plate was read at
450 nm in spectrophotometer.

Results

Hsc70 facilitates tau-mediated microtubule stabilization
Previous work from our lab and others suggested that the Hsp70
chaperone network plays a critical role in Tau biology and could be
used as a therapeutic target for tauopathies (13, 14, 17, 30, 31). Of
the Hsp70 family members, the Hsc70 protein expression level was
found to be highest in the neurons from adult brain (21, 32,–34).
Based on this evidence, we investigated the role of Hsc70 on Taumediated microtubule polymerization. We used our recently optimized
assay for the analysis of microtubule polymerization in oocyte extract
(23). Using purified recombinant Hsc70 and Tau, we incubated
Xenopus oocyte extracts with Tau, Hsc70, or a combination of both Tau
and Hsc70 for 30 min. These extracts were then treated with 20 µm
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nocodazole or vehicle for an additional 30 min. Microtubule formation
was analyzed using fluorescent microscopy (Figure B1). Tubulinpositive signal was detected using the same threshold for each image
as determined by ImageJ software (26, 27), and the fraction of the
total area of the field covered by the tubulin signal was collected for
statistical analysis (Figure B1 B). The extracts incubated with Tau
alone and Hsc70 alone showed similar levels of microtubule formation
(Figure B1). However, we observed a significant increase in
microtubule formation when Tau was supplemented with Hsc70.
Nocodazole was able to abrogate microtubule formation under all the
previously mentioned conditions as seen in the representative image
(Figure B1 A). These findings suggest that Hsc70 could be a potent
enhancer of Tau-mediated microtubule polymerization, suggesting that
microtubule dynamics could be critical for facilitating the Tau/Hsc70
interface.

Tau associates with Hsc70 upon microtubule destabilization
Although Hsc70 facilitated Tau-mediated microtubule assembly in
normal cellular oocyte extracts, we found that microtubule
destabilization with nocodazole overrode this activity (Figure B1).
Based on this result, we wanted to determine how microtubule
destabilization may impact the association of Hsc70 with endogenous
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Tau in an intact cellular environment. First, we performed fluorescent
immunostaining on neuroblastoma cells (IMR32) following microtubule
destabilization to determine whether colocalization of these two
proteins was increased. The cells were grown on chamber slides and
treated with nocodazole for 30 min and then fixed, and the levels of
Tau and Hsc70 were assessed by immunofluorescent confocal
microscopy. Image analysis showed no significant colocalization
between Tau and Hsc70 in the vehicle-treated cells as determined by
Pearson's correlation coefficient; however, Hsc70 and Tau were found
to be colocalized by Pearson's correlation coefficient after nocodazole
treatment (Figure B2). These data suggested that Hsc70 and Tau do
have a greater propensity to interact following microtubule
destabilization. However, we wanted to further confirm these data
using coimmunoprecipitation studies.

We tested whether the interaction of Tau with Hsc70 could be
enhanced with microtubule destabilization in cells overexpressing Tau,
as well as cells with endogenous Tau levels. We treated IMR32 cells
that have endogenous levels of Tau with three microtubuledestabilizing drugs: albendazole, nocodazole, and colchicine. These
compounds did not increase Hsc70 levels; however, consistent with our
colocalization data, they did increase the binding of Tau with HSc70
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(Figure B3, A and B). A similar result was found with HeLa cell
overexpressing wild type human Tau (Figure B3 C). As a control in this
overexpressing cell model, we also treated with the microtubule
stabilizer, paclitaxel, and saw no increase in Tau association to Hsc70
(Figure B3 C). We then tested whether the association of Hsc70 with
Tau could be increased by microtubule destabilization in the brain. We
injected albendazole and vehicle control into the hippocampal region of
mice. Brain tissue was harvested 24 h after injection, and
homogenates were analyzed by an IP with Tau antibody followed by
Western blot probing with Hsc70 antibody. Again, we found that
microtubule destabilization increased the association of Tau with Hsc70
(Figure B3 D).

ATPase activity of Hsp70/Hsc70 regulates tau upon microtubule
destabilization
Based on these findings and our previous work with Hsp/Hsc70
chemical inhibitors (14), we speculated that chemically inhibiting
Hsc70 activity when the number of Hsc70·Tau complexes is highest
(after microtubule destabilization) would lead to enhanced efficacy for
reducing Tau levels. To determine this, we performed dose-response
studies with an Hsp70 ATPase inhibitor (methylene blue) in the
presence or absence of a 30-min pretreatment with albendazole.
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Indeed we found that reductions in both endogenous and
overexpressed Tau by Hsc70 inhibition were enhanced following
microtubule destabilization in IMR32 cells and HeLa cells, respectively
(Figure B4). These findings provide further evidence that the
association of Hsc70 with Tau is rapidly enhanced following
microtubule destabilization, which forms more Hsc70·Tau complexes
that can be targeted by inhibitors.

Hsc70 folds tau into MC1 conformation
Based on our results, we hypothesized that Hsc70 could be
contributing to some of the early pathological modifications to Tau
depending on the cellular environment. Because Hsc70 largely
functions as a protein “foldase” (35), and Tau folding is thought to be
an early event in disease progression (11, 12, 36), we investigated
what impact Hsc70 could be having on Tau folding.

We first tested whether the folding of Tau into the MC1
conformation coincided with Hsc70 binding to Tau. Again we treated
two cell models, one with endogenous Tau and the other with
overexpressed Tau, with microtubule destabilizers for 30 min and
performed IPs with the MC1 antibody, which recognizes folded Tau,
and a total Tau antibody. We found that MC1-reactive Tau was
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increased within 30 min in both cell models, similar to the time frame
of Hsc70 binding to Tau (Figure B5, A and B); however, this effect was
more pronounced in cells overexpressing Tau (Figure B5 B). Although
this suggested that Hsc70 and Tau folding were occurring in a similar
time frame, we still were not certain that Hsc70 was facilitating the
MC1 conformation for Tau. To test this more directly, we performed an
in vitro enzyme-linked immunosorbent assay experiment using purified
recombinant proteins to look for the amount of MC1 reactive Tau in the
presence and absence of Hsc70. Impressively, we found more MC1reactive Tau species when Tau was incubated with Hsc70 versus bovine
serum albumin (Figure B5 C). Based on our findings that the MC1 Tau
conformation could be rapidly facilitated by Hsc70, we speculated that
Tau hyperphosphorylation might be impacted as well when
microtubules are destabilized.

Microtubule destabilization affects tau phosphorylation pattern
We first investigated the phosphorylation of Tau within the first
24 h following microtubule destabilization. Again we investigated this
for both endogenous Tau and overexpressed Tau. Interestingly, we
observed an initial decrease in Tau phosphorylation at 30 min, the
same time that MC1 Tau formation and Hsc70 binding to Tau were
increased. Tau phosphorylation then began to recover over the next
181

several hours and eventually was increased by 24 h in both cell lines
(Figure B6). Total Tau levels remained largely unaffected. Thus,
microtubule destabilization decouples Tau phosphorylation from MC1
formation and Hsc70 binding. Perhaps more importantly, MC1
formation and Hsc70 actually preceded endogenous phosphorylation of
Tau following microtubule destabilization. This led us to consider what
would happen to both the MC1 conformation of Tau and Hsc70 binding
to Tau if microtubules were destabilized in the face of aberrant kinase
activation.

A hyperphosphorylating environment blocks folding of tau but
enhances Hsc70 binding
Although we have demonstrated that Hsc70 associates to Tau
upon microtubule destabilization, we wanted to determine how this
association is affected in a hyperphosphorylating environment. Tau
protein can be phosphorylated by a number of proline-directed serine/
threonine kinases at several sites. The prevalence and chronology of
these phosphorylation events have been rigorously correlated with AD
tangle pathology (5, 6). GSK3β is a primary kinase for several key
sites that are associated with Tau pathology, and it can lead to Tau
hyperphosphorylation (37). Here, we have created a
hyperphosphorylating environment for Tau by overexpressing a
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constitutively active form of GSK3β. Lysates from cells overexpressing
either the constitutively active form of GSK3β or empty vector treated
with nocodazole for 30 min were analyzed by IP as described above.
Although we found that phosphorylation of Tau (as measured by
increased immunoreactivity to PHF1 antibody) did increase its
association with Hsc70, we were surprised to find that
hyperphosphorylation of Tau actually blocked MC1 formation (Figure
B7). Thus, when microtubule destabilization occurs in a
hyperphosphorylating environment, MC1 formation is blocked, but
Hsc70 binding goes up. In this way, Hsc70 may be preserving
hyperphosphorylated Tau in a more exposed, linear conformation that
may be more prone to toxic intracellular interactions than it would be
in the condensed MC1 conformation.

Discussion

Apart from the known association of the members of the Hsp70
family of chaperones with Tau in the brain, their role in the initiation
and progression of AD and other tauopathies is not clear. Here, we
aimed to explore the role of the most prevalent cytosolic member of
the Hsp70 family, Hsc70, in the early events of Tau pathogenesis. We
developed a model using microtubule-destabilizing compounds to
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explore the consequences of loss of function for Tau and then coupled
t h i s w i t h a t o x i c g a i n o f f u n c t i o n b y p r o m o t i n g Ta u
hyperphosphorylation with GSK3β overexpression (14, 38, 39). Our
results were surprising: we found that the MC1 conformation of Tau
can be decoupled from Tau hyperphosphorylation. Moreover, Hsc70
facilitated MC1 formation while also enhancing Tau-mediated
microtubule polymerization. Although MC1 has indeed been shown to
be an early pathological structure of Tau pathology, as assessed by
post-mortem tissue analysis (10) and a conformation that emerges
during fibrillarization (11), our results suggest that there might be
multiple phases of MC1 formation: one at the onset of Tau dysfunction,
as described here, and others after Tau tangles have been seeded and
become self-perpetuating (29, 40).
Based on our results, we speculate that Tau folding into the MC1
conformation after microtubule destabilization could be a protective
mechanism facilitated by Hsc70 to control the disordered nature of Tau
and prevent its self-assembly in the neuron. In fact, this would be
expected given the known “foldase” functionality of Hsc70 and
previous work showing that it prevents disordered proteins from
aggregating (41,–44). However, when microtubules are destabilized in
a hyperphosphorylating environment, Hsc70 still binds to Tau, but this
phospho-Tau can no longer be protectively folded into the MC1
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conformation. In this way, Hsc70 may be a double-edged sword; when
Tau loses its function, Hsc70 can hold it in a labile folded state,
returning it to the microtubule once the insult on microtubule stability
has resolved. But when Tau loses its function and gains a toxic
modification such as aberrant phoshorylation, Hsc70 still holds Tau but
fails to protect it, perhaps inadvertently contributing to the
preservation of hyperphosphorylated Tau in the cell (Figure B8). This
notion that unfolded proteins are intrinsically prone to aggregation is
an emerging principle for the field of protein chemistry, as recently
reviewed (45).

This necessity for Tau to both lose its function and gain toxic
post-translational modifications could be precisely why single
mechanisms linking amyloid accumulation to Tau pathogenesis have
been challenging to prove. The Tau dysfunction seen in AD might
require a pleiotropic activation strategy, where a number of pathways
activated by the pluripotency of amyloid must converge to promote
Tau pathogenesis. In fact, amyloid is known to destabilize microtubules
and activate kinases (37, 46). Thus, our model may recapitulate some
aspects of amyloid-induced Tau pathogenesis and describe the very
earliest part of this cascade.
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Our study also shows that regardless of the neuronal
environment, Hsc70 is engaged with Tau when microtubule stability is
altered. Thus, inhibitors of Hsc70 ATPase activity that facilitate the
release and degradation of Tau, such as those that we have recently
described (14, 35), could be broadly applicable throughout the Tau
pathogenic cycle. Although not investigated here, we would anticipate
that Hsp90 and other chaperone proteins would also be involved in Tau
processing when it disengages from the microtubule. Therefore
developing diverse therapeutic strategies aimed at modulating distinct
chaperone functions could be highly applicable for AD.

In summary, our data suggest that the dissociation of Tau from
microtubules enhances its association with the chaperone network,
specifically with Hsc70. This association, as our data suggest, seems to
be crucial for Tau folding and restoration of Tau function. However,
abnormal phosphorylation of Tau, coupled with its loss of function,
circumvents the protective surveillance of Hsc70, and Hsc70 may
actually become an unwitting accomplice to Tau pathogenesis by
holding onto abnormal Tau. Based on these data, pharmacological
manipulation of the Hsp70 family of proteins may prevent the disease
progression in certain Tau-related neurodegenerative diseases where
microtubule disruption has occurred in a hyperphosphorylating
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environment, a likely scenario in AD. However, in circumstances where
disease arises only from a loss of function for Tau, then inhibiting
Hsc70 may accelerate pathogenicity by subverting the attempts of
Hsc70 to restore Tau to the microtubule. By understanding the
mechanisms involved in Tau pathogenesis, we can continue to identify
therapeutic targets and strategies that may be customizable based on
disease etiology.
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Figure B1

195

Figure B1. Hsc70 facilitates Tau-mediated microtubule
stabilization. A, in vitro microtubule assembly assays were
performed using Xenopus oocyte extracts supplemented with
rhodamine-labeled tubulin. Recombinant proteins, Tau, Hsc70, or both
in combination, were added to the Xenopus extracts, and microtubules
were detected with fluorescent microscopy. Control indicates no
protein added. As a negative control, microtubules were disrupted
using nocodazole in the presence of Hsc70 and Tau. B, microtubules
were quantified as the percentage of area distributed throughout the
total area of the field; see details under “Materials and Methods” (n =
19; **, p (hsc70 versus both) < 0.001; and ***, p (Tau versus both)
< 0.0001).
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Figure B2

197

Figure B2. Dramatic increase in Tau colocalization with Hsc70
upon microtubule destabilization. IMR32 cells were treated with 20
µM nocodazole or vehicle control for 30 min. Immunofluorescent
staining of Tau (green) and Hsc70 (red) in cells shows enhanced
colocalization of these two proteins upon treatment with microtubule
destabilize nocodazole.
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Figure B3
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Figure B3. In vitro and in vivo enhanced association of Hsc70 to
microtubule-destabilized Tau. A, IMR32 cells treated with
microtubule-destabilizing agents albendazole, nocodazole, colchicine or
vehicle Me2SO as a control for 30 min. Treated cell lysates were
immunoprecipitated (IP) with total Tau antibody and immunoblotted
with Hsc70 antibody. B, quantitation of immunoblot from A after
normalization to corresponding inputs shows increased binding of
Hsc70 to Tau upon destabilization of microtubules by various drugs
compared with vehicle control. The values are presented as Hsc70
association to Tau as a percentage of vehicle-treated cells ± S.D. C, In
HeLa cells stably transfected with Tau were treated with microtubule
stabilizer paclitaxel and destabilizer albendazole or nocodazole for 30
min. An IP with total Tau antibody followed by immunoblotting with
Hsc70 antibody, showed only increased association of Hsc70 with Tau
upon treatment with microtubule destabilizer not with stabilizer
treatment. D, in vivo study was performed in mice. Brain hippocampus
of mice (n = 4) were injected with albendazole or vehicle as a control.
24 h after injection, the mouse brains were homogenized. An IP with
total Tau antibody followed by immunoblot analysis showed significant
increased of Tau association to Hsc70 upon treatment with albendazole
compared with vehicle-injected animals.
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Figure B4
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Figure B4. Tau released from microtubules is regulated by
ATPase activity of Hsc70. A, IMR32 cells were treated with 20 µM
albendazole or vehicle for 30 min, followed by 1 h of treatment with
various doses of methylene blue (MB). B, a similar experiment as in A
was performed in HeLa cells stably transfected with Tau. Quantitation
plots of the Western blots after actin normalization illustrates
microtubule destabilization favors further reduction of Tau by the
Hsc70 ATPase inhibitor methylene blue. The gray lines depict the
efficacy of the Hsp70 complex ATPase modulators alone, and black
lines depict the efficacy of the ATPase modulators in conjunction with
albendazole treatment. The values are presented as Tau levels as
percentages of vehicle-treated cells ± S.D. *, p < 0.05; **, p < 0.001
by Student's t test.

202

Figure B5
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Figure B5. Hsc70 folds Tau into MC1 conformation. A, IMR32
cells having endogenous Tau were treated with 20 µM albendazole or
nocodazole for 30 min prior to an IP using a MC1 (folded) Tau
antibody. An increased binding of Hsc70 to folded Tau was observed
upon treatment with drugs. B, HeLa cells stably transfected with Tau
(overexpressing Tau) were treated with 20 µM albendazole or
nocodazole for 30 min prior to an IP using a MC1 (folded) Tau
antibody. An increased binding of Hsc70 to folded Tau was observed
upon treatment with drugs. C, an enzyme-linked immunosorbent
assay (ELISA) for folding of Tau (folded, MC1) was performed using
recombinant Tau and Hsc70 in a buffer containing ATP. The plate was
read at 450 nm, and the data are represented as black bars. A
significant increase in Tau folding by Hsc70 suggests that Hsc70 folds
Tau. The values are presented as Tau levels as percentages of vehicle
(Veh)-treated cells ± S.D. ***, p < 0.0001 by Student's t test.
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Figure B6
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Figure B6. Microtubule destabilization affects Tau
phosphorylation pattern. A, IMR32 cells were treated with
nocodazole for 0, 0.5, 1, 3, 6, and 24 h. Tau phosphorylation was
found to be reduced initially and in later on phosphorylation was
increased. B, HeLa cells stably transfected with Tau were treated with
nocodazole for 0, 0.5, 1, 3, 6, and 24 h. Tau phosphorylation was
found to be reduced initially, and later on phosphorylation was
increased. Quantitation plots of the Western blots after actin
normalization illustrates a time-dependent initial reduction and later on
up-regulation of Tau phosphorylation. The gray bars represent
phospho-Tau, and the black bars represent total Tau. The values are
presented as Tau levels as percentages of vehicle-treated cells ± S.D.
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Figure B7
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Figure B7. A hyperphosphorylating environment reduces
folding of Tau but enhances Hsc70 binding. A, HeLa cells stably
expressing Tau were transfected with and without constitutively active
GSK-3β followed by a treatment with nocodazole for 30 min. Two
separate IPs were performed: one with total Tau antibody and another
with MC1 antibody (folded Tau). B–D, quantitation of the immunoblots
from A was performed after input normalization. The values are
presented as percentages of vehicle (veh)-treated cells ± S.D. for
Hsc70 binding to total Tau (B), total Tau following MC1 IP (C), and
Hsc70 binding to MC1 Tau (D).
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Figure B8

209

Figure B8. A hyperphosphorylating environment reduces
folding of Tau but enhances Hsc70 binding. A, HeLa cells stably
expressing Tau were transfected with and without constitutively active
GSK-3β followed by a treatment with nocodazole for 30 min. Two
separate IPs were performed: one with total Tau antibody and another
with MC1 antibody (folded Tau). B–D, quantitation of the immunoblots
from A was performed after input normalization. The values are
presented as percentages of vehicle (veh)-treated cells ± S.D. for
Hsc70 binding to total Tau (B), total Tau following MC1 IP (C), and
Hsc70 binding to MC1 Tau (D).
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APPENDIX C4:

Neuronal Life Span Versus Health Span
Principles of Natural Selection at Work in the Degenerating
Brain

Abstract

Impaired nutrient delivery to the brain due to decreased blood
flow contributes to cognitive decline and dementia in Alzheimer’s
disease (AD). Considering this, many studies have suggested that
neuroprotective agents like those used in stroke could prevent AD
onset or progression by promoting cell survival. However, research in
the past decade suggests that the culprit behind the cognitive loss in
AD models is actually the soluble tau accumulating inside of surviving

4

This work was previously published in the Journal of Molecular
Neuroscience (O’Leary III, J. C., Koren III, J., & Dickey, C. A. (2011).
Neuronal Life Span Versus Health Span: Principles of Natural Selection
at Work in the Degenerating Brain. Journal of Molecular Neuroscience,
45(3), 467-472.), and is used here with permission of the publisher.
The permissions are available in Appendix F.
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neurons. In fact, tau reductions improve cognition in mouse models of
AD, even those that only deposit amyloid plaques. There is emerging
evidence that neuroprotection alone in these AD models may be
insufficient to restore neuron function and cognition. Only when
soluble tau is reduced on a neuroprotective background could memory
be rescued. Thus, once a neuron begins to accumulate tau, it may
survive in a malfunctioning capacity, leading to impaired electrical
signaling and memory formation in the brain. These data imply that
multiple drugs may be necessary to ameliorate the different disease
components. In fact, strategies to preserve neurons without affecting
the soluble protein burden within neurons may accelerate the disease
course.

Review

Cerebral angiopathy and blood flow dysregulation in AD
Current research in Alzheimer’s disease (AD) suggests that
cerebral angiopathy (CA) can occur from excess neuronal secretion of
amyloid beta (Aβ) and from preexisting vascular disease (Iadecola
2004; Zlokovic 2008). Aβ can be cleared from the brain by vascular
transport across the blood–brain barrier. This free Aβ can bind to
different transport-binding proteins like apolipoprotein J (Ghiso et al.
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1993) and E (Yang et al. 1997), transthyretin (Schwarzman et al.
1994), lipoprotein receptors (Matsubara et al. 1999), and several
others. Vascular smooth muscle cells (VSMC) have recently been an
intense area of focus due to their ability to internalize and clear Aβ and
contract the capillary (Urmoneit et al. 1997). Thus, modulation of
VSMC could provide a cellular and molecular link between vascular
disorders and AD. The VSMC can clear Aβ by using lipoprotein
receptor-related protein-1 to sequester it (Shibata et al. 2000;
Urmoneit et al. 1997). It is speculated that when the neuron begins
secreting excess amyloid, the VSMC becomes saturated, allowing Aβ to
accumulate. Aβ is also capable of potentiating the cell’s constriction
capability (Niwa et al. 2001; Paris et al. 2002). In fact, when Aβ 1–40
peptide is administered to wild-type mice by topical superfusion, the
subjects display reduced resting cerebral blood flow (Niwa et al. 2001).
Also, it has been found that serum response factor and myocardin are
upregulated in AD tissue (Chow et al. 2007). They are transcription
factor proteins that facilitate the VSMC-differentiated phenotype.
Hence, AD patients may have a hypercontractile phenotype that can be
further potentiated by Aβ. The amyloid cascade hypothesis is further
supported by studies showing that the overexpression of amyloid
precursor protein (APP) in mice is capable of causing pathologic
changes before the detectable appearance of amyloid plaques. In the
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PDAPP mice, dentate gyrus volume is reduced before plaque formation
(Redwine et al. 2003). Mice overexpressing the Swedish APP mutation
exhibit a reduction in hyperemia (Niwa et al. 2000). On the other
hand, vascular disease on its own is also capable of reducing blood
flow across the blood–brain barrier, creating a hypoxic state. Hypoxia
has been shown to decrease the ability of VSMC to clear Aβ (Bell et al.
2009). Another complication arising from CA is that reduced blood flow
leads to energy deprivation, which in turn potentiates beta-secretase 1
(BACE1) levels (O’Connor et al. 2008). Since BACE1 is the rate-limiting
step of Aβ production, more BACE1 proteins create more Aβ peptide.
Ultimately, a cascade can arise from CA that becomes selfperpetuating, manifesting in dementia.

Neuroprotective agents for AD
Because of the strong vascular component in AD, there has been
a search for compounds that can elongate the life of neurons. Many
drugs have been proposed to have possible neuroprotective effects in
AD based on their ability to scavenge antioxidants and free radicals.
Examples of these drugs are indole-3-propionic acid (IPA), vitamin E,
and resveratrol.
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IPA is an inhibitor of Aβ fibril formation, an antioxidant, and
neuroprotectant. To assess its ability to protect neurons from ischemic
damage, it was administered for 15 days at a 10 mg/kg dose to mice.
Tissue was collected, and IPA was shown to spare neurons from
ischemic damage ~300% (Hwang et al. 2009). IPA has also been
shown to inhibit Aβ fibril formation, but other indole derivatives like
indole 3-acetic acid, indole 3-carbinol, and tryptophol were more
effective (Morshedi et al. 2007).

Vitamin E is currently in phase III of clinical trials to treat AD.
However, beneficial effects of vitamin E in patients with moderate to
severe AD have been modest (Brewer 2010). Vitamin E treatment of
2,000 IU slowed the functional deterioration of patients, improving
their daily living, but failing to improve the mini-mental exam score
(Grundman 2000; Petersen et al. 2005).

Resveratrol can promote antioxidant activity, has neuroprotective
effects, and activates sirtuins and their positive effect on aging (Albani
et al. 2010). This compound, derived from grapes, improves cognition
and reduces plaque pathology in animal models of AD
(Karuppagounder et al. 2009; Kim et al. 2007; Wang et al. 2006).
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Resveratrol is one of the more promising compounds that have entered
clinical trials.

Pharmacological agents like resveratrol and IPA may indeed be
neuroprotective, but questions about a strategy designed to spare sick
neurons are beginning to emerge. In some sense, this is in direct
violation of Darwinian principles: Culling of the weak or sick from the
herd is better for the species population as a whole. This same
principle may be in play in the brain. Perhaps, sparing neurons that
harbor aberrantly accumulated proteins could worsen brain function.
Thus, extending the life of neurons that have already begun to
accumulate tau may not be an effective strategy. Perhaps, the brain is
able to adapt when a neuron dies, as has been shown in stroke and
occlusion diseases; the plasticity in the brain can reroute processes to
perform essential functions. However, when a neuron is chronically
sick, but surviving, the brain may continue to route information
through it, but that neuron may simply be unable to propagate the
signal (Figure C1).
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Pathologically visible tau or invisible soluble intermediates; what
should we be targeting?
Although there are strong data demonstrating the adverse
effects of vascular dysfunction and amyloid accumulation in AD,
research in the last decade suggests that tau may be a better
therapeutic target. Recent work has demonstrated a critical role for tau
in amyloid-induced deficits of the human amyloid precursor protein
(hAPP) mice (Roberson et al. 2007). Since these mice do not develop
tau pathology, it was long assumed that tau did not have a role in their
cognitive deficits. However, when the hAPP transgenic mice were
crossed onto a tau null background, the cognitive deficits induced by
amyloid accumulation were ameliorated. Moreover, tau depletion
protected against both kainate- and GABAA receptor antagonist
(pentylenetetrazol)-induced seizures. Furthermore, tau reduction did
not change Aβ deposition, neuritic dystrophy, or aberrant sprouting.
This study suggests that tau may be a better therapeutic target
because it is necessary for Aβ-mediated cognitive deficits and
excitotoxicity. Also, it suggests that cognition can be improved despite
amyloid pathology.

Another piece of evidence that supports tau-induced cognitive
decline is the creation of the rTg4510 mouse model (Santacruz et al.
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2005), which is doubly transgenic for the tetracycline operator driven
by the CamKII promoter and human P301L tau driven by the PrP
promoter and regulated by the tetracycline-responsive element. These
mice accumulate tau tangles and develop severe neurodegeneration
and cognitive deficits. A large group of rTg4510 mice were trained to
find the hidden escape platform in the Morris water maze (MWM) at
2.5 months of age. It was found that tau was not affecting all mice
equally. As a result, the mice were split into two cohorts. To test the
effect of tau reduction and pathology on cognition in a suboptimally
performing cohort, tau expression was shut off at 2.5 months of age in
half of the mice, while the other half received control diet. The mice
were retrained and tested at 4.5 months, an age prior to onset of
neurodegeneration. Suppressing tau expression for 2 months enabled
mice that had previously performed poorly in the MWM to now learn
and recall the location of the escape platform, while the performance
of the vehicle-treated rTg4510 mice continued to decline. Next, the
higher-performing cohort had doxycycline treatment initiated at
5.5 months, a point when neurodegeneration and frank tangle
pathology begin in this model. These mice had improved cognitive
function despite increasing tangle formation. These two studies
showed that not only is soluble tau able to impair learning and
memory but tangles failed to correlate with memory improvement.
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A role for soluble tau in altering cognitive function was reemphasized
in a subsequent study using the rTg4510 model (O’Leary et al. 2010).
Seven-month-old rTg4510 mice were treated with the pleiotropic
compound, methylene blue (MB), which is currently in clinical trials for
AD. Direct hippocampal infusion of MB improved learning and memory
in the rTg4510 mice, but neither pathology nor neuronal morphology
was altered: Only soluble tau was extensively reduced.

In a more recent study, the role of caspase cleavage of tau was
tested in the rTg4510 model. Caspase activation was shown to occur
before tangle formation, tangle-bearing neurons were long lived, and
aggregated tau was able to suppress caspase activity (de Calignon et
al. 2010). Conversely, injection with a virus expressing wild-type
human tau induced caspase cleavage of tau, suggesting that soluble
cytosolic tau could activate caspase. This work suggests that tau
tangles may protect the neuron from apoptosis, while soluble tau can
induce caspase activation and possibly neurotoxicity.

There is still more evidence for the importance of soluble tau in
disrupting neuronal function. Mice overexpressing wild-type human tau
show no tau insolubility or neuronal loss, yet these mice have memory
deficits and synaptic dysfunction. Conversely, mice overexpressing the
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P301L variant of human tau did develop neuronal loss and tau
insolubility, but these mice were cognitively intact and synapses were
functional (Kimura et al. 2010). This concept provides further support
to the notion that accumulation of soluble tau essentially clogs the
neuron, but does not kill it, leading to reduced overall brain function.
In fact, neuronal death and insolubility of tau are less deleterious
compared to soluble tau accumulation and survival of suboptimally
performing neurons.

There are several mechanisms through which soluble tau might
accumulate and take on a deleterious function. Pre-fibrillar Aβ can
cause microtubule disassembly, resulting in a loss of function for tau
and an increased cytosolic burden of free tau (King et al. 2006;
Rapoport et al. 2002). Aberrant phosphorylation and mutations
associated with some tauopathies also reduce tau’s affinity for the
microtubules (Wagner et al. 1996), possibly enlarging the pool of tau
that is not microtubule bound (Dayanandan et al. 1999). Another
possible way that soluble tau becomes enriched in the cytosol would
be by overexpression. Indeed, this occurs naturally in sporadic
Parkinson’s disease (Simon-Sanchez et al. 2009). It has been shown
that overexpression of wild-type human tau leads to excess free tau in
the cytosol (Andorfer et al. 2003), providing a greater opportunity for
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tau to interact with itself and aggregate into a soluble nonfunctioning
intermediate. Thus, perhaps when tau loses its microtubule function, it
can gain a toxic function. For example, tau can mediate Aβ
excitotoxicity by allowing fyn to phosphorylate the NMDA receptor
subunit 2 (Ittner et al. 2010). In this study, crossing the APP23
transgenic mouse line with tau null mice disrupted the dendritic
targeting of fyn. Interestingly, the same result was achieved by
overexpressing a truncated form of tau that lacks the microtubulebinding domains of tau. Again, this suggests that soluble, free tau
without the capacity to interact with microtubules may be even more
deleterious to neuronal function.

All of these evidences strengthen the rationale for developing
strategies to deplete free, soluble tau to treat AD. While reducing all
tau has been thought likely to be harmful, there are several findings
that suggest that the brain may be more tolerant of such a strategy
than first imagined. In particular, tau knockout mice are functionally
intact, due in part to compensation by MAP1a (Harada et al. 1994;
Tucker et al. 2001). Moreover, fast axonal transport is not affected in
tau knockout mice (Yuan et al. 2008). Considering this evidence and
that many of the patients who would receive anti-tau therapies would
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be elderly, reducing tau may indeed be a well-tolerated strategy to
ameliorate AD symptoms and modify disease course.

Life span versus health span for neurons: do Darwinian
principles apply in a degenerating brain?
The phenothiazine class of compounds includes the controversial
compound, methylene blue (MB). The pleiotropy of MB has raised a
number of concerns about its clinical application. More than a decade
passed between the time that MB was first reported to prevent tau
aggregation in solution and the time that the first reports emerged
describing successful use of MB in the clinic (Wischik and Staff 2009;
Wischik et al. 1996). Since then, a number of studies have begun to
dissect the mechanisms contributing to the efficacy of this drug. MB
was shown to reduce Aβ levels in the 3xTg-AD mouse model and
improve learning and memory (Medina et al. 2011). In this study, MB
treatment was given for 4 months, beginning at the age of 6 months.
MB treatment ameliorated learning and memory deficits in this mouse
model and reduced Aβ levels, but failed to alter tau.
Other studies have ascribed one mechanism of MB action to its
ability to inhibit the molecular chaperone Hsp70. Indeed, this activity
was shown to destabilize tau in cells and mice (Jinwal et al. 2009). MB
treatment was recently shown to improve cognitive function in rTg4510
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mice, but only when sufficiently high doses were present in the brain
(O’Leary et al. 2010). Interestingly, tau tangle pathology as assessed
by histology was unchanged in these mice compared to those treated
with vehicle. When stereological analyses were performed on tissues
from these mice, MB facilitated neuroprotection in all treated mice;
however, this neuroprotection did not correlate with cognitive function.
Biochemical analyses of tissue from these mice showed that soluble
tau levels were reduced by MB treatment, but only in mice with high
concentrations in their brain. Surprisingly, reduced soluble tau burden
correlated with improved cognitive function in this study.

An additional report recently showed that reducing soluble tau
burden with a purely genetic approach could improve neuronal
function in the rTg4510 mice, as measured by long-term potentiation
(Abisambra et al. 2010). Moreover, overexpression of wild-type human
tau in mice does not beget tau insolubility or neuronal loss, but does
cause cognitive dysfunction, while overexpression of mutant tau
causes neuronal loss and insolubility of tau, but does not lead to
memory deficits (Kimura et al. 2010). These results allow for several
conclusions to be drawn. First, neuroprotection alone is insufficient to
rescue memory function in tau transgenic mice, decoupling two
processes that have always been intertwined. Secondly, reductions in
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tau tangle pathology are not necessary for neuroprotection or
cognitive improvement. Lastly, reducing soluble tau levels is necessary
for cognitive improvement in this model, but it is not required for
neuroprotection.

This work has several important implications regarding classical
paradigms about the relationship of neuronal survival, neuronal health,
and overall brain function. When soluble proteins accumulate in the
cytosol, the endgame may be neuronal death, but there are likely
many neurons that continue to survive for long periods of time in a
suboptimal, or functionally impaired, state. This is likely due to the
intracellular accumulation of “sticky” proteins. Strategies aimed at only
protecting these sick neurons may ultimately be deleterious to brain
function. Instead, focusing on amelioration of the protein accumulation
in these neurons to restore their function may prove more therapeutic.
Simply prolonging the life of nonfunctioning neurons may prevent
compensatory brain plasticity mechanisms from being triggered to
overcome the loss of function of a discreet circuit (Figure C1). While
neuroprotective strategies may indeed be beneficial, it might be critical
to couple such agents with a treatment that can reduce the soluble
protein accumulation that burdens neurons in many neurodegenerative
diseases. Neuroprotection has proven successful in stroke; however,
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these neurons do not have toxic soluble proteins accumulating within.
In neurodegenerative diseases resulting from proteotoxicity,
neuroprotection without reducing the toxic protein burden may be
harmful.

Conclusions

The population with AD is expected to grow tremendously within
the next 20 years as the first wave of baby boomers reaches 65 years
of age this year. In addition to AD, there are more than 15 other
neurodegenerative diseases where tau is pathogenic. Research from
the most recent decade suggests that ameliorating soluble tau protein
accumulation may provide patients with greater cognitive
improvement and behavioral health. This, coupled with neuroprotective
agents, may be an even more effective clinical strategy. However,
neuroprotection without also rescuing the soluble proteotoxic burden in
neurons may be unsuccessful, essentially allowing malfunctioning
neurons to evade the “survival of the fittest” principle. Thus, the brain
may be unable to recognize a need to reconfigure damaged circuitry.
Strategies aimed at only neuroprotection may ultimately accelerate the
course of these disorders.
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Figure C1
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Figure C1. Suboptimally function- ing neurons surviving with
pro- teotoxic tau accumulation subvert brain plasticity that
nor- mally occurs in response to neuronal death. (A) Neuronal
transmission in normal brain. (B) Suboptimally performing neu- rons
due to tau accumulation cannot transmit a signal to the postsynaptic
neuron, and the brain fails to reroute connectiv- ity since the neuron is
not dead. (C) Neuronal death facilitates net- work rerouting, allowing
the plastic brain to adapt and rees- tablish downstream connectivity.
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APPENDIX D:

The Role of FKBP5 in Mood Disorders:
Action of FKBP5 on Steroid Hormone Receptors Leads to
Questions About its Evolutionary Importance

Abstract

Research on the FKBP5 gene and FKBP51 protein has more than
doubled since the discovery that polymorphisms in this gene could
alter treatment outcomes and depressive behavior in humans. This
coincided with other data suggesting that the stress hormone axis
contributes to the development of numerous mental illnesses. As a
result, FKBP51 now lies at the heart of the research of many stress
related psychiatric disorders, which has led to advances in the
understanding of this protein and its role in humans and in animal
models. Specifically, FKBP5-/- mice and a naturally existing
overexpression of FKBP5 in 3 genera of new world monkeys have
helped understand the effects of FKBP5 in vivo. This review will
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highlight these finding as well as discuss the current evolutionary need
for the FKBP5 gene.

Introduction

Mood disorders are characterized by feelings of sadness,
frustration, loss, anger, anxiety, fear, or panic that in disease become
chronic and interfere with normal life. Research in the last decade has
found that dysregulation of steroid hormone receptors can cause mood
disorders. The hypothalamus-pituitary-adrenal (HPA) axis, for
example, which produces glucocorticoids and releases them into the
blood stream, has been linked to depression (Holsboer, 2000; de Kloet
et al., 2005).

Steroid hormones, produced in the periphery by endocrine
glands (Belelli and Lambert, 2005), can cross the blood-brain-barrier
and bind to steroid hormone receptor complexes that produce changes
at the cellular level and global level, such as acting as transcription
factors for gene expression upregulation, altering neuronal excitability,
and modifying mood and behavior. Steroid hormone receptors are
ubiquitously expressed in almost all human tissues including the brain,
and are especially abundant in the parts of the brain that control mood
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and emotion: the hypothalamus, hippocampus, amygdala, and
prefrontal cortex (de Kloet et al., 2005). As a result, the brain is
susceptible to mood disorders generated by aberrant function of
steroid hormone receptors (De Kloet et al., 1998).

To this end, researchers have looked for genetic and
environmental factors that increase the risk of psychiatric disease.
Genome wide association studies for single nucleotide polymorphisms
(SNPs) have revealed significant associations between allelic variants
of the FKBP5 gene and depression (Binder et al., 2004; Tatro et al.,
2010), post-traumatic stress disorder (PTSD) (Xie et al., 2010), bipolar
disorder (Willour et al., 2009), peritraumatic dissociation (Koenen et
al., 2005), suicide (Brent et al., 2010; Roy et al., 2010; Supriyanto et
al., 2011; Roy et al., 2012), negative personality traits (Shibuya et al.,
2010), and aggression (Bevilacqua et al., 2012). An environmental
factor found to interact with this gene is stress (Binder, 2009; Lupien
et al., 2009). The current primary biological role of FKBP51 is thought
to be with the protein heterocomplex of steroid hormone receptors
within the HPA axis, where it helps regulate receptor sensitivity
(Jaaskelainen et al., 2011).
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Due to the overwhelming evidence that stress and the FKBP5
gene are involved in psychiatric diseases, studying how this gene
works is imperative to understanding the mechanisms of mood
disorders and finding therapies.

Review

HPA-axis and stress
A general definition for stress is a disruption of homeostasis due
to a real or perceived threat to the well-being of the organism
(Chrousos and Gold, 1992; de Kloet et al., 2005). For example, upon
the perception of threat, the amygdala immediately activates the
autonomic nervous system and the HPA-axis.

The hypothalamic-pituitary connection provides the brain with
endocrine function (Ulrich-Lai and Herman, 2009). This system
evolved to allow the brain to turn the production of hormones that are
made distally in the periphery off and on. These hormones travel
through the blood, cross the blood brain barrier and bind to their
specific receptors in distinctive brain areas.
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The brain uses multiple hormones to trigger the synthesis of
cortisol, which is the most abundant stress hormone. The
Hypothalamic neurons synapse at the pituitary where they release
corticotropin-releasing hormone (CRH), also known as corticotropinreleasing factor (CRF) (Lupien et al., 2009). The pituitary will then
respond by producing adrenocorticotropic hormone (ACTH), and
releasing it into the blood stream. ACTH will bind to its receptor in the
adrenal gland, which is located above the kidneys, and trigger the
adrenal cortex to synthesize glucocorticoids, including cortisol, and
release them into the blood stream (Lupien et al., 2009).

Glucocorticoids have two main receptors in the brain, the
mineralcorticoid receptor (MR) and the glucocorticoid receptor (GR). At
low concentrations, the MR is the main active receptor, while at high
concentrations the GR is the main active receptor since all MRs are
occupied (Reul and de Kloet, 1985; Arriza et al., 1988).

The MR and GR are cytoplasmic receptors that translocate to the
nucleus upon hormone binding (Datson et al., 2001). There, they
activate as well as suppress transcription of many genes. The system
is also self-regulating, such that activation of GR triggers a negative
feedback loop that attenuates the axis and consequently stress239

hormone production (Lupien et al., 2009). Thus the rate of feedback
inhibition can have dramatic impact on the length of time that the
stress hormone system is active. GR is in virtually every tissue of the
body, helping to coordinate the body’s response to stress; however the
feedback inhibition primarily occurs in the amygdala, hypothalamus,
and the pituitary to shut down production. Some systemic functions of
GR activation other than those affecting mood, decision-making or
memory function, include increased metabolism and inhibition of
inflammation (Sapolsky et al., 2000).

Cellular role and biochemistry of FKBP51 with focus on steroid
hormone receptors
FKBP51 (FK506 binding protein 51) is part of the immunophilin
family, a superfamily of highly conserved proteins first characterized
by their ability to bind to immunosuppressant drugs (Barik, 2006). The
superfamily is divided into two sequence families by the type of
immunosuppressant to which it binds.

FKBPs are able to bind to

FK506 and rapamycin, two immunosuppressants of fungal origin. In
addition to their drug-binding capability, some FK506-binding
immunophilins are also protein chaperones, with the related but
apparently separate ability to isomerize proline residues (Barik, 2006).
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FKBP51 (FK-506 Binding Protein 51kDa, p54, FKBP54) was originally
identified as a novel FK-506 binding protein capable of peptidyl-prolyl
cis-trans isomerization (PPIase) activity (Wiederrecht et al., 1992).
PPIases, like FKBP51, are able to change the conformation of proline
residues, a unique amino acid with the capability of existing in cis and
trans conformations (Barik, 2006). Proline cis-trans transitions are
important for proper protein folding (Barik, 2006), yet deletion of the
N-terminal PPIase domain (FK1) had little effect on FKBP51’s efficacy
as a chaperone. Instead, the C-terminus of FKBP51, which includes
three highly degenerate 34-amino-acid repeats known as
tetratricopeptide repeats (TPRs),

has been found to exhibit

independent protein-folding activity.

Up until recently, however, FKBP51 was relatively unstudied,
particularly because its function in cellular processes was not well
known. In fact, it is not understood whether PPIase activity in general
is necessary for cell viability. But studies have begun to elucidate its
role in the biology of the cell. For example, FKBP51 was recently found
to regulate the phosphorylation of the microtubule associating protein
tau (MAPT, tau), a protein whose aggregates are a hallmark of
Alzheimer’s disease (Jinwal et al., 2010). FKBP51, and other
immunophilins, have also been found to interact with steroid hormone
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receptor heterocomplexes, an interaction mediated by the chaperone
heat shock protein 90 (Hsp90) (Chen et al., 1996), (Davies et al.,
2005).

Three hormone receptor complexes that interact with FKBP51
are the glucocorticoid receptor (GR), progesterone receptor (PR), and
androgen receptor (AR). Each, are transcriptionally active steroid
hormone receptor complexes whose activation leads to a change in the
transcription rate of many genes, one of which is FKBP5. Paradoxically,
FKBP51 also inhibits the activation of GR (Denny et al., 2000) and PR
(Hubler et al., 2003). These receptors thus have a short negative
feedback loop built into their activity, while AR, on the other hand, is
positively regulated by FKBP51 (Denny et al., 2005). Two questions
arise from the effect of FKBP51 on GR, PR and AR. Is PPIase activity
necessary? Is binding to Hsp90 necessary?

The exact mechanism of action within the steroid hormone
receptor heterocomplex has been difficult to piece together, since the
importance of PPIase activity of immunophilins is questionable. One
study analyzing the relative importance of the PPIase and TPR domains
in squirrel monkey FKBP51 rendered each of the protein domains
inactive via site-directed mutagenesis and showed that while only the
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TPR domain was required for FKBP51 to bind to the GR and PR
complex with Hsp90, both PPIase and TPR domains were required for
the FKBP51 inhibitory effect on GR to be effective (Denny et al., 2005).
Other studies, however, showed that PPIase activity is not necessary
for its inhibitory action on GR(Wochnik et al., 2005) but is necessary
for its activating action on AR (Ni et al.). All three complexes do
require Hsp90 for FKBP51 to have an effect, as Hsp90 was found
necessary to be bound to FKBP51 for it to have its inhibitory action on
GR (Denny et al., 2005), PR (Hubler et al., 2003), and its activating
action on AR (Ni et al.). The data indicate that, perhaps due to
structural reasons, the physical presence of FKBP51 may be more
important than its PPIase enzymatic activity.

SNPs and FKBP51 mechanism of action
Genome-wide association studies (GWAS) have enabled
scientists to look at small changes in DNA and the effects of single
base pair variations called single nucleotide polymorphisms (SNPs) on
gene expression and function. SNPs in FKBP5 have been associated
with mood disorders and an increased risk for PTSD, suicide, and overt
aggressive behavior. One particular SNP in the FKBP5 gene,
rs1360780, was associated with an increased number of depressive
episodes (Binder et al., 2004). A closer look at the SNP revealed three
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different polymorphisms possible at the site:

TT homozygotes, CT

heterozygotes, and CC homozygotes. Association of these SNP
variations with episodes of depression and responses to antidepressant
treatment showed that individuals with TT homozygosity had more
frequent episodes of depression but also a faster recovery from
antidepressant therapy. SNP association studies were performed with
FKBP51 and other psychiatric disorders, with findings that FKBP51
SNPs are also associated with mood disorders, many of which were
formed in conjunction with childhood trauma. Increased risks of
developing PTSD (Xie et al., 2010), suicide (Roy et al., 2010; Roy et
al., 2012), and overt aggressive behavior were also associated with
certain FKBP51 polymorphisms (Bevilacqua et al., 2012).

Mechanistically, the effect of FKBP5 polymorphisms on mood
disorders is elusive.

One particular area of study is the HPA axis, as

FKBP51 is a known regulator of HPA-axis activity. The HPA-axis has
major roles in both PTSD and depression, albeit with opposite
phenotypes. Patients with Major Depressive Disorder (MDD) have a
hyperactive HPA-axis, where an increased stimulation of adrenal
corticotropic hormone (ACTH) and GR desensitization cause high
amounts of cortisol to be released and retained in the bloodstream.
PTSD patients, on the other hand, have hypersensitive GR and a
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hypersuppression of cortisol (Binder, 2009). The SNP rs1360780 is
thus of great interest here, as it is associated with increased risks of
both PTSD and depression, despite these diseases having different GR
sensitivities. For example, the TT genotype may provide mechanistic
evidence on how FKBP51 could cause HPA-axis dysregulation, as it was
shown that individuals with TT had higher basal levels of FKBP51 and
thus very likely a greater inhibition effect on GR activity. However
Depressed patients with TT genotypes had greater decreases of ACTH
and cortisol levels in response to the DEX/CRH test than depressed
patients with CC and TC genotypes. The study did not, however,
compare the FKBP51 levels of healthy controls with the TT genotype
versus depressed patients with the same genotype, and so it is unclear
if FKBP51 levels are higher due to depression or if all people with the
genotype exhibit increased levels of FKBP51.

Nevertheless healthy

individuals with the TT genotype were shown to lack a normalization of
cortisol levels after stress as compared to the CC and CT genotypes;
TT individuals had higher cortisol levels for a longer period of time
(Ising et al., 2008). The data from the healthy controls resembled
those having high FKBP51 levels, and the data of the depressed
patients resembles those having low FKBP51 levels.
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How do we make sense of the fact that people with the same
genotype had different GR phenotypes depending on the disease
state? It may be that healthy individuals only have high levels of
FKBP51 in the short term, but the chronic stress state may increase
FKBP51 levels in the long term, which could drive adaptive changes in
GR activity. However, if FKBP51 protein levels were elevated in this
genotype irrespective of disease state, it may be that another risk
factor is interacting with FKBP51 to promote depression. In individuals
with this genotype with probable PTSD, baseline cortisol activity was
not elevated as compared to healthy controls (Binder et al., 2008),
while it was in depressed patients (Binder et al., 2004). Thus it is clear
that while genotypes do not consistently affect GR in the same way,
the risk for mood disorders is clearly elevated by the rs1360780 SNP.
This suggests that factors other than just GR must be responsible for
the differential disease phenotypes.

FKBP5 animal models
Studies of FKBP51 in animal models have proven helpful in
determining endogenous and stress-response levels of FKBP51
expression in different regions of the brain. A study of FKBP5 mRNA
levels in the murine brain discovered that under basal conditions, the
highest levels occurred in the hippocampus (Scharf et al., 2011),
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especially the dentate gyrus, and the premammillary nucleus, the
motor nuclei of the nervus trigeminus and the nervus facialis.
Interestingly, lower levels of FKBP5 mRNA were found in the amygdala
and the hypothalamic paraventricular nucleus (PVN), the latter of
which is a part of the HPA axis and a stress response mediator.
Stressing the mice, however, showed a marked increase in FKBP5
mRNA levels in these two regions. Both moderate and short-term
stress and strong and long-lasting stress caused FKBP5 mRNA levels to
rise in dose-dependent fashion. Moderate stress was caused through a
4-hour restrain, and a 1-day food deprivation paradigm was used as
the long-lasting stressor. Upregulation of FKBP5 mRNA was observed
in the central amygdala, the hypothalamic PVN, and the hippocampus
after both conditions, with a stronger response after food deprivation
in all regions. Injecting the mice with dexamethasone, a corticosteroid
analog and GR agonist, also increased the levels of FKBP51 mRNA,
supporting the hypothesis that the stress response and FKBP5 mRNA
levels are linked to the GR.

However, while all three regions showed increased levels of
FKBP5 mRNA, the relative increase differed based on the baseline
levels already observed in the mouse brain. The hypothalamic PVN and
the central amygdala, which had low endogenous FKBP5 mRNA levels,
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had average FKBP5 mRNA increases of over 600% from baseline, while
the hippocampus, which has a relatively high basal level of FKBP5
mRNA, had average increases of less than 200%. It appears that
higher endogenous levels of FKBP5 mRNA caused the GR in those
particular brain regions to become less responsive to corticosteroid
stimulation. In cases of chronic stress, constant high levels of stress
could result in potentially long-term elevated corticosteroid levels, and
induce high levels of FKBP5 mRNA expression, in turn causing GR
activity to become resistant.

Two additional models have been studied intensively, FKBP5-/mice and new world monkeys. Three genera of new world monkeys
have been discovered to have naturally occurring GR resistance due to
excess production of FKBP51 (Scammell et al., 2001).

This begs the

question of whether this affects the behavior of the monkeys. An
induced model of depression in monkeys exist (Clark and Gay, 1980),
and extreme social stress causes coronary artery disease (Petticrew
and Davey Smith, 2012), presumably due to hypercortisolemia, but it
is not clear whether it is FKBP5 dependent. However, it does suggest
that the hypercortisolemia seen in humans with depression could be
aided by a reduction in the levels of FKBP51.
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The function of the HPA axis was studied in the FKBP51-/- mice.
The mice displayed a moderate GR hypersensitivity, as they produced
less corticosterone (the main murine glucocorticoid) and recovered
faster after dexamethasone (DEX) and stress treatment (Touma et al.,
2011). The DEX/CRH test was compared between FKBP51-/- mice and
healthy humans of the rs1360780 SNP. Healthy humans with the TT
genotype displayed GR hyposensitivity to dexamethasone while the
FKBP51-/- mice displayed GR hypersensitivity, showing that reduction
in levels of FKBP51 may be a successful therapy for GR insensitivity.
In terms of protein levels and protein expression, FKBP51-/- mice
exposed to chronic social defeat stress produced equal amounts of
CRH mRNA as compared to wild type before and after stress, although
levels did increase after stress (Hartmann et al., 2012). This
demonstrated that corticosterone levels were not reduced in the
FKBP51-/- mice due to the lack of HPA activation, but rather due to the
FKBP51-GR negative feedback mechanism that has been characterized
so well. It was found, on the other hand, that the lack of FKBP51 alters
the levels of GR. In wild type mice, GR levels decreased during a 1 hr
restraint stress experiment, yet in FKBP5-/- mice they increased at 15
minutes then went down slightly, but remained significantly higher
than wild type. It is also possible that FKBP51 may actually be
regulating the levels of GR, particularly since Hsp90 is intimately linked
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to proteasomal degradation (Ballatore et al.) and Hsp90 is a part of
the GR complex.

Surprisingly, general behavior was not changed in 10-16 week
old (young) FKBP5-/- mice. As a result, changes in behavior after
stress were studied. Young FKBP5-/- mice showed significantly less
time immobile in the forced swim test than wild type mice after
restraint stress (Touma et al., 2011). Moreover, FKBP51 is a protein
whose expression increases with age (Jinwal et al., 2010), and young
mice have low basal levels in the hypothalamus and amygdala. It may
be that the young mice needed FKBP51 to be expressed after stress to
modulate behavior, since basal FKBP51 levels were low. Twenty-two
month old mice (old), however, displayed this phenotype in the forced
swim test without prior stress (O'Leary et al., 2011). General behavior
in the old mice was also unchanged, especially in learning and
memory, implying that FKBP51 may have a role limited to the biology
of the stress response. But this role may be protective, as stress and
its related molecules are known to cause cognitive impairment
(Diamond et al., 1992; de Quervain et al., 1998; Diamond et al., 1999;
Diamond et al., 2004; Sandi, 2004; Diamond et al., 2005; Diamond et
al., 2006).
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FKBP5 and neuropsin-mediated effects in the amygdala
Recently, FKBP51 was found to be involved in stress response in
the amygdala. FKBP51 was found to be upregulated by NMDA
activation and caused anxiety in mice after stress (Attwood et al.,
2011).

This effect was dependent on the cleavage of EphB2 by

neuropsin, causing EphB2 to disassociate from the NR1 subunit of the
NMDA receptor and enhancing NMDA receptor current. Neuropsin is an
extracellular serine protease and EphB2 is a receptor tyrosine kinase,
and both are heavily expressed in the amygdala and hippocampus,
with higher basal expression in the hippocampus, similar to FKBP51.
After stress, neuropsin is dramatically upregulated in the amygdala.
This data was not shown in the hippocampus; it would be interesting
to find out if neuropsin had a similar expression profile to FKBP51 and
to see the basal and stress-induced expression of FKBP51 in neuropsin
knockout mice. In amygdala neuronal cell cultures, the majority of
FKBP51 expression was found to be due to the activity of neuropsin
and not by corticosterone, and it may be that FKBP51 has a primary
role in stress behavior in a neuropsin dependent mechanism, and that
its role with GR is secondary to that. Additionally, despite FKBP51
expression upregulation by NMDA receptor activation, no effects are
shown in learning and memory. It may be that a large threshold of
NMDA receptor activation is needed to trigger the upregulation of
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FKBP51, and the large threshold would only be reached during
extreme situations like stress, and thus FKBP5 would be activated to
promote behavioral signatures of anxiety.

The need of the FKBP51 gene in the brain is unclear, as it seems
to be extremely problematic, and its absence does not seem to have
negative effects. A posited theory for the development of FKBP51 may
be within the fear response. Evolutionary genetics suggest that these
genes arose early in development; analysis of phylogenetic
relationships among 100 FKBP domains show a clustering pattern that
suggests the emergence of the FKBP genes early in eukaryotic
evolution (Patterson et al., 2002), and another study suggests that
FKBP proteins arose even before the divergence of prokaryotes from
eukaryotes (Trandinh et al., 1992). As a result, FKBP5 may have
played an important role in the evolution of the stress response.

In

the past we needed to exhibit a proper response to fear, since the
reaction was critical to survival. The problem is, we no longer have the
same life or death triggers.
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Conclusion

It is clear that FKBP51 is a significant player in the human
response to stress. It has a dramatic effect on the biology of steroid
hormone receptors, and is upregulated in the amygdala as part of a
stress response. SNPs within the FKBP5 gene are associated with
mood disorders, but the mechanism of how this happens is not well
understood. Surprisingly, the lack of FKBP51 does not appear to have
deleterious side effects in mice and its presence causes steroid
hormone receptor hypersensitivity. This not only makes FKBP51 an
excellent drug target, but it also suggests that FKBP5 may be genetic
baggage that no longer provides a competitive advantage for natural
selection. As successful adaptation allows for a species to age, genes
like FKBP5, which at one point during the evolutionary process were
necessary for their survival and propagation, may actually become
deleterious to the aging process. Furthermore, societal success no
longer follows Darwinian principles. As a result, it may be the role of
society to combat these processes; in the same way that bacteria
adapt to antibiotic pressure, society may need to develop ways to
suppress or even remove these genetic leftovers.
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List of Abbreviations

ACTH: Adrenocorticotropic hormone
AR: Adrogen receptor
CRH/CRF: Corticotropin releasing hormone/factor
FKBP5: Gene name for FKBP51 protein
FKBP51: FK506-binding protein 51
GR: Glucocorticoid receptor
GWAS: Genome-wide association studies
HPA-axis: Hypothalamic-pituitary-adrenal-axis
MDD: Major depressive disorder
MR: Mineralocorticoid receptor
NMDA: N-methyl-D-aspartate
PPIase: Peptydil-prolyl cis-trans Isomerase activity
PR: Progesterone receptor
PTSD: Post-traumatic stress disorder
PVN: Paraventricular nucleus of the hypothalamus
TPR: Tetratricopeptide repeat
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Figure D1. FKBP5 genotype as a modulator of GR phenotype.
Everyone may be vulnerable to mood disorders involving depression
following stress. However, the length of time that an individual remains
vulnerable can be dramatically affected by FKBP51 levels due to its
ability to decrease GR activity. FKBP51 may widen the length of time
after stress that a person is susceptible to stress, while individuals with
low FKBP51 levels may be in this state for a shorter period of time.
While the magnitude of the acute GR response to stress following an
insult may be higher in individuals with low FKBP51 levels, the length
of time that an individual with high levels of FKBP51 spends in a
susceptible state is longer. As a result, SNP’s in the FKBP5 gene may
increase the likelihood of developing psychiatric disorders by altering
the levels of FKBP51. This in turn changes the responsiveness of the
GR, whose balance appears to be critical for normal function. Thus, in
MDD, chronic stress may have a greater effect on those individuals
with too much FKBP51.
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APPENDIX E:

Sequence of FKBP5 Gene

It is often that one underestimates the power of that which is
small. Similarly, we commonly underestimate our potential for great
achievement, precisely because we are small. Ironically, small things
can have tremendous impact. Single nucleotide polymorphisms in the
FKBP5 gene enlarge the size of the stress response, and interact with
traumatic stress in childhood to dramatically increase the risk of major
depressive disorder, and post-traumatic stress disorder. Some of these
polymorphisms are also overrepresented in people who commit
suicide, and develop bipolar disorder. To appreciate the size of a single
nucleotide change, I have included the DNA sequence of mRNA
transcript 1 from the Homo Sapiens FK506 binding protein 51. If a
single nucleotide can have so much impact, maybe we can too.
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Origin
G ATT C G G G C C G G C T C G C G G G C G C T G C C A G T C T C G G G C G G C
G G TG TC C G G C G C G C G G G C G G C C TG C TG G G C G G G C TG A A G G
G TTA G C G G A G C A C G G G C A A G G C G G A G A G T G A C G G A G T C G G
CGAGCCCCCG CGGCGACAGG TTCTCTACTT AAAAGACAAT GACTACTGAT
G A A G G T G C C A A G A A C A AT G A A G A A A G C C C C A C A G C C A C T G
TTGCTGAGCA GGGAGAGGAT ATTACCTCCA AAAAAGACAG GGGAGTATTA
A A G AT T G T C A A A A G A G T G G G G A AT G G T G A G G A A A C G C C G A
TGATTGGAGA CAAAGTTTAT GTCCATTACA AAGGAAAATT GTCAAATGGA
AAGAAGTTTG ATTCCAGTCA TGATAGAAAT GAACCATTTG TCTTTAGTCT
T G G C A A A G G C C A A G T C AT C A A G G C AT G G G A C AT T G G G G T G
GCTACCATGA AGAAAGGAGA GATATGCCAT TTACTGTGCA AACCAGAATA
TGCATATGGC TCGGCTGGCA GTCTCCCTAA AATTCCCTCG AATGCAACTC
TCTTTTTTGA GATTGAGCTC CTTGATTTCA AAGGAGAGGA TTTATTTGAA
G AT G G A G G C A T TAT C C G G A G A A C C A A A C G G A A A G G A G A G G
GATATTCAAA TCCAAACGAA GGAGCAACAG TAGAAATCCA CCTGGAAGGC
C G C T G T G G T G G A A G G AT G T T T G A C T G C A G A G AT G T G G C AT
TCACTGTGGG CGAAGGAGAA GACCACGACA TTCCAATTGG AATTGACAAA
GCTCTGGAGA AAATGCAGCG GGAAGAACAA TGTATTTTAT ATCTTGGACC
AAGATATGGT TTTGGAGAGG CAGGGAAGCC TAAATTTGGC ATTGAACCTA
ATGCTGAGCT TATATATGAA GTTACACTTA AGAGCTTCGA AAAGGCCAAA
GAATCCTGGG AGATGGATAC CAAAGAAAAA TTGGAGCAGG CTGCCATTGT
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C A A A G A G A A G G G A A C C G TAT A C T T C A A G G G A G G C A A ATA C
ATGCAGGCGG TGATTCAGTA TGGGAAGATA GTGTCCTGGT TAGAGATGGA
ATATGGTTTA TCAGAAAAGG AATCGAAAGC TTCTGAATCA TTTCTCCTTG
CTGCCTTTCT GAACCTGGCC ATGTGCTACC TGAAGCTTAG AGAATACACC
A A A G C T G T T G A AT G C T G T G A C A A G G C C C T T G G A C T G G A C A
G T G C C A AT G A G A A A G G C T T G TATA G G A G G G G T G A A G C C C A
G C T G C T C AT G A A C G A G T T T G A G T C A G C C A A G G G T G A C T T T
G A G A A A G T G C T G G A A G TA A A C C C C C A G A AT A A G G C T G C A A
G A C T G C A G AT C T C C AT G T G C C A G A A A A A G G C C A A G G A G C A
C A A C G A G C G G G A C C G C A G G A TATA C G C C A A C AT G T T C A A G
A A G T T T G C A G A G C A G G AT G C C A A G G A A G A G G C C A ATA A A G
C A AT G G G C A A G A A G A C T T C A G A A G G G G T C A C TA AT G A A A A
AGGAACAGAC AGTCAAGCAA TGGAAGAAGA GAAACCTGAG
G G C C A C G TAT G A C G C C A C G C C A A G G A G G G A A G A G T C C C A G
TGAACTCGGC CCCTCCTCAA TGGGCTTTCC CCCAACTCAG GACAGAACAG
TGTTTAATGT AAAGTTTGTT ATAGTCTATG TGATTCTGGA AGCAAATGGC
A A A A C C A G TA G C T T C C C A A A A A C A G C C C C C C T G C T G C T G C
C C G G A G G G TT C A C T G A G G G G T G G C A C G G G A C C A C T C C A G G
T G G A A C A A A C A G A A AT G A C T G T G G T G T G G A G G G A G T G A G C
CAGCAGCTTA AGTCCAGCTC ATTTCAGTTT CTATCAACCT TCAAGTATCC
AATTCAGGGT CCCTGGAGAT CATCCTAACA ATGTGGGGCT GTTAGGTTTT
ACCTTTGAAC TTTCATAGCA CTGCAGAAAC CTTTAAAAAA AAAATGCTTC
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ATGAATTTCT CCTTTCCTAC AGTTGGGTAG GGTAGGGGAA GGAGGATAAG
CTTTTGTTTT TTAAATGACT GAAGTGCTAT AAATGTAGTC TGTTGCATTT
TTAACCAACA GAACCCACAG TAGAGGGGTC TCATGTCTCC CCAGTTCCAC
AGCAGTGTCA CAGACGTGAA AGCCAGAACC TCAGAGGCCA
CTTGCTTGCT GACTTAGCCT CCTCCCAAAG TCCCCCTCCT CAGCCAGCCT
CCTTGTGAGA GTGGCTTTCT ACCACACACA GCCTGTCCCT GGGGGAGTAA
TTCTGTCATT CCTAAAACAC CCTTCAGCAA TGATAATGAG CAGATGAGAG
TTTCTGGATT AGCTTTTCCT ATTTTCGATG AAGTTCTGAG ATACTGAAAT
GTGAAAAGAG CAATCAGAAT TGTGCTTTTT CTCCCCTCCT CTATTCCTTT
TAGGGAATAA TATTCAATAC ACAGTACTTC CTCCCAGCAT TGCTACTGCT
CAGCTTCTTC TTTCATTCTA ATCCTTGCTA TTAAGAATTT AAGACTTGTG
CTTACAATAT TTTTGACCTG GAGTGGATCT ATTTACATAG TCATTTAGGA
TCCATGCAGC TTTTTTTGTC TTTTTAAGAT TATTGGCTCA TAAGCATATG
TATACTGGTT TATGGAACTT TATTTACACT CCTCTATCAT GCAAAAAAAT
TTTGACTTTT TAGTACTAAG CTTAATTTTT AAAAACAAAA TCTGTAGGGT
TGACAAATAA ATAGTTGCTC TTCTACACTA GGGGTTTCAC CTGCAGGTTT
GACACGCAGT TGCTCGCTTT TCCTGCCCTG TCAAGCTTCT CTGTTCTGGC
G T G A G T T G T G A A A G A G T T G A A G A C A G C T T C C C AT G C C G G T
ACACAGCCAG TAGCCTAAAT CTCCAGTACT TGAGCTGACC ATTGAACTAG
GGCAAGTCTT AAATGTGTAC ATGTAGTTGA ATTTCAGTCC TTACGGGTAA
ACAGATTGAG CATGGCTCTC TATTCCCTCA GCCTAAGAAA CACTCATGGG
AATGCATTTG GCAACCCAAG GAACCATTTG CTTAAACCTG GAACATCTCA
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CCTTTTTAAA TCCTAAAAAA CACTGGCAGT TATATTTTAA ATTAGTTTTT
ATTTTTATGA TGGTTTTATC AAAAGACTTT TATTATTAGA TTGGGACCCC
CTTCAAACCT AAAAATCAAG TTATTTCCTT TTATAATACT TTTCTTCCCC
ATGGAACAAA TGGGATCAAT TTGTGAGTTT TTTCCTTTAA TGATAACTAA
AATCCCTCTA ATTTCTCATT TATGCTTTTG TCTTTTTTAT GAAATATTTC
TTTTAAAAGC CCCAGTCTCA CCTACGAAAT ATGAAGAGCA AAAGCTGATT
TTGCTTACTT GCTAAACTGT TGGGAAAGCT CTGTAGAGCA TGGTTCCAGT
GAGGCCAAGA TTGAAATTTG ATACTAAAAA GGCCACCTAG CTTTTTGCAG
ATAACAAACA AGAAAGCTAT TCCAAGACTC AGATGATGCC AGCTGTCTCC
C A C G T G T G TA T TAT G G T T C A C C A G G G G G A A C T G G C A A A A G
T G T G T G T G G G G A G G G G A A G G G T G T G T G A G T G G TT C T G A G C
AAATAACTAC AGGGTGCCCA TTACCACTCA AGAAGACACT TCACGTATTC
TTGTATCAAA TTCAATAATC TTAAACAATT TGTGTAGAAG TCCACAGACA
TCTTTCAACC ACCTTTTAGG CTGCATATGG ATTGCCAAGT CAGCATATGA
GGAATTAAAG ACATTGTTTT TAAAAAAAAA AAATCATTTA GATGCACTTT
TTTGTGTGTT CTTTAAATAA ATCCAAAAAA AATGTGACTT CCAAAAAAAA
AAA
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APPENDIX F:

Permissions

This appendix contains the copyright permissions to use the
material previously published in a journal.

Chapter Two Permission

BioMed Central copyright and license agreement
In submitting a research article ('article') to any of the journals
published by BioMed Central Ltd ('BioMed Central') I certify that:
1.

I am authorized by my co-authors to enter into these
arrangements.

2.
a.

I warrant, on behalf of myself and my co-authors, that:
the article is original, has not been formally published in any
other peer-reviewed journal, is not under consideration by
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any other journal and does not infringe any existing copyright
or any other third party rights;
b.

I am/we are the sole author(s) of the article and have full
authority to enter into this agreement and in granting rights
to BioMed Central are not in breach of any other obligation. If
the law requires that the article be published in the public
domain, I/we will notify BioMed Central at the time of
submission upon which clauses 3 through 6 inclusive do not
apply;

c.

the article contains nothing that is unlawful, libellous, or
which would, if published, constitute a breach of contract or
of confidence or of commitment given to secrecy;

d.

I/we have taken due care to ensure the integrity of the
article. To my/our - and currently accepted scientific knowledge all statements contained in it purporting to be
facts are true and any formula or instruction contained in the
article will not, if followed accurately, cause any injury, illness
or damage to the user.
And I agree to the following license agreement:
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BioMed Central Open Access license agreement Brief summary of
the agreement.
Anyone is free:
•

to copy, distribute, and display the work;

•

to make derivative works;

•

to make commercial use of the work;
Under the following conditions: Attribution

•

the original author must be given credit;

•

for any reuse or distribution, it must be made clear to others
what the license terms of
this work are;

•

any of these conditions can be waived if the authors gives
permission.
Statutory fair use and other rights are in no way affected by
the above.
Full BioMed Central Open Access license agreement
(Identical to the 'Creative Commons Attribution License')
License
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THE WORK (AS DEFINED BELOW) IS PROVIDED UNDER THE
TERMS OF THIS BIOMED CENTRAL OPEN ACCESS LICENSE
("LICENSE"). THE WORK IS PROTECTED BY COPYRIGHT AND/OR
OTHER APPLICABLE LAW. ANY USE OF THE WORK OTHER THAN AS
AUTHORIZED UNDER THIS LICENSE IS PROHIBITED.

BY EXERCISING ANY RIGHTS TO THE WORK PROVIDED HERE,
YOU ACCEPT AND AGREE TO BE BOUND BY THE TERMS OF THIS
LICENSE. THE LICENSOR GRANTS YOU THE RIGHTS CONTAINED HERE
IN CONSIDERATION OF YOUR ACCEPTANCE OF SUCH TERMS AND
CONDITIONS.

1. Definitions
a.

"Collective Work" means a work, such as a periodical issue,
anthology or encyclopedia, in which the Work in its entirety in
unmodified form, along with a number of other contributions,
constituting separate and independent works in themselves,
are assembled into a collective whole. A work that constitutes
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a Collective Work will not be considered a Derivative Work (as
defined below) for the purposes of this License.
b.

"Derivative Work" means a work based upon the Work or
upon the Work and other pre-existing works, such as a
translation, musical arrangement, dramatization,
fictionalization, motion picture version, sound recording, art
reproduction, abridgment, condensation, or any other form in
which the Work may be recast, transformed, or adapted,
except that a work that constitutes a Collective Work will not
be considered a Derivative Work for the purpose of this
License. For the avoidance of doubt, where the Work is a
musical composition or sound recording, the synchronization
of the Work in timed-relation with a moving image
("synching") will be considered a Derivative Work for the
purpose of this License.

c.

"Licensor" means the individual or entity that offers the Work
under the terms of this License.

d.

"Original Author" means the individual or entity who created
the Work.
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e.

"Work" means the copyrightable work of authorship offered
under the terms of this
License.

f.

"You" means an individual or entity exercising rights under
this License who has not previously violated the terms of this
License with respect to the Work, or who has received express
permission from the Licensor to exercise rights under this
License despite a previous violation.
2. Fair Use Rights
Nothing in this license is intended to reduce, limit, or restrict any

rights arising from fair use, first sale or other limitations on the
exclusive rights of the copyright owner under copyright law or other
applicable laws.

3. License Grant
Subject to the terms and conditions of this License, Licensor
hereby grants You a worldwide, royalty-free, non-exclusive, perpetual
(for the duration of the applicable copyright) license to exercise the
rights in the Work as stated below:
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a.

to reproduce the Work, to incorporate the Work into one or
more Collective Works, and to reproduce the Work as
incorporated in the Collective Works;

b.

to create and reproduce Derivative Works;

c.

to distribute copies or phonorecords of, display publicly,
perform publicly, and perform publicly by means of a digital
audio transmission the Work including as incorporated in
Collective Works;

d.

to distribute copies or phonorecords of, display publicly,
perform publicly, and perform publicly by means of a digital
audio transmission Derivative Works;

e.

For the avoidance of doubt, where the work is a musical
composition:
i. Performance Royalties Under Blanket Licenses. Licensor
waives the exclusive right to collect, whether individually or
via a performance rights society (e.g. ASCAP, BMI, SESAC),
royalties for the public performance or public digital
performance (e.g. webcast) of the Work.
ii. Mechanical Rights and Statutory Royalties. Licensor waives
the exclusive right to collect, whether individually or via a
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music rights agency or designated agent (e.g. Harry Fox
Agency), royalties for any phonorecord You create from the
Work ("cover version") and distribute, subject to the
compulsory license created by 17 USC Section 115 of the US
Copyright Act (or the equivalent in other jurisdictions).
f.

Webcasting Rights and Statutory Royalties. For the avoidance
of doubt, where the Work is a sound recording, Licensor
waives the exclusive right to collect, whether individually or
via a performance-rights society (e.g. SoundExchange),
royalties for the public digital performance (e.g. webcast) of
the Work, subject to the compulsory license created by 17
USC Section 114 of the US Copyright Act (or the equivalent in
other jurisdictions).

The above rights may be exercised in all media and formats
whether now known or hereafter devised. The above rights include the
right to make such modifications as are technically necessary to
exercise the rights in other media and formats. All rights not expressly
granted by Licensor are hereby reserved.

280

4. Restrictions
The license granted in Section 3 above is expressly made subject
to and limited by the following restrictions:
a.

You may distribute, publicly display, publicly perform, or
publicly digitally perform the Work only under the terms of
this License, and You must include a copy of, or the Uniform
Resource Identifier for, this License with every copy or
phonorecord of the Work You distribute, publicly display,
publicly perform, or publicly digitally perform. You may not
offer or impose any terms on the Work that alter or restrict
the terms of this License or the recipients' exercise of the
rights granted hereunder. You may not sublicense the Work.
You must keep intact all notices that refer to this License and
to the disclaimer of warranties. You may not distribute,
publicly display, publicly perform, or publicly digitally perform
the Work with any technological measures that control access
or use of the Work in a manner inconsistent with the terms of
this License Agreement. The above applies to the Work as
incorporated in a Collective Work, but this does not require
the Collective Work apart from the Work itself to be made
subject to the terms of this License. If You create a Collective
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Work, upon notice from any Licensor You must, to the extent
practicable, remove from the Collective Work any reference to
such Licensor or the Original Author, as requested. If You
create a Derivative Work, upon notice from any Licensor You
must, to the extent practicable, remove from the Derivative
Work any reference to such Licensor or the Original Author, as
requested.
b.

If you distribute, publicly display, publicly perform, or publicly
digitally perform the Work or any Derivative Works or
Collective Works, You must keep intact all copyright notices
for the Work and give the Original Author credit reasonable to
the medium or means You are utilizing by conveying the
name (or pseudonym if applicable) of the Original Author if
supplied; the title of the Work if supplied; to the extent
reasonably practicable, the Uniform Resource Identifier, if any,
that Licensor specifies to be associated with the Work, unless
such URI does not refer to the copyright notice or licensing
information for the Work; and in the case of a Derivative
Work, a credit identifying the use of the Work in the
Derivative Work (e.g., "French translation of the Work by
Original Author," or "Screenplay based on original Work by
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Original Author"). Such credit may be implemented in any
reasonable manner; provided, however, that in the case of a
Derivative Work or Collective Work, at a minimum such credit
will appear where any other comparable authorship credit
appears and in a manner at least as prominent as such other
comparable authorship credit.

5. Representations, Warranties and Disclaimer
UNLESS OTHERWISE MUTUALLY AGREED TO BY THE PARTIES IN
WRITING, LICENSOR OFFERS THE WORK AS-IS AND MAKES NO
REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE
WORK, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, INCLUDING,
WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTIBILITY,
FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR THE
ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE
P R E S E N C E O F A B S E N C E O F E R R O R S , W H E T H E R O R N OT
DISCOVERABLE. SOME JURISDICTIONS DO NOT ALLOW THE
EXCLUSION OF IMPLIED WARRANTIES, SO SUCH EXCLUSION MAY
NOT APPLY TO YOU.
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6. Limitation on Liability
EXCEPT TO THE EXTENT REQUIRED BY APPLICABLE LAW, IN NO
EVENT WILL LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY
FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR
EXEMPLARY DAMAGES ARISING OUT OF THIS LICENSE OR THE USE
OF THE WORK, EVEN IF LICENSOR HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES.

7. Termination
a.

This License and the rights granted hereunder will terminate
automatically upon any breach by You of the terms of this
License. Individuals or entities who have received Derivative
Works or Collective Works from You under this License,
however, will not have their licenses terminated provided such
individuals or entities remain in full compliance with those
licenses. Sections 1, 2, 5, 6, 7, and 8 will survive any
termination of this License.

b.

Subject to the above terms and conditions, the license
granted here is perpetual (for the duration of the applicable
copyright in the Work). Notwithstanding the above, Licensor
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reserves the right to release the Work under different license
terms or to stop distributing the Work at any time; provided,
however that any such election will not serve to withdraw this
License (or any other license that has been, or is required to
be, granted under the terms of this License), and this License
will continue in full force and effect unless terminated as
stated above.

8. Miscellaneous
a.

Each time You distribute or publicly digitally perform the Work
or a Collective Work, the Licensor offers to the recipient a
license to the Work on the same terms and conditions as the
license granted to You under this License.

b.

Each time You distribute or publicly digitally perform a
Derivative Work, Licensor offers to the recipient a license to
the original Work on the same terms and conditions as the
license granted to You under this License.

c.

If any provision of this License is invalid or unenforceable
under applicable law, it shall not affect the validity or
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enforceability of the remainder of the terms of this License,
and without further action by the parties to this agreement,
such provision shall be reformed to the minimum extent
necessary to make such provision valid and enforceable.
d.

No term or provision of this License shall be deemed waived
and no breach consented to unless such waiver or consent
shall be in writing and signed by the party to be charged with
such waiver or consent.

e.

This License constitutes the entire agreement between the
parties with respect to the Work licensed here. There are no
understandings, agreements or representations with respect
to the Work not specified here. Licensor shall not be bound by
any additional provisions that may appear in any
communication from You. This License may not be modified
without the mutual written agreement of the Licensor and
You.
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Chapter Three Permission

PLoS One
Open-Access License
No Permission Required
PLOS applies the Creative Commons Attribution License (CCAL)
to all works we publish (read the human-readable summary or the full
license legal code). Under the CCAL, authors retain ownership of the
copyright for their article, but authors allow anyone to download,
reuse, reprint, modify, distribute, and/or copy articles in PLOS
journals, so long as the original authors and source are cited. No
permission is required from the authors or the publishers.

In most cases, appropriate attribution can be provided by simply
citing the original article (e.g., Kaltenbach LS et al. (2007) Huntingtin
Interacting Proteins Are Genetic Modifiers of Neurodegeneration. PLOS
Genet 3(5): e82. doi:10.1371/journal.pgen.0030082). If the item you
plan to reuse is not part of a published article (e.g., a featured issue
image), then please indicate the originator of the work, and the
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volume, issue, and date of the journal in which the item appeared. For
any reuse or redistribution of a work, you must also make clear the
license terms under which the work was published.

This broad license was developed to facilitate open access to,
and free use of, original works of all types. Applying this standard
license to your own work will ensure your right to make your work
freely and openly available. Learn more about open access. For queries
about the license, please contact us.

Appendix B Permission

Copyright Permission Policy
These guidelines apply to the reuse of articles, figures, charts
and photos in the Journal of Biological Chemistry, Molecular & Cellular
Proteomics and the Journal of Lipid Research.

For authors reusing their own material:
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Authors need NOT contact the journal to obtain rights to reuse
their own material. They are automatically granted permission to do
the following:
•

Reuse the article in print collections of their own writing.
Present a work orally in its entirety.
Use an article in a thesis and/or dissertation.
Reproduce an article for use in the author's courses. (If the
author is employed by an academic institution, that institution
also may reproduce the article for teaching purposes.)

•

Reuse a figure, photo and/or table in future commercial and
noncommercial works. Post a copy of the paper in PDF that
you submitted via BenchPress.
Link to the journal site containing the final edited PDFs
created by the publisher.

EXCEPTION: If authors select the Author’s Choice publishing
option:
The final version of the manuscript will be covered under the
Creative Commons Attribution license (CC BY), the most
accommodating of licenses offered. Click here for details.
The final version of the manuscript will be released immediately on the
publisher’s website and PubMed Central.
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Please note that authors must include the following citation when
using material that appeared in an ASBMB journal: "This research was
originally published in Journal Name. Author(s). Title. Journal Name.
Year; Vol:pp-pp. © the American Society for Biochemistry and
Molecular Biology."

For other parties using material for noncommercial use:
Other parties are welcome to copy, distribute, transmit and adapt the
work — at no cost and without permission — for noncommercial use as
long as they attribute the work to the original source using the citation
above.

Examples of noncommercial use include: Reproducing a figure
for educational purposes, such as schoolwork or lecture presentations,
with attribution. Appending a reprinted article to a Ph.D. dissertation,
with attribution.

For other parties using material for commercial use:
Navigate to the article of interest and click the "Request Permissions"
button on the middle navigation bar. (See diagram at right.) It will
walk you through the steps for obtaining permission for reuse.
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Examples of commercial use by parties other than authors include:
Reproducing a figure in a book published by a commercial publisher.
Reproducing a figure in a journal article published by a commercial
publisher.

Updated March 20, 2013

Appendix C Permission

SPRINGER LICENSE TERMS AND CONDITIONS

This is a License Agreement between John C O'Leary ("You") and
Springer ("Springer") provided by Copyright Clearance Center ("CCC").
The license consists of your order details, the terms and conditions
provided by Springer, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions,
please see information listed at the bottom of this form.

May 15, 2013
License Number: 3150350457452
License date: May 15, 2013
Licensed content publisher: Springer
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Licensed content publication: Journal of Molecular Neuroscience
Licensed content title: Neuronal Life Span Versus Health Span:
Principles of Natural Selection at Work in the Degenerating Brain
Licensed content author: John C. O’Leary III
Licensed content date: Jan 1, 2011
Volume number: 45
Issue number: 3
Type of Use: Thesis/Dissertation
Portion: Full text
Number of copies: 1
Author of this Springer article: Yes and you are the sole author of the
new work
Order reference number
Title of your thesis / dissertation: The Role of Molecular Chaperones in
the Etiology and Treatment of Psychiatric Diseases in the Elderly
Expected completion date: Jun 2013
Estimated size(pages): 325
Total: 0.00 USD
Terms and Conditions
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Introduction
The publisher for this copyrighted material is Springer Science +
Business Media. By clicking "accept" in connection with completing this
licensing transaction, you agree that the following terms and
conditions apply to this transaction (along with the Billing and Payment
terms and conditions established by Copyright Clearance Center, Inc.
("CCC"), at the time that you opened your Rightslink account and that
are available at any time at http://myaccount.copyright.com).

Limited License
With reference to your request to reprint in your thesis material
on which Springer Science and Business Media control the copyright,
permission is granted, free of charge, for the use indicated in your
enquiry.

Licenses are for one-time use only with a maximum distribution
equal to the number that you identified in the licensing process.
This License includes use in an electronic form, provided its password
protected or on the university’s intranet or repository, including UMI
(according to the definition at the Sherpa website: http://
www.sherpa.ac.uk/romeo/). For any other electronic use, please
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contact Springer at (permissions.dordrecht@springer.com or
permissions.heidelberg@springer.com).

The material can only be used for the purpose of defending your
thesis, and with a maximum of 100 extra copies in paper.
Although Springer holds copyright to the material and is entitled to
negotiate on rights, this license is only valid, subject to a courtesy
information to the author (address is given with the article/chapter)
and provided it concerns original material which does not carry
references to other sources (if material in question appears with credit
to another source, authorization from that source is required as well).
Permission free of charge on this occasion does not prejudice any
rights we might have to charge for reproduction of our copyrighted
material in the future.

Altering/Modifying Material: Not Permitted
You may not alter or modify the material in any manner.
Abbreviations, additions, deletions and/or any other alterations shall
be made only with prior written authorization of the author(s) and/or
Springer Science + Business Media. (Please contact Springer at
( p e r m i s s i o n s . d o r d r e c h t @ s p r i n g e r. c o m
permissions.heidelberg@springer.com).
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or

Reservation of Rights
Springer Science + Business Media reserves all rights not
specifically granted in the combination of (i) the license details
provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and
Payment terms and conditions.

Copyright Notice:Disclaimer
You must include the following copyright and permission notice
in connection with any reproduction of the licensed material: "Springer
and the original publisher /journal title, volume, year of publication,
page, chapter/article title, name(s) of author(s), figure number(s),
original copyright notice) is given to the publication in which the
material was originally published, by adding; with kind permission
from Springer Science and Business Media."

Warranties: None
Example 1: Springer Science + Business Media makes no
representations or warranties with respect to the licensed material.
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Example 2: Springer Science + Business Media makes no
representations or warranties with respect to the licensed material and
adopts on its own behalf the limitations and disclaimers
established by CCC on its behalf in its Billing and Payment terms and
conditions for this licensing transaction.

Indemnity
You hereby indemnify and agree to hold harmless Springer
Science + Business Media and CCC, and their respective officers,
directors, employees and agents, from and against any and all claims
arising out of your use of the licensed material other than as
specifically authorized pursuant to this license.

No Transfer of License
This license is personal to you and may not be sublicensed,
assigned, or transferred by you to any other person without Springer
Science + Business Media's written permission.

No Amendment Except in Writing
This license may not be amended except in a writing signed by
both parties (or, in the case of Springer Science + Business Media, by
CCC on Springer Science + Business Media's behalf).
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Objection to Contrary Terms
Springer Science + Business Media hereby objects to any terms
contained in any purchase order, acknowledgment, check endorsement
or other writing prepared by you, which terms are inconsistent with
these terms and conditions or CCC's Billing and Payment terms and
conditions. These terms and conditions, together with CCC's Billing and
Payment terms and conditions (which are incorporated herein),
comprise the entire agreement between you and Springer Science +
Business Media (and CCC) concerning this licensing transaction. In the
event of any conflict between your obligations established by these
terms and conditions and those established by CCC's Billing and
Payment terms and conditions, these terms and conditions shall
control.

Jurisdiction
All disputes that may arise in connection with this present
License, or the breach thereof, shall be settled exclusively by
arbitration, to be held in The Netherlands, in accordance with Dutch
law, and to be conducted under the Rules of the 'Netherlands Arbitrage
Instituut' (Netherlands Institute of Arbitration). OR: All disputes that
may arise in connection with this present License, or the breach
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thereof, shall be settled exclusively by arbitration, to be held in the
Federal Republic of Germany, in accordance with German law.
Other terms and conditions: v1.3

If you would like to pay for this license now, please remit this
license along with your payment made payable to "COPYRIGHT
CLEARANCE CENTER" otherwise you will be invoiced within 48 hours of
the license date. Payment should be in the form of a check or money
order referencing your account number and this invoice number
RLNK501021965.

Once you receive your invoice for this order, you may pay your
invoice by credit card. Please follow instructions provided at that time.
Make Payment To: Copyright Clearance Center Dept 001
P.O. Box 843006 Boston, MA 02284-3006.

For suggestions or comments regarding this order, contact
RightsLink Customer Support: customercare@copyright.com or
+1-877-622-5543 (toll free in the US) or +1- 978-646-2777. Gratis
licenses (referencing $0 in the Total field) are free. Please retain this
printable license for your reference. No payment is required.
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